US20220372158A1 - Rna-coded antibody - Google Patents
Rna-coded antibody Download PDFInfo
- Publication number
- US20220372158A1 US20220372158A1 US17/813,530 US202217813530A US2022372158A1 US 20220372158 A1 US20220372158 A1 US 20220372158A1 US 202217813530 A US202217813530 A US 202217813530A US 2022372158 A1 US2022372158 A1 US 2022372158A1
- Authority
- US
- United States
- Prior art keywords
- rna
- cancer
- antibody
- triphosphate
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims abstract description 117
- 238000000338 in vitro Methods 0.000 claims abstract description 107
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 95
- 238000013518 transcription Methods 0.000 claims abstract description 85
- 230000035897 transcription Effects 0.000 claims abstract description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 241000700605 Viruses Species 0.000 claims abstract description 23
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 146
- 125000003729 nucleotide group Chemical group 0.000 claims description 145
- 201000001441 melanoma Diseases 0.000 claims description 144
- 239000002773 nucleotide Substances 0.000 claims description 130
- 239000000427 antigen Substances 0.000 claims description 99
- 108091007433 antigens Proteins 0.000 claims description 97
- 102000036639 antigens Human genes 0.000 claims description 97
- 150000007523 nucleic acids Chemical group 0.000 claims description 96
- 102000039446 nucleic acids Human genes 0.000 claims description 85
- 108020004707 nucleic acids Proteins 0.000 claims description 85
- 108020004705 Codon Proteins 0.000 claims description 75
- 230000004048 modification Effects 0.000 claims description 68
- 238000012986 modification Methods 0.000 claims description 68
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 59
- 239000000872 buffer Substances 0.000 claims description 50
- 238000013519 translation Methods 0.000 claims description 49
- -1 CAP-I Proteins 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 48
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 47
- 206010006187 Breast cancer Diseases 0.000 claims description 46
- 208000026310 Breast neoplasm Diseases 0.000 claims description 46
- 108091026890 Coding region Proteins 0.000 claims description 44
- 201000005202 lung cancer Diseases 0.000 claims description 44
- 208000020816 lung neoplasm Diseases 0.000 claims description 44
- 238000000746 purification Methods 0.000 claims description 42
- 206010009944 Colon cancer Diseases 0.000 claims description 41
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 41
- 206010005003 Bladder cancer Diseases 0.000 claims description 40
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 39
- 206010060862 Prostate cancer Diseases 0.000 claims description 39
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 38
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 38
- 206010033128 Ovarian cancer Diseases 0.000 claims description 38
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 38
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 34
- 206010039491 Sarcoma Diseases 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 32
- 208000032839 leukemia Diseases 0.000 claims description 31
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 29
- 150000001413 amino acids Chemical group 0.000 claims description 28
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 28
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 25
- 229910052770 Uranium Inorganic materials 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 201000002528 pancreatic cancer Diseases 0.000 claims description 23
- 206010025323 Lymphomas Diseases 0.000 claims description 20
- 108090000765 processed proteins & peptides Chemical class 0.000 claims description 20
- 238000011534 incubation Methods 0.000 claims description 19
- 201000009030 Carcinoma Diseases 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 239000001226 triphosphate Substances 0.000 claims description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 15
- 206010017758 gastric cancer Diseases 0.000 claims description 15
- 201000011549 stomach cancer Diseases 0.000 claims description 15
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 14
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 14
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 14
- 210000002307 prostate Anatomy 0.000 claims description 14
- 102100034256 Mucin-1 Human genes 0.000 claims description 13
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 13
- 238000001890 transfection Methods 0.000 claims description 13
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 11
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 11
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 11
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
- 230000001363 autoimmune Effects 0.000 claims description 11
- 201000010881 cervical cancer Diseases 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 9
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 230000007815 allergy Effects 0.000 claims description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 108700026244 Open Reading Frames Proteins 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 8
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 7
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 108010002687 Survivin Proteins 0.000 claims description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 claims description 7
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 claims description 7
- 150000003838 adenosines Chemical class 0.000 claims description 7
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 230000004807 localization Effects 0.000 claims description 7
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 7
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 claims description 6
- 241000193738 Bacillus anthracis Species 0.000 claims description 6
- 241000242722 Cestoda Species 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 108010070675 Glutathione transferase Proteins 0.000 claims description 6
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims description 6
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 claims description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 6
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 108010002616 Interleukin-5 Proteins 0.000 claims description 6
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 6
- 102100023123 Mucin-16 Human genes 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 108060006580 PRAME Proteins 0.000 claims description 6
- 102000036673 PRAME Human genes 0.000 claims description 6
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 claims description 6
- 108010090804 Streptavidin Proteins 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 108700020467 WT1 Proteins 0.000 claims description 6
- 101150084041 WT1 gene Proteins 0.000 claims description 6
- 210000003128 head Anatomy 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 108060000903 Beta-catenin Proteins 0.000 claims description 5
- 102000015735 Beta-catenin Human genes 0.000 claims description 5
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 5
- 108010065524 CD52 Antigen Proteins 0.000 claims description 5
- 102100026548 Caspase-8 Human genes 0.000 claims description 5
- 108090000538 Caspase-8 Proteins 0.000 claims description 5
- 101150084967 EPCAM gene Proteins 0.000 claims description 5
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 5
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 claims description 4
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 claims description 4
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims description 4
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims description 4
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 4
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims description 4
- 206010059313 Anogenital warts Diseases 0.000 claims description 4
- 101100288313 Arabidopsis thaliana KTI4 gene Proteins 0.000 claims description 4
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 claims description 4
- 108010064528 Basigin Proteins 0.000 claims description 4
- 102000015279 Basigin Human genes 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 101150108242 CDC27 gene Proteins 0.000 claims description 4
- 241000282836 Camelus dromedarius Species 0.000 claims description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 claims description 4
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 4
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010018612 Gonorrhoea Diseases 0.000 claims description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 claims description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 4
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims description 4
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 claims description 4
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 claims description 4
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 4
- 101710123134 Ice-binding protein Proteins 0.000 claims description 4
- 101710082837 Ice-structuring protein Proteins 0.000 claims description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- 229930010555 Inosine Natural products 0.000 claims description 4
- 108050002021 Integrator complex subunit 2 Proteins 0.000 claims description 4
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 108060008487 Myosin Proteins 0.000 claims description 4
- 102000003505 Myosin Human genes 0.000 claims description 4
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 claims description 4
- 206010033971 Paratyphoid fever Diseases 0.000 claims description 4
- 206010035148 Plague Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims description 4
- 208000033464 Reiter syndrome Diseases 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 102100021466 Sarcoma antigen 1 Human genes 0.000 claims description 4
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 4
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims description 4
- 101150033985 TPI gene Proteins 0.000 claims description 4
- 101150032817 TPI1 gene Proteins 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 4
- 102100033598 Triosephosphate isomerase Human genes 0.000 claims description 4
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 4
- 208000037386 Typhoid Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 4
- 206010046914 Vaginal infection Diseases 0.000 claims description 4
- 208000000260 Warts Diseases 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims description 4
- 208000028104 epidemic louse-borne typhus Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 4
- 208000002574 reactive arthritis Diseases 0.000 claims description 4
- 235000002020 sage Nutrition 0.000 claims description 4
- 206010039667 schwannoma Diseases 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 201000010153 skin papilloma Diseases 0.000 claims description 4
- 201000002612 sleeping sickness Diseases 0.000 claims description 4
- 208000006379 syphilis Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000008297 typhoid fever Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims description 3
- 108050003189 SH2B adapter protein 1 Proteins 0.000 claims description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 241000700647 Variola virus Species 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 150000008298 phosphoramidates Chemical class 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- 108091008726 retinoic acid receptors α Proteins 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 claims description 2
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 claims description 2
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 claims description 2
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 claims description 2
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 claims description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 claims description 2
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 claims description 2
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 claims description 2
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 claims description 2
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 claims description 2
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 claims description 2
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 claims description 2
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 claims description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 2
- IWFHOSULCAJGRM-UAKXSSHOSA-N 5-bromouridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(Br)=C1 IWFHOSULCAJGRM-UAKXSSHOSA-N 0.000 claims description 2
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 claims description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 claims description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 claims description 2
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 claims description 2
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 claims description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 2
- 206010063409 Acarodermatitis Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 claims description 2
- 206010001986 Amoebic dysentery Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000003508 Botulism Diseases 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- 241001415830 Bubo Species 0.000 claims description 2
- 241000252983 Caecum Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 208000024699 Chagas disease Diseases 0.000 claims description 2
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 208000008158 Chorioamnionitis Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000008853 Ciguatera Poisoning Diseases 0.000 claims description 2
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 claims description 2
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010013029 Diphyllobothriasis Diseases 0.000 claims description 2
- 241001137876 Diphyllobothrium Species 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000244160 Echinococcus Species 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 201000000628 Gas Gangrene Diseases 0.000 claims description 2
- 241001123589 Gorilla papillomavirus Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 206010023927 Lassa fever Diseases 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 208000004554 Leishmaniasis Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 241001115401 Marburgvirus Species 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 2
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 241000204048 Mycoplasma hominis Species 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 claims description 2
- 208000006816 Neonatal Sepsis Diseases 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- 241000714209 Norwalk virus Species 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 241000243985 Onchocerca volvulus Species 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 241001674048 Phthiraptera Species 0.000 claims description 2
- 206010035104 Pituitary tumour Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 claims description 2
- 241000447727 Scabies Species 0.000 claims description 2
- 206010039587 Scarlet Fever Diseases 0.000 claims description 2
- 206010042135 Stomatitis necrotising Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 claims description 2
- 241000244159 Taenia saginata Species 0.000 claims description 2
- 241000244157 Taenia solium Species 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 206010043515 Throat cancer Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 2
- 206010044620 Trichomoniasis Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 2
- 206010057293 West Nile viral infection Diseases 0.000 claims description 2
- CAEFEWVYEZABLA-UUOKFMHZSA-N XTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 CAEFEWVYEZABLA-UUOKFMHZSA-N 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- GKVHYBAWZAYQDO-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=S)C=C1 GKVHYBAWZAYQDO-XVFCMESISA-N 0.000 claims description 2
- KHYOUGAATNYCAZ-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 KHYOUGAATNYCAZ-XVFCMESISA-N 0.000 claims description 2
- ABOQIBZHFFLOGM-UAKXSSHOSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(I)=C1 ABOQIBZHFFLOGM-UAKXSSHOSA-N 0.000 claims description 2
- QTWNSBVFPSAMPO-IOSLPCCCSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-imino-1-methylpurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QTWNSBVFPSAMPO-IOSLPCCCSA-N 0.000 claims description 2
- LCQWKKZWHQFOAH-IOSLPCCCSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O LCQWKKZWHQFOAH-IOSLPCCCSA-N 0.000 claims description 2
- CABDYDUZLRXGTB-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(2,6-diaminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CABDYDUZLRXGTB-UUOKFMHZSA-N 0.000 claims description 2
- YWHNPOKVSACYOQ-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(2-amino-1-methyl-6-oxopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O YWHNPOKVSACYOQ-KQYNXXCUSA-N 0.000 claims description 2
- GLIPDAOPPNSQCA-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O GLIPDAOPPNSQCA-KQYNXXCUSA-N 0.000 claims description 2
- NCKFQXVRKKNRBB-SHUUEZRQSA-N [[(2r,3s,4r,5r)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=N1 NCKFQXVRKKNRBB-SHUUEZRQSA-N 0.000 claims description 2
- WJUFDWJKJXOYSB-XVFCMESISA-N [[(2r,3s,4r,5r)-5-(4-amino-2-sulfanylidenepyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 WJUFDWJKJXOYSB-XVFCMESISA-N 0.000 claims description 2
- DBFUQOZREOHGAV-UAKXSSHOSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-bromo-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 DBFUQOZREOHGAV-UAKXSSHOSA-N 0.000 claims description 2
- ZPZGYYNOHSQDQC-UAKXSSHOSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-iodo-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 ZPZGYYNOHSQDQC-UAKXSSHOSA-N 0.000 claims description 2
- GVVRDIINMFAFEO-KCGFPETGSA-N [[(2r,3s,4r,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O GVVRDIINMFAFEO-KCGFPETGSA-N 0.000 claims description 2
- UOVXAGVICVPZQP-SHUUEZRQSA-N [[(2r,3s,4r,5r)-5-(5-amino-3-oxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=NN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 UOVXAGVICVPZQP-SHUUEZRQSA-N 0.000 claims description 2
- PQISXOFEOCLOCT-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(6-amino-8-azidopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound [N-]=[N+]=NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O PQISXOFEOCLOCT-UUOKFMHZSA-N 0.000 claims description 2
- WDPOFPOWJQWIPX-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(7-aminotriazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WDPOFPOWJQWIPX-UUOKFMHZSA-N 0.000 claims description 2
- 206010000210 abortion Diseases 0.000 claims description 2
- 231100000176 abortion Toxicity 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000007538 anal carcinoma Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 208000016335 bubo Diseases 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 210000004534 cecum Anatomy 0.000 claims description 2
- 208000003796 chancre Diseases 0.000 claims description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 2
- 210000000795 conjunctiva Anatomy 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 208000001848 dysentery Diseases 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 210000000959 ear middle Anatomy 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 208000001606 epiglottitis Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 210000002683 foot Anatomy 0.000 claims description 2
- 208000024386 fungal infectious disease Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000011475 meningoencephalitis Diseases 0.000 claims description 2
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 208000008588 molluscum contagiosum Diseases 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 claims description 2
- 201000008585 noma Diseases 0.000 claims description 2
- 208000003177 ocular onchocerciasis Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 229950010131 puromycin Drugs 0.000 claims description 2
- 208000020615 rectal carcinoma Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 208000005687 scabies Diseases 0.000 claims description 2
- 201000004409 schistosomiasis Diseases 0.000 claims description 2
- 206010039766 scrub typhus Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 201000002311 trypanosomiasis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 206010061393 typhus Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical class C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 68
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 18
- 238000001415 gene therapy Methods 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 description 79
- 102000004169 proteins and genes Human genes 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 52
- 230000014616 translation Effects 0.000 description 47
- 238000002347 injection Methods 0.000 description 44
- 239000007924 injection Substances 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 32
- 239000002609 medium Substances 0.000 description 32
- 208000014829 head and neck neoplasm Diseases 0.000 description 28
- 239000012071 phase Substances 0.000 description 28
- 201000010536 head and neck cancer Diseases 0.000 description 26
- 150000001768 cations Chemical class 0.000 description 25
- 208000029742 colonic neoplasm Diseases 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 25
- 229960004641 rituximab Drugs 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 210000000987 immune system Anatomy 0.000 description 19
- 230000003053 immunization Effects 0.000 description 19
- 238000002649 immunization Methods 0.000 description 19
- 102000001301 EGF receptor Human genes 0.000 description 16
- 108060006698 EGF receptor Proteins 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 235000000346 sugar Nutrition 0.000 description 16
- 108020004566 Transfer RNA Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 230000000087 stabilizing effect Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 208000006265 Renal cell carcinoma Diseases 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 229940001447 lactate Drugs 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 101150029707 ERBB2 gene Proteins 0.000 description 8
- 108010008707 Mucin-1 Proteins 0.000 description 8
- 229960005395 cetuximab Drugs 0.000 description 8
- 230000002349 favourable effect Effects 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 229940022353 herceptin Drugs 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 210000003705 ribosome Anatomy 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229960000575 trastuzumab Drugs 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 201000004101 esophageal cancer Diseases 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000003151 transfection method Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 6
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 6
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930185560 Pseudouridine Natural products 0.000 description 6
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 6
- 230000001588 bifunctional effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940082789 erbitux Drugs 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 102100039897 Interleukin-5 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 102100022748 Wilms tumor protein Human genes 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000000368 destabilizing effect Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000011239 genetic vaccination Methods 0.000 description 5
- 230000008105 immune reaction Effects 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010042863 synovial sarcoma Diseases 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- QYICDXXLKSTPLF-UHFFFAOYSA-N 5-aminoheptane-1,3-diol Chemical class CCC(N)CC(O)CCO QYICDXXLKSTPLF-UHFFFAOYSA-N 0.000 description 4
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 4
- 102100034929 Cell division cycle protein 27 homolog Human genes 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 4
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 4
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 4
- 101001131990 Homo sapiens Peroxidasin homolog Proteins 0.000 description 4
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 4
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102100034601 Peroxidasin homolog Human genes 0.000 description 4
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 150000001342 alkaline earth metals Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 150000001805 chlorine compounds Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000002288 golgi apparatus Anatomy 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 150000002891 organic anions Chemical class 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- 101800000504 3C-like protease Proteins 0.000 description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 102100029968 Calreticulin Human genes 0.000 description 3
- 108090000549 Calreticulin Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010000851 Laminin Receptors Proteins 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 208000024556 Mendelian disease Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 3
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 3
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 3
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 3
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 3
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229950009760 epratuzumab Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000002314 glycerols Chemical class 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 101800000607 p15 Proteins 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 201000002628 peritoneum cancer Diseases 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WMLBMYGMIFJTCS-HUROMRQRSA-N (2r,3s,5r)-2-[(9-phenylxanthen-9-yl)oxymethyl]-5-purin-9-yloxolan-3-ol Chemical compound C([C@H]1O[C@H](C[C@@H]1O)N1C2=NC=NC=C2N=C1)OC1(C2=CC=CC=C2OC2=CC=CC=C21)C1=CC=CC=C1 WMLBMYGMIFJTCS-HUROMRQRSA-N 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102100039583 116 kDa U5 small nuclear ribonucleoprotein component Human genes 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 2
- 102100036526 Anoctamin-7 Human genes 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 101150116874 CML28 gene Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100039532 Calcium-activated chloride channel regulator 2 Human genes 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- 241000710127 Cricket paralysis virus Species 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 2
- 102100037238 E3 ubiquitin-protein ligase UBR4 Human genes 0.000 description 2
- 102100035078 ETS-related transcription factor Elf-2 Human genes 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108010055196 EphA2 Receptor Proteins 0.000 description 2
- 108010055191 EphA3 Receptor Proteins 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102100038975 Exosome complex component RRP46 Human genes 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 2
- 102100039717 G antigen 1 Human genes 0.000 description 2
- 102100040003 G antigen 2D Human genes 0.000 description 2
- 102100039698 G antigen 5 Human genes 0.000 description 2
- 101710092267 G antigen 5 Proteins 0.000 description 2
- 102100039713 G antigen 6 Human genes 0.000 description 2
- 101710092269 G antigen 6 Proteins 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 description 2
- 101710144640 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100032530 Glypican-3 Human genes 0.000 description 2
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 102000004989 Hepsin Human genes 0.000 description 2
- 108090001101 Hepsin Proteins 0.000 description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000608799 Homo sapiens 116 kDa U5 small nuclear ribonucleoprotein component Proteins 0.000 description 2
- 101000928370 Homo sapiens Anoctamin-7 Proteins 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 2
- 101000888580 Homo sapiens Calcium-activated chloride channel regulator 2 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 2
- 101000807547 Homo sapiens E3 ubiquitin-protein ligase UBR4 Proteins 0.000 description 2
- 101000877377 Homo sapiens ETS-related transcription factor Elf-2 Proteins 0.000 description 2
- 101100389965 Homo sapiens EXOSC5 gene Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 2
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 2
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 2
- 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 description 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 2
- 101001036689 Homo sapiens Melanoma-associated antigen B5 Proteins 0.000 description 2
- 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 2
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 2
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 2
- 101001057154 Homo sapiens Melanoma-associated antigen D2 Proteins 0.000 description 2
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 2
- 101001057132 Homo sapiens Melanoma-associated antigen F1 Proteins 0.000 description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 2
- 101000588345 Homo sapiens Nuclear transcription factor Y subunit gamma Proteins 0.000 description 2
- 101001109282 Homo sapiens NudC domain-containing protein 1 Proteins 0.000 description 2
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 2
- 101001114052 Homo sapiens P antigen family member 4 Proteins 0.000 description 2
- 101000619805 Homo sapiens Peroxiredoxin-5, mitochondrial Proteins 0.000 description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
- 101001093143 Homo sapiens Protein transport protein Sec61 subunit gamma Proteins 0.000 description 2
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 description 2
- 101000711466 Homo sapiens SAM pointed domain-containing Ets transcription factor Proteins 0.000 description 2
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 2
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 102100038356 Kallikrein-2 Human genes 0.000 description 2
- 101710176220 Kallikrein-2 Proteins 0.000 description 2
- 102100034872 Kallikrein-4 Human genes 0.000 description 2
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102000002297 Laminin Receptors Human genes 0.000 description 2
- 102100028333 MAGE-like protein 2 Human genes 0.000 description 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 102100039475 Melanoma-associated antigen B5 Human genes 0.000 description 2
- 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 2
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 2
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 2
- 102100027251 Melanoma-associated antigen D2 Human genes 0.000 description 2
- 102100027257 Melanoma-associated antigen D4 Human genes 0.000 description 2
- 102100027258 Melanoma-associated antigen F1 Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102100034263 Mucin-2 Human genes 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 2
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 2
- 102100031719 Nuclear transcription factor Y subunit gamma Human genes 0.000 description 2
- 102100021010 Nucleolin Human genes 0.000 description 2
- 102100022475 NudC domain-containing protein 1 Human genes 0.000 description 2
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 102000004264 Osteopontin Human genes 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 102100023240 P antigen family member 4 Human genes 0.000 description 2
- 241000577979 Peromyscus spicilegus Species 0.000 description 2
- 102100022078 Peroxiredoxin-5, mitochondrial Human genes 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 208000007932 Progeria Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102100036306 Protein transport protein Sec61 subunit gamma Human genes 0.000 description 2
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 description 2
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102000004879 Racemases and epimerases Human genes 0.000 description 2
- 108090001066 Racemases and epimerases Proteins 0.000 description 2
- 101000737809 Rattus norvegicus Cadherin-related family member 5 Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 102100034018 SAM pointed domain-containing Ets transcription factor Human genes 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 108010041216 Sirtuin 2 Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108010032166 TARP Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108060002566 ephrin Proteins 0.000 description 2
- 102000012803 ephrin Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 108010024383 kallikrein 4 Proteins 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Chemical compound [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229950001869 mapatumumab Drugs 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 description 2
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 108010036112 nuclear matrix protein 22 Proteins 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 108010044762 nucleolin Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 229950007283 oregovomab Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108010079891 prostein Proteins 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- XYSQXZCMOLNHOI-UHFFFAOYSA-N s-[2-[[4-(acetylsulfamoyl)phenyl]carbamoyl]phenyl] 5-pyridin-1-ium-1-ylpentanethioate;bromide Chemical compound [Br-].C1=CC(S(=O)(=O)NC(=O)C)=CC=C1NC(=O)C1=CC=CC=C1SC(=O)CCCC[N+]1=CC=CC=C1 XYSQXZCMOLNHOI-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108060008004 synaptotagmin Proteins 0.000 description 2
- 102000003137 synaptotagmin Human genes 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- GVJHHUAWPYXKBD-QLVXXPONSA-N (S,R,R)-alpha-tocopherol Chemical compound [H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C GVJHHUAWPYXKBD-QLVXXPONSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 1
- LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical group COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100032959 Alpha-actinin-4 Human genes 0.000 description 1
- 101710115256 Alpha-actinin-4 Proteins 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000295638 Australian bat lyssavirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 241001493154 Bunyamwera virus Species 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 102100025933 Cancer-associated gene 1 protein Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000466177 Cansumys canus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 102100023509 Chloride channel protein 2 Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 102100031552 Coactosin-like protein Human genes 0.000 description 1
- 101710105549 Coactosin-like protein Proteins 0.000 description 1
- 102100032368 Coiled-coil domain-containing protein 110 Human genes 0.000 description 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 102100040501 Contactin-associated protein 1 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000150528 Dobrava-Belgrade orthohantavirus Species 0.000 description 1
- 102100030072 Doublesex- and mab-3-related transcription factor 3 Human genes 0.000 description 1
- 101100219190 Drosophila melanogaster byn gene Proteins 0.000 description 1
- 241001520695 Duvenhage lyssavirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 101100129584 Escherichia coli (strain K12) trg gene Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000579695 European bat 1 lyssavirus Species 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 102100039709 G antigen 2A Human genes 0.000 description 1
- 101710098406 G antigen 2A Proteins 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000713158 Hazara virus Species 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 description 1
- 101000797917 Homo sapiens 1,5-anhydro-D-fructose reductase Proteins 0.000 description 1
- 101000933825 Homo sapiens Cancer-associated gene 1 protein Proteins 0.000 description 1
- 101000741072 Homo sapiens Caspase-5 Proteins 0.000 description 1
- 101000946837 Homo sapiens Cell division cycle protein 27 homolog Proteins 0.000 description 1
- 101000906633 Homo sapiens Chloride channel protein 2 Proteins 0.000 description 1
- 101000868824 Homo sapiens Coiled-coil domain-containing protein 110 Proteins 0.000 description 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101000864825 Homo sapiens Doublesex- and mab-3-related transcription factor 3 Proteins 0.000 description 1
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101001054842 Homo sapiens Leucine zipper protein 4 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001036688 Homo sapiens Melanoma-associated antigen B1 Proteins 0.000 description 1
- 101001036686 Homo sapiens Melanoma-associated antigen B2 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000978949 Homo sapiens NADP-dependent malic enzyme Proteins 0.000 description 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 101000741896 Homo sapiens POTE ankyrin domain family member D Proteins 0.000 description 1
- 101001095095 Homo sapiens Proline-rich acidic protein 1 Proteins 0.000 description 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101000863978 Homo sapiens Protein downstream neighbor of Son Proteins 0.000 description 1
- 101000613391 Homo sapiens Protocadherin beta-16 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 description 1
- 101000643620 Homo sapiens Synaptonemal complex protein 1 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100026011 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229910021575 Iron(II) bromide Inorganic materials 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021579 Iron(II) iodide Inorganic materials 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 241001113666 Khasan virus Species 0.000 description 1
- 208000000588 Klippel-Trenaunay-Weber Syndrome Diseases 0.000 description 1
- 208000034642 Klippel-Trénaunay syndrome Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150048357 Lamp1 gene Proteins 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 1
- 241001123008 Leukoma Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 101000832988 Lumbricus terrestris Extracellular globin-4 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010031030 Mammaglobin A Proteins 0.000 description 1
- 102000005727 Mammaglobin A Human genes 0.000 description 1
- 241000711937 Marburg marburgvirus Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 102100039477 Melanoma-associated antigen B1 Human genes 0.000 description 1
- 102100039479 Melanoma-associated antigen B2 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100348669 Mus musculus Nkx3-1 gene Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OXZZMWVZYFVMKG-UHFFFAOYSA-N N-diazo-[hydroxy(phosphonooxy)phosphoryl]oxyphosphonamidic acid Chemical class [N-]=[N+]=NP(=O)(O)OP(=O)(O)OP(=O)(O)O OXZZMWVZYFVMKG-UHFFFAOYSA-N 0.000 description 1
- 102100023175 NADP-dependent malic enzyme Human genes 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 108010025568 Nucleophosmin Proteins 0.000 description 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical class CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 201000007908 Ocular Albinism Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 description 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 description 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 description 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100038762 POTE ankyrin domain family member D Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101710124046 Palmitoyl-acyl carrier protein thioesterase, chloroplastic Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 101001128814 Pandinus imperator Pandinin-1 Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000710884 Powassan virus Species 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 241000150258 Prospect Hill orthohantavirus Species 0.000 description 1
- 102100033514 Prostate and testis expressed protein 1 Human genes 0.000 description 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100443768 Rattus norvegicus Dock9 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 101710130046 Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000150288 Sin Nombre orthohantavirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001115376 Sudan ebolavirus Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 1
- 241001115374 Tai Forest ebolavirus Species 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 101710070533 Testin Proteins 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 241000713154 Toscana virus Species 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102100034030 Transient receptor potential cation channel subfamily M member 8 Human genes 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 241000150289 Tula orthohantavirus Species 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 241000711973 Vesicular stomatitis Indiana virus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- RTGGYPQTXNSBPD-XVFCMESISA-N [(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound F[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 RTGGYPQTXNSBPD-XVFCMESISA-N 0.000 description 1
- OWNKJJAVEHMKCW-XVFCMESISA-N [(2r,3s,4r,5r)-4-amino-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound N[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 OWNKJJAVEHMKCW-XVFCMESISA-N 0.000 description 1
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- JPNBLHSBLCCTEO-VPCXQMTMSA-N [[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 JPNBLHSBLCCTEO-VPCXQMTMSA-N 0.000 description 1
- HCXHLIFQJYSIBK-XVFCMESISA-N [[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound F[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 HCXHLIFQJYSIBK-XVFCMESISA-N 0.000 description 1
- YCZSHICNESTART-ZOQUXTDFSA-N [[(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)N=C(N)C=C1 YCZSHICNESTART-ZOQUXTDFSA-N 0.000 description 1
- YKEIUAOIVAXJRI-XVFCMESISA-N [[(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YKEIUAOIVAXJRI-XVFCMESISA-N 0.000 description 1
- RJZLOYMABJJGTA-XVFCMESISA-N [[(2r,3s,4r,5r)-4-amino-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 RJZLOYMABJJGTA-XVFCMESISA-N 0.000 description 1
- WNVZQYHBHSLUHJ-XVFCMESISA-N [[(2r,3s,4r,5r)-4-amino-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)N=C(N)C=C1 WNVZQYHBHSLUHJ-XVFCMESISA-N 0.000 description 1
- JKLOYZCVXRYXFE-XVFCMESISA-N [[(2r,3s,4r,5r)-4-azido-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound [N-]=[N+]=N[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 JKLOYZCVXRYXFE-XVFCMESISA-N 0.000 description 1
- HWSNFUNJICGTGY-XVFCMESISA-N [[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-azido-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](N=[N+]=[N-])[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HWSNFUNJICGTGY-XVFCMESISA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 206010001689 alkaptonuria Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 208000012948 angioosteohypertrophic syndrome Diseases 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000389 anti-prion effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 201000006715 brachydactyly Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical group CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006529 extracellular process Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000056735 human MART-2 Human genes 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 description 1
- FZGIHSNZYGFUGM-UHFFFAOYSA-L iron(ii) fluoride Chemical compound [F-].[F-].[Fe+2] FZGIHSNZYGFUGM-UHFFFAOYSA-L 0.000 description 1
- BQZGVMWPHXIKEQ-UHFFFAOYSA-L iron(ii) iodide Chemical compound [Fe+2].[I-].[I-] BQZGVMWPHXIKEQ-UHFFFAOYSA-L 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ZQAUNTSBAZCVIO-UHFFFAOYSA-N methoxyphosphonamidic acid Chemical class COP(N)(O)=O ZQAUNTSBAZCVIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 208000018066 neoplasm of oropharynx Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 208000010918 peritoneal neoplasm Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical class CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 108010049718 pseudouridine synthases Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000005706 short rib-polydactyly syndrome Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy.
- the present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.
- tumours and cancer diseases The occurrence of tumours and cancer diseases is, alongside cardiovascular and infectious diseases, one of the most frequent causes of death in modern societies and is associated with usually considerable costs during the therapy and subsequent rehabilitation measures.
- the treatment of tumours and cancer diseases depends greatly, for example, on the nature of the tumour which occurs and at present conventionally is undertaken by using radio- or chemotherapy, in addition to invasive interventions.
- these therapies represent an exceptional burden on the immune system, and in some cases can be employed to only a limited extent.
- these therapy forms usually require long pauses between the individual treatments for regeneration of the immune system.
- molecular biology programmes in particular have emerged as promising for the treatment or for assisting these therapies.
- An example of these molecular biology methods comprises the use of antibodies or immunoglobulins as essential effectors of the immune system.
- Antibodies or immunoglobulins can be generated either in vitro by using known molecular biology methods or by the immune system of the organism itself to be treated.
- the immune system of higher vertebrates thus has two separate functions of the immune system: the innate immune system, which reacts non-specifically to pathogens (e.g. by macrophage-mediated phagocytosis) and the adaptive immune system, which reacts specifically to pathogens by means of specialized effector cells (e.g. B and T cells).
- the antibodies or immunoglobulins which are secreted by plasma cells during an immune response are part of this adaptive immune system. Together with the complement system, they form the humoral branch of the immune response.
- antibodies are capable of binding specifically to their target structures (e.g. antigens, which substantially comprise proteins, peptides, in some cases lipids, carbohydrates etc.) and of thereby blocking (inhibiting) or, where appropriate, labelling these. They can moreover activate the immune system by means of their Fc part, so that the labelled cells are destroyed.
- target structures e.g. antigens, which substantially comprise proteins, peptides, in some cases lipids, carbohydrates etc.
- Fc part e.g. antigens, which substantially comprise proteins, peptides, in some cases lipids, carbohydrates etc.
- Antibodies which can be employed in cancer therapy play by far the greatest role in this context.
- antibodies prepared for this at present are monoclonal antibodies which originate originally, for example, from the mouse.
- chiefly humanized or human antibodies are employed for therapy (cf. David Male; “Immunologie auf nie Magnolia [Immunology at a Glance]”, 1st German edition, 2005, Elsevier-Urban & Fischer Verlag; Charles A.
- Antibodies generally can be assigned to the group of immunoglobulins. These immunoglobulins can in turn be differentiated into five main classes of immunoglobulins on the basis of their heavy chain, the IgM ( ⁇ ), IgD ( ⁇ ), IgG ( ⁇ ), IgA ( ⁇ ) and IgE ( ⁇ ) antibodies, IgG antibodies making up the largest proportion. Immunoglobulins can moreover be differentiated into the isotypes ⁇ and ⁇ on the basis of their light chains.
- IgG antibodies typically are built up two identical light and two heavy protein chains which are bonded to one another via disulfide bridges.
- the light chain comprises the N-terminal variable domain V L and the C-terminal constant domain C L .
- the heavy chain of an IgG antibody can be divided into an N-terminal variable domain V H and three constant domains C H 1, C H 2 and C H 3 (cf. FIG. 1 ). While the amino acid sequence is largely the same in the region of the constant domains, wide differences in sequence are typically found within the variable domains.
- the antibody repertoire of a human comprises about at least 10 11 different antibody specificities.
- the formation of antibodies takes place naturally in the immune system by somatic recombination.
- an organism is indeed theoretically capable of generating an antibody of appropriate specificity against any antigen.
- each of these antibodies were to be coded by an endogenous gene, they would burst the human genome.
- antibody genes are composed of a large number of individual gene segments.
- the part of the antibody gene which codes for the variable region of a light chain is formed from a V gene segment and a J gene segment.
- numerous different V and J segments are available, which can be combined with one another virtually as desired.
- the variable region of a heavy chain is composed of three different gene segments.
- V H , D H and J H segments can likewise be combined with one another virtually as desired to form the variable region of the heavy chain (cf. FIG. 2 ).
- the mechanism by which the various gene segments are combined to form complete antibody genes is called immunoglobulin rearrangement or somatic recombination. It takes place exclusively in B lymphocytes at certain times of cell development.
- junctional diversity in this context describes controlled imprecise joining together of the rearranged gene segments, as a result of which random removal and insertion of nucleotides occurs at the cleavage sites.
- a further combinatorial diversity results from the possibility of combining a particular rearranged light chain with a particular rearranged heavy chain.
- the diversity of antibodies is also additionally increased after successful rearrangement and later activation of B cells, in that an affinity maturation of antibodies occurs due to an increased rate of mutation in the region of the variable regions of activated B cells (somatic hypermutation).
- antibodies can also be generated by molecular biology methods.
- the formation of antibodies is at present typically induced in selected organisms by injection of a particular antigen, and the antibody is then isolated from the organism for further use.
- the B lymphocytes of the organism are conventionally purified selectively and fused with an immortal myeloma cell to form a hybridoma cell. Those cells which secrete the corresponding antigen-specific antibodies are then determined by selection methods.
- hybridoma cells In addition to use of hybridoma cells, recombinant preparation of these antibodies with the desired specificity is also possible after isolation and sequencing. Cells which provide the required posttranslational modifications are typically used for this. On the basis of the immune reaction with formation of human anti-mouse antibodies in the human organism in the case of native antibodies produced in the mouse (or in other hosts), chimeric, humanized or human antibodies are preferably prepared here.
- these antibodies can be employed as agents both in biochemical and molecular biology research, and in diagnostics and for medical uses.
- antibodies can be employed directly only with difficulty, since these usually have only a very short half-life in vivo and therefore, possibly, cannot reach their target antigen or their target nucleic acid at all. This requires either high active compound concentrations of the desired antibody, or alternative methods which are suitable for providing large amounts of antibodies in vivo.
- Such methods include, e.g. molecular medicine methods of gene therapy and genetic vaccination which, when used generally in the therapy and prevention of diseases, have considerable effects on medical practice. Both methods are based on the introduction of nucleic acids into cells or into tissue of the patient and on subsequent processing by the cells or, respectively, tissue of the information coded by the nucleic acids introduced, i.e. expression of the desired polypeptides, e.g. antibodies, in the cells or respectively, the tissue.
- the desired polypeptides e.g. antibodies
- the conventional procedure of methods of gene therapy and of genetic vaccination to date is based on the use of DNA to sluice the required genetic information into the cell.
- Various methods for introducing DNA into cells have been developed in this connection, such as, for example, calcium phosphate transfection, polyprene transfection, protoplast fusion, electroporation, microinjection, lipofection and the use of gene canons, lipofection in particular having emerged as a suitable method.
- a further method which has been proposed in particular in the case of genetic vaccination methods is the use of DNA viruses as DNA vehicles.
- DNA viruses have the advantage that because of their infectious properties a very high transfection rate can be achieved.
- the viruses used are genetically modified, so that no functional infectious particles are formed in the transfected cell.
- the use of DNA viruses as DNA vehicles has been criticized in recent years because of the risk of recombination of non-active viruses to give active viruses.
- DNA as an agent in gene therapy and genetic vaccination or for passive immunization (by passive vaccines), e.g. by using coding sequences for antibodies, may, however, also be less advantageous from some points of view.
- DNA is degraded only relatively slowly in the bloodstream, so that when (foreign) DNA is used as the coding sequence for a desired protein, a formation of anti-DNA antibodies may occur, which has been confirmed in an animal model in the mouse (Gilkeson et al., J. Clin. Invest. 1995, 95: 1398-1402).
- (foreign) DNA can interact with the host genome, and in particular cause mutations by integration into the host genome.
- the (foreign) DNA introduced may be inserted into an intact gene, which represents a mutation which can impede or even completely switch off the function of the endogenous gene.
- Active immunization thus creates a permanent immunization of the organism against the particular antigen, which can be associated with the disadvantages described above.
- passive immunization in contrast, only an antiserum or the purified antibody itself (“passive vaccine”) is administered to the organism.
- the coding sequence for the antibody can likewise be administered, as described above, as a so-called passive vaccine for passive immunization.
- an RNA (sequence) for intracellular expression of an antibody wherein the RNA (sequence) codes for an antibody or contains at least one coding region, which codes for at least one antibody, respectively.
- an antibody-coding RNA according to the invention includes any RNA which encodes an antibody. More generally, the RNA of the present invention (directed to intracellular expression) contains at least one coding region, wherein the at least one coding region codes for at least one antibody. If more than one coding region is contained in the RNA molecule of the invention, the second, third etc. coding region may code for antibodies as well, which may be the same or distinct from the first antibody coding region.
- the inventive RNA contains at least two coding regions, all of them coding for identical or distinct antibodies.
- an inventive RNA may code for more than one antibody within the same coding region.
- the inventive RNA may be mono-, bi- or multicistronic, codes for at least one antibody.
- the antibody-coding RNA according to the invention can be single-stranded or double-stranded, linear or circular, or in particular in the form of mRNA.
- the antibody-coding RNA according to the invention is particularly preferably in the form of single-stranded RNA, even more preferably in the form of mRNA.
- An antibody-coding RNA according to the invention preferably has a length of from 50 to 15,000 nucleotides, more preferably a length of from 50 to 10,000 nucleotides, even more preferably a length of from 500 to 10,000 nucleotides and most preferably a length of from 500 to 7,000, 500 to 5,000 or 700 to 3,000 nucleotides.
- the antibodies coded by the RNA according to the invention can be chosen from all antibodies, e.g. from all antibodies which are generated by recombinant methods or are naturally occurring and are known to a person skilled in the art from the prior art, in particular antibodies which are (can be) employed for therapeutic purposes or for diagnostic or for research purposes or have been found with particular diseases, e.g. cancer diseases, infectious diseases etc.
- antibodies which are coded by an RNA according to the invention typically include all antibodies (described above) which are known to a person skilled in the art, e.g. naturally occurring antibodies or antibodies generated in a host organism by immunization, antibodies prepared by recombinant methods which have been isolated and identified from naturally occurring antibodies or antibodies generated in a host organism by (conventional) immunization or have been generated with the aid of molecular biology methods, as well as chimeric antibodies, human antibodies, humanized antibodies, bispecific antibodies, intrabodies, i.e. antibodies expressed in cells and possibly localized in particular cell compartments, and fragments of the abovementioned antibodies.
- the term antibody is to be understood in its broadest meaning.
- antibodies in general typically comprise a light chain and a heavy chain, both of which have variable and constant domains.
- the light chain comprises the N-terminal variable domain V L and the C-terminal constant domain C L .
- the heavy chain of an IgG antibody in contrast, can be divided into an N-terminal variable domain V H and three constant domains C H 1, C H 2 and C H 3 (cf. FIG. 1 ).
- RNA molecules according to the invention can also be prepared on the basis of polyclonal antibodies or, as an antibody-coding RNA cocktail, can have a polyclonal character.
- polyclonal antibodies are typically mixtures of antibodies against a specific antigen or immunogen or epitope of a protein which have been generated by immunization of a host organism, for example mammals, i.e. animals, including cattle, pigs, dogs, cats, donkeys, monkeys, including rodents, e.g. mice, hamsters, rabbits etc., and man.
- Polyclonal antibodies conventionally recognize different epitopes or regions of the same specific antigen, each of these epitopes in turn being capable of generating a clone of B lymphocytes which produces an antibody against this epitope. From such polyclonal antibodies or from the antibody sera obtained from the host organism, the individual antibodies specific against the particular epitopes can be obtained by individualization to monoclonal antibodies.
- the present invention accordingly also provides RNA which codes for a monoclonal antibody obtained by individualization of polyclonal antibodies.
- Monoclonal antibodies in the context of this invention are therefore typically antibodies which are specific for a particular antigen or epitope (of a protein), i.e. bind this antigen or epitope (of a protein) with a high affinity, and conventionally are expressed by a hybridoma cell.
- the corresponding antigen or immunogen or epitope of a protein is typically injected at least once, but typically several times, into a host organism as described here, as a result of which the immune system of the host organism, in the presence of suitable adjuvants, is preferably stimulated to antibody production via activation of correspondingly specific B cells.
- the B lymphocytes are then conventionally selectively purified from the spleen or other organs or fluids suitable for this from an animal immunized in this manner, and are fused with an immortal myeloma cell to give the so-called hybridoma cell.
- hybridoma cell After selection methods and cloning of the hybridomas or hybridoma cells formed, those clones which secernate, i.e. express and secrete, antibodies of the desired specificity can be determined. These clones can be isolated and sequenced with known molecular biology methods.
- the data obtained from such a sequencing can serve further in a nucleic acid synthesis for generation of synthetic DNA sequences or for screening a cDNA library and isolation of the cDNA fragments and generation of a DNA or nucleic acid template for in vitro or in vivo synthesis of the RNA according to the invention which codes for an antibody.
- the RNA contained in the hybridomas can also be isolated, for example by fractionation, and subsequently the RNA molecules according to the invention which code for the hybridoma antibody can be purified by methods known to the person skilled in the art.
- RNA molecules which code for non-human monoclonal or polyclonal antibody e.g. murine monoclonal antibodies or monoclonal antibodies from other, as described here, non-human host organisms or hybridoma cells are of only limited suitability for therapeutic use in humans, since in the human organism itself they conventionally cause an immune reaction with formation of human anti-antibodies directed against these non-human host antibodies.
- non-human monoclonal or polyclonal antibodies as a rule can be administered to a person only a single time.
- RNA molecules which code for chimeric, humanized and human antibodies can also be provided according to the invention.
- Chimeric antibodies in the context of the present invention are preferably antibodies in which the constant domains of an antibody as described here have been replaced by human sequences.
- chimeric antibodies are formed from monoclonal or polyclonal antibodies as described here.
- Humanized antibodies in the context of the present invention are antibodies in which the constant and variable domains described above of the non-human monoclonal or polyclonal antibodies, with the exception of the hypervariable regions, have been replaced by human sequences.
- RNA molecules which code for human antibodies i.e. antibodies which have completely human sequences, that is to say in the constant and variable domains, including the hypervariable regions, can furthermore be used in the context of the present invention.
- Such RNA molecules which code for human antibodies can be isolated from human tissue or originate from immunized host organisms as described here, e.g. mice, which are then transgenic for the human IgG gene locus.
- RNA molecules which code for human antibodies and have been isolated by means of phage display and cloned with the aid of molecular biology methods are furthermore provided (see below).
- Antibodies which are coded by RNAs according to the invention particularly preferably include so-called full length antibodies, i.e. antibodies which comprise both the complete heavy and the complete light chains, as described above.
- RNAs which alternatively code for one or more antibody fragment(s) of the antibodies described above, instead of the corresponding full length antibody, can furthermore be provided in the context of the present invention.
- antibody fragments are any antibody fragments known to a person skilled in the art, e.g. Fab, Fab′, F(ab′) 2 , Fc, Facb, pFc′, Fd, and Fv fragments of the abovementioned antibodies etc.
- a diagram of the structure of such antibody fragments is shown by way of example in FIG. 4 .
- Protein fragments consisting of the minimal binding subunit of antibodies known as single-chain antibodies (scFvs) have excellent binding specificity and affinity for their ligands. In contrast to antibodies, scFvs lack the non-binding regions. Accordingly, RNA encoding scFvs are also encompassed by the present invention.
- an Fab (fragment antigen binding) fragment typically comprises the variable and a constant domain of a light and a heavy chain, e.g. the C H 1 and the V H domain of the heavy chain and the complete light chain. The two chains are bonded to one another via a disulfide bridge.
- An Fab fragment thus conventionally contains the complete antigen-binding region of the original antibody and usually has the same affinity for the antigen, the immunogen or an epitope of a protein.
- Antibody fragments, as also described above for antibodies, can be prepared with the aid of molecular biology methods. In this context, the DNA sequences which code for the various domains of the antibody fragment are cloned into a specific expression vector.
- RNA which codes for these antibody fragments can then be expressed e.g. in suitable host cells.
- suitable host cells in connection with the present invention include, inter alia, E. coli , yeasts, transgenic plants or mammalian cells etc. (see below).
- an scFv fragment single chain variable fragment typically comprises the variable domain of the light and of the heavy chain, which are bonded to one another via an artificial polypeptide linker.
- RNAs which code for a V H and V L these being linked to one another by a polypeptide linker, are preferably provided.
- a polypeptide built up from 15-25 glycine, proline and/or serine residues (cf. FIG. 5 ) or the associated nucleotide sequence is used at the RNA level for the provision of this component.
- RNA molecules which code for bispecific antibodies can also be provided in the context of the present invention.
- Bispecific antibodies in the context of the present invention are preferably antibodies which can act as adaptors between an effector and a corresponding target, e.g. for recruiting effector molecules (e.g. toxins, active compounds (drugs), cytokines etc.), targeting of effector cells (e.g. CTL, NK cells, macrophages, granulocytes etc. (see, for example, review by Kontermann R. E., Acta Pharmacol. Sin, 2005, 26(1): 1-9).
- bispecific antibodies are in principle built up such as is described here in general for antibodies, these bispecific antibodies e.g.
- bispecific antibodies can also be single-chain antibodies (e.g. scFv fragments etc.). Bispecific antibodies can be used, for example, to bring two reaction partners, e.g.
- bispecific antibodies are used above all to bring effector cells (such as, for example, T cells, NK cells, macrophages etc.) and target cells (e.g. tumour cells, infected cells etc.) spatially close.
- effector cells such as, for example, T cells, NK cells, macrophages etc.
- target cells e.g. tumour cells, infected cells etc.
- bispecific antibodies can include, without being limited thereto, e.g. those antibodies or antibody fragments which bind on the one hand a surface factor as described here, and on the other hand an antigen as described here, preferably a tumour antigen as described here. This includes e.g. CD28 and a tumour antigen (Grosse-Hovest L.
- RNAs which code for antibodies inter alia code for those antibodies which bind antigens or specific nucleic acids.
- Antigens in the context of the present invention are typically molecules which are recognized as exogenous by the immune system and conventionally cause an immune reaction or immune response with the formation of antibodies directed specifically against them.
- antigens can also include, especially in the case of autoimmune diseases, endogenous molecules or structures which are incorrectly recognized as exogenous by the immune system and thereby trigger an immune reaction.
- antigens are therefore all molecules which are recognized by an antibody in the context of the present invention.
- Antigens substantially comprise proteins, peptides or epitopes of these proteins or peptides.
- epitopes are typically small regions (molecular sections) lying on the surface of such protein or peptide structures and having a length of from 5 to 15, in rare case also to 25, preferably 6 to 9 amino acids.
- Antigens can furthermore also include lipids, carbohydrates etc.
- antigens also include, for example, so-called immunogens, i.e. antigens which lead to an immunity of the organism transfected therewith.
- Antigens by way of example include, without being limited thereto, surface antigens of cells, tumour antigens etc.
- antibodies can bind the following antigens (which typically occur in vertebrates), e.g.
- tumour-specific surface antigens e.g. 5T4, ⁇ 5 ⁇ 1-integrin, 707-AP, AFP, ART-4, B7H4, BAGE, ⁇ -catenin/m, Bcr-abl, MN/C IX-antigen, CA125, CAMEL, CAP-1, CASP-8, CD4, CD19, CD20, CD22, CD25, CDC27/m, CD 30, CD33, CD52, CD56, CD80, CDK4/m, CEA, CT, Cyp-B, DAM, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ETV6-AML1, G250, GAGE, GnT-V, Gp100, HAGE, HER-2/neu, HLA-A*0201-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT), iCE, IGF-1R, IL-2R, IL-5, KIAA
- Tumour antigens can, for example, typically be responsible for metastasing, that is to say dissolving of tumour cells out of their native tissue, transfer into the vascular system (lymph or blood vessel system), exit from the vascular system and colonization in a new tissue.
- metastasing that is to say dissolving of tumour cells out of their native tissue, transfer into the vascular system (lymph or blood vessel system), exit from the vascular system and colonization in a new tissue.
- tumour antigens which cause modified cell-cell interactions compared with the native state are of interest in particular.
- Antibodies encoded by the inventive RNA may also be directed against tumour antigens listed by Table 1 or Table 2.
- RNA encoding those antibodies may be used to treat (or, may be used to prepare a medicament to treat, respectively) the cancer diseases given in the last column of Tables 1 and 2.
- antibodies encoded by the inventive RNA are directed against the following (protein) antigens (whereby the RNA molecules may be used for the preparation of a medicament, e.g. a pharmaceutical composition or more preferably a (passive) vaccine in the meaning of the present inventino), are selected from the group consisting of 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, alpha-5-beta-1-integrin, alpha-5-beta-6-integrin, alpha-actinin-4/m, alpha-methylacyl-coenzyme A racemase, ART-4, ARTC1/m, B7H4, BAGE-1, BCL-2, bcr/abl, beta-catenin/m, BING-4, BRCA1/m, BRCA2/m, CA 15-3/CA 27-29, CA 19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8/m, cathepsin B, cathepsin
- the RNA codes for antibodies which are directed against protein antigens selected from the group consisting of MAGE-A1, MAGE-A6, melan-A, GP100, tyrosinase, survivin, CEA, Her-2/neu, WT1, PRAME, EGFRI (epidermal growth factor receptor 1), mucin-1 and SEC61G, hTERT, 5T4, NY-Eso1, and TRP-2, more preferably from sequences of group consisting of MAGE-A1 [accession number M77481], MAGE-A6 [accession number NM_005363], melan-A [accession number NM_005511], GP100 [accession number M77348], tyrosinase [accession number NM_000372], survivin [accession number AF077350], CEA [accession number NM_004363], Her-2/neu [accession number M11730], WT1 [accession number MAGE-A
- Antibodies (and therefore also the RNAs according to the invention on which these antibodies are based) which bind the antigens described here and, possibly, other antigens or nucleic acids can be identified e.g. by means of the method of phage display developed by George P. Smith. In this context, antibodies or antibody fragments are typically expressed on the surface of filamentous phages (Smith, G. P., 1985, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface”, Science 228; 1315-1317).
- the DNA for an antibody fragment which codes the antigen-binding variable domain is then cloned in-frame before the gpIII gene.
- a fusion protein is formed therefrom, which is expressed on the virus surface without the phage losing its infectiousness.
- the aid of the phage display technique it is possible to generate large antibody libraries, each phage expressing a different antibody fragment on the surface. To this extent, the underlying RNA is therefore also available.
- a particular antibody fragment can be isolated from such a library by a method called “phage panning”. For this, the corresponding antigen is bound to a matrix and incubated with the phage suspension. The phages which present an appropriate antibody fragment interact with the fixed antigen, while the other phages are removed by a washing step. The phages isolated are multiplied, for example, in E. coli . The DNA is isolated accordingly and the gene sequence is determined. Expression constructs which contain the cDNA coding for the entire antibody or antibody fragments can then be developed with the aid of genetic engineering methods. An RNA (mRNA) which codes for the antibody can be generated from this cDNA by means of in vitro transcription (see below). Nucleic acids or, respectively, mRNA coding for monoclonal antibodies which are entirely of human origin are obtained in this manner.
- mRNA RNA
- RNA according to the invention which codes for antibodies as described above is also suitable for coding so-called intrabodies or for rendering possible an expression of intrabodies.
- Intrabodies in the context of the present invention can include any of the antibodies or antibody fragments described here.
- Intrabodies are intracellularly expressed antibodies, i.e. antibodies which are coded by nucleic acids localized in the cell and are expressed there.
- an RNA according to the invention which encodes the antibodies or antibody fragments as described above is introduced into cells beforehand, for example with the aid of transfection methods according to the invention or other suitable transfection methods (see below) and, where appropriate, thereafter transplanted into an organism or being or introduced directly as nucleic acids into an organism or being.
- the RNA according to the invention (or a corresponding nucleic acid) can be introduced in the naked form or as a complex with suitable carriers (e.g. liposomes) into the organism or the being or can have such modifications (of the RNA) which, where appropriate together with one of the transfection methods mentioned, lead to a better cell uptake, e.g. any of the RNA modifications mentioned here, such as, for example, lipid modifications of the RNA according to the invention.
- suitable carriers e.g. liposomes
- An organism or a being in connection with the present invention typically means mammals, i.e. animals, including cattle, pig, dog, cat, donkey, monkey, rodents, e.g.
- Intrabodies can be localized and expressed at certain sites in the cell.
- intrabodies can be expressed in the cytoplasm, the formation of disulfide bridges usually being decreased under the reducing conditions of the cytoplasm. It has been possible to demonstrate, however, that cytoplasmic intrabodies, and in particular scFv fragments, can be functional. Cytoplasmic expression by the RNA according to the invention opens up the possibility of also inhibiting cytoplasmic proteins. This is not possible with treatment with monoclonal antibodies from the prior art, since these antibodies can reach only secreted and membrane-located (extracellular) proteins due to their secretion from the cell after intracellular expression (which represents the major difference between antibodies and intrabodies).
- intrabodies By expression of a signal peptide, intrabodies can be transported into the endoplasmic reticulum (ER) and then secreted as with regular antibodies. In this case, typically only secreted or membrane-located proteins are a target for these antibodies.
- ER retention signal for example KDEL (SEQ ID NO: 18)
- the intrabody can remain in the ER (where it may bind to specific antigen located in the ER) and prevent secretion of its antigen and/or transport of its antigen or its target molecule to the plasma membrane.
- intrabodies can include full length antibodies or antibody fragments as described above.
- Intrabodies in the context of the present invention preferably initially include full length antibodies, which are retained in the cell and not secreted from the cell (by whatever technique, e.g. retention signal sequences etc.). However, if e.g. intracellular expression of full length antibodies is technically not possible or not appropriate, antibody fragments as described above can also be employed as intrabodies.
- Antibodies which are coded by the RNA according to the invention furthermore also include those antibodies or antibody fragments which have a sequence identity to one of the antibodies or antibody fragments described here of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the coding nucleic acid or amino acid sequence of an antibody or antibody fragment as described here.
- such antibodies or antibody fragments have the same biological function as or, respectively, the specific activity of the corresponding full length antibody, e.g. the specific binding of particular antigens or nucleic acids. Accordingly, it is preferred, if the hypervariable region(s) are conserved or are modified by merely conservative mutations.
- the biological function of antibodies described here which are coded by the RNA according to the invention includes e.g. neutralization of antigens, complement activation or opsonization.
- the antibody can bind to an antigen and thereby neutralize this.
- the antibody is conventionally blocked by the binding of the antigen, and can therefore display its action only against one antigen, or two antigens in the case of bispecific antibodies.
- scFv antibody fragments are suitable above all for this (neutralization) function of an antibody, since they do not include the functions of the constant domains of an antibody.
- complement activation the complex system of complement proteins which are dependent upon the Fc part of the antibody can be activated via binding of antibodies.
- End products of the complement cascade typically lead to lysis of cells and to the creation of a phlogistic (inflammatory) milieu.
- pathogens or foreign particles are rendered accessible to phagocytes by binding by an antibody via the constant domains of the antibody.
- the opsonized cells which are recognized as foreign, can be lysed via an antibody-dependent, cell-mediated cytotoxicity (ADCC).
- ADCC antibody-dependent, cell-mediated cytotoxicity
- NK cells in particular can perform lytic functions in this manner via activation of their Fc receptors.
- the term “identity” means that the sequences are compared with one another as follows. In order to determine the percentage identity of two nucleic acid sequences, the sequences can first be aligned with respect to one another in order subsequently to make a comparison of these sequences possible. For this e.g. gaps can be inserted into the sequence of the first nucleic acid sequence and the nucleotides can be compared with the corresponding position of the second nucleic acid sequence. If a position in the first nucleic acid sequence is occupied by the same nucleotide as is the case at a position in the second sequence, the two sequences are identical at this position.
- the percentage identity between two sequences is a function of the number of identical positions divided by the number of all the positions compared in the sequences investigated. If e.g. a specific sequence identity is assumed for a particular nucleic acid (e.g. a nucleic acid which codes for a protein, as described above) in comparison with a reference nucleic acid (e.g. a nucleic acid from the prior art) of defined length, this percentage identity is stated relatively with reference to this reference nucleic acid.
- this nucleic acid can be a nucleic acid 50 nucleotides long which is completely identical to a 50 nucleotides long section of the reference nucleic acid. Indeed, it can also be a nucleic acid 100 nucleotides long which has 50% identity, i.e. in this case 50% identical nucleic acids, with the reference nucleic acid over the entire length thereof. Alternatively, this nucleic acid can be a nucleic acid 200 nucleotides long which is completely identical in a 100 nucleotides long section of the nucleic acid to the reference nucleic acid 100 nucleotides long.
- nucleic acids of course equally meet these criteria.
- identity statements described for nucleic acids apply equally to the antibodies and antibody fragments coded by the RNA according to the invention. The same holds for the determination of the sequence identity between two (poly)peptides, based on the comparison/alignment of the respective amino acid sequences.
- the percentage identity of two sequences can be determined with the aid of a mathematical algorithm.
- a preferred, but not limiting, example of a mathematical algorithm which can be used for comparison of two sequences is the algorithm of Karlin et al. (1993), PNAS USA, 90:5873-5877. Such an algorithm is integrated in the NBLAST program, with which sequences which have a desired identity to the sequences of the present invention can be identified.
- the “Gapped BLAST” program can be used, as is described in Altschul et al. (1997), Nucleic Acids Res, 25:3389-3402. If BLAST and Gapped BLAST programs are used, the preset parameters of the particular program (e.g.
- NBLAST NBLAST
- the sequences can be aligned further using version 9 of GAP (global alignment program) of the “Genetic Computing Group” using the preset (BLOSUM62) matrix (values ⁇ 4 to +11) with a gap open penalty of ⁇ 12 (for the first zero of a gap) and a gap extension penalty of ⁇ 4 (for each additional successive zero in the gap).
- GAP global alignment program
- BLOSUM62 preset
- the percentage identity is calculated by expressing the number of agreements as a percentage content of the nucleic acids in the sequence claimed.
- the methods described for determination of the percentage identity of two nucleic acid sequences can also be used correspondingly, if necessary, on the coded amino acid sequences, e.g. the antibodies described here.
- the antibody-coding RNA according to the invention contains according regions which codes for one of the antibodies listed in Table 3.
- the antibody encoding RNA may be used to treat (or, may be used to provide a pharmaceutical composition to treat) one of the diseases, disorders, pathologies listed in the right-hand column of Table 3.
- the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 2 and the light chains according to SEQ ID NO: 4. According to an even more preferred embodiment, the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 5 or SEQ ID NO: 51, respectively.
- the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 7 and the light chains according to SEQ ID NO: 9.
- the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 10 or SEQ ID NO: 52, respectively.
- the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 12 and the light chains according to SEQ ID NO: 14. According to an even more preferred embodiment, the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 15 or SEQ ID NO: 53, respectively.
- Antibodies which are coded by the RNA according to the invention can furthermore also encode such antibodies which have a sequence identity to one of the coding sequences of the antibodies described here, e.g. as described by Table 3 or by SEQ ID NO: 5 (51), 10 (52) or 15 (53), of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the nucleic acid sequence or amino acid sequence of an antibody as described here, e.g. as described by Table 3 or by SEQ ID NO: 5 (51), 10 (52) or 15 (53).
- Such antibodies which are coded by the RNA according to the invention likewise include antibodies according to SEQ ID NO: 5 (51), 10 (52) or 15 (53) or according to Table 3 which contain or have, in one of the heavy chains described here according to SEQ ID NO: 2, 7 or 12 and/or in one of the light chains described here according to SEQ ID NO: 4, 9 or 14, a nucleic acid or amino acid sequence identity of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the coding sequence for the particular light and/or heavy chain, with an otherwise unchanged coding antibody sequence of SEQ ID NO: 5 (51), 10 (52) or 15 (53) or e.g antibodies of Table 3.
- RNA in particular mRNA
- angiogenesis inhibitors based on antibodies, for example bevacizumab (monoclonal immunoglobulin Gi antibody which binds to the vascular growth factor VEGF (vascular endothelial growth factor); or trastuzumab (Herceptin), an indirect inhibitor which inhibits the action of tumour proteins on receptors, or for example rituximab or cetuximab (directed against the epidermal growth factor receptor (EGFR)), based on RNA
- the inventive RNA contains at least one coding region which codes for at least one of these antibodies.
- the antibody-coding RNA according to the invention typically additionally has at least one of the following modifications, which are preferably suitable for increasing the stability of the coding RNA, improving the expression of the antibody thereby coded, increasing the cell permeability, rendering possible localization of the antibody on or in certain cell compartments etc.
- modifications of the RNA according to the invention described here modified RNA
- modify RNA can be combined with one another in a suitable manner, such modifications which do not interfere with one another or adversely influence the stability or cell permeability of the antibody-coding, modified RNA according to the invention or the expression of the antibody thereby coded preferably being combined with one another.
- the nomenclature “modified” is equated with the content of “optionally modified”.
- Modifications of the RNA according to the invention described here can include, for example, modifications of the nucleotides of the RNA.
- An RNA (modified RNA) according to the invention can thus include, for example, backbone modifications, sugar modifications or base modifications.
- the antibody-coding RNA according to the invention typically first contains nucleotides which can be chosen from all naturally occurring nucleotides and analogues thereof (modified nucleotides), such as e.g. ribonucleotides and/or deoxyribonucleotides.
- Nucleotides in the context of the present invention therefore include, without being limited thereto, for example purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and as modified nucleotides analogues or derivatives of purines and pyrimidines, such as e.g.
- an antibody-coding RNA according to the invention can contain RNA backbone modifications.
- a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are modified chemically.
- backbone modifications typically include, without being limited thereto, modifications from the group consisting of methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g. cytidine 5′-O-(1-thiophosphate)), boranophosphates, positively charged guanidinium groups etc., which means by replacing the phosphodiester linkage by other anionic, cationic or neutral groups.
- An antibody-coding RNA according to the invention can likewise also contain sugar modifications.
- a sugar modification in connection with the present invention is a chemical modification of the sugar of the nucleotides it contains and typically includes, without being limited thereto, sugar modifications chosen from the group consisting of 2′-deoxy-T-fluoro-oligoribonucleotide (2′-fluoro-2′-deoxycytidine 5′-triphosphate, 2′-fluoro-2′-deoxyuridine 5′-triphosphate), 2′-deoxy-2′-deamine-oligoribonucleotide (2′-amino-2′-deoxycytidine 5′-triphosphate, 2′-amino-2′-deoxyuridine 5′-triphosphate), 2′-O-alkyloligoribonucleotide, 2′-deoxy-T-C-alkyloligoribonucleotide (2′-O-methylcytidine 5′-triphosphate, 2′-methyluridine 5′-triphosphat
- the modified RNA sequence according to the invention contains no sugar modifications or backbone modifications if e.g. an in vitro transcription is necessary.
- the reason for this preferred exclusion lies in the problem that certain backbone modifications and sugar modifications of RNA sequences on the one hand can prevent or at least greatly reduce in vitro transcription thereof.
- an in vitro transcription of eGFP carried out by way of example functions, for example, only with the sugar modifications 2′-amino-2′-deoxyuridine 5′-phosphate, 2′-fluoro-2′-deoxyuridine 5′-phosphate and 2′-azido-T-deoxyuridine 5′-phosphate.
- the translation of the protein, i.e. the protein expression, in vitro or in vivo typically can be reduced considerably by backbone modifications and, independently thereof, by sugar modifications of RNA sequences. It was possible to demonstrate this, for example, for eGFP in connection with the backbone modifications and sugar modifications selected above.
- an antibody-coding RNA according to the invention can likewise also contain modifications of the bases of the nucleotides it contains (base modifications).
- the antibody-coding RNA according to the invention can be modified such that only one or several of the nucleotides of the modified RNA are exchanged for nucleotides having base modifications, which are preferably suitable for increasing the expression of the antibody coded by the RNA significantly compared with the non-modified, i.e. native RNA sequence.
- significant means an increase in the expression of the antibody on the basis of the modified RNA sequence compared with the native RNA sequence by at least 20%, preferably at least 30%, 40%, 50% or 60%, even more preferably by at least 70%, 80%, 90% or even 100% and most preferably by at least 150%, 200% or even 300%.
- a modified nucleotide which contains a base modification is called a base-modified nucleotide and, without being limited thereto, is preferably chosen from the group consisting of: 2-amino-6-chloropurine riboside 5′-triphosphate, 2-aminoadenosine 5′-triphosphate, 2-thiocytidine 5′-triphosphate, 2-thiouridine 5′-triphosphate, 4-thiouridine 5′-triphosphate, 5-aminoallylcytidine 5′-triphosphate, 5-aminoallyluridine 5′-triphosphate, 5-bromocytidine 5′-triphosphate, 5-bromouridine 5′-triphosphate, 5-iodocytidine 5′-triphosphate, 5-iodouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate, 5-methyluridine 5′-triphosphate, 6-azacytidine 5′-triphosphate, 6-azauridine 5′-triphosphate,
- the inventors attribute an increase in the expression of the antibody coded by the (base)-modified RNA according to the invention to, inter alia, the improvement in the stabilizing of secondary structures and, where appropriate, to the “more rigid” structure formed in the RNA and the increased base stacking.
- pseudouridine 5′-triphosphate it is known of pseudouridine 5′-triphosphate that this occurs naturally in structural RNAs (tRNA, rRNA and snRNA) in eukaryotes as well as in prokaryotes.
- pseudouridine is necessary in rRNA for stabilizing secondary structures.
- RNA has increased, and it has been possible to demonstrate, surprisingly, that the translation depends on the presence of pseudouridine in the tRNA and rRNA, the interaction between tRNA and mRNA presumably being intensified in this context.
- the conversion of uridine into pseudouridine takes place posttranscriptionally by pseudouridine synthase.
- a posttranscriptional modification of RNA likewise takes place in the case of 5-methylcytidine 5′-triphosphate, and is catalysed by methyltransferases.
- a further increase in the content of pseudouridine and the base modification of other nucleotides is assumed to lead to similar effects, which, in contrast to the naturally occurring increased contents of pseudouridine in the sequence, can be carried out in a targeted manner and with a considerably wider variability.
- a similar mechanism to that for pseudouridine 5′-triphosphate is therefore assumed, i.e. an improved stabilizing of secondary structures, and on the basis of this an improved translation efficiency.
- a positive effect on the translation is presumed, independently of the stabilizing of secondary structures and a “more rigid” structure of the RNA. Further causes of the increase in expression are also to be found, possibly, in the lower degradation rate of the RNA sequences by RNAses in vitro or in vivo.
- RNA modifications of the antibody-coding RNA according to the invention which are described above can be introduced into the RNA with the aid of methods known to a person skilled in the art. Possible methods for this are, for example, synthesis methods using (automatic or semi-automatic) oligonucleotide synthesis apparatuses, biochemical methods, such as e.g. in vitro transcription methods, etc.
- synthesis methods using (automatic or semi-automatic) oligonucleotide synthesis apparatuses and also in vitro transcription methods can be employed.
- biochemical methods are preferred, such as, for example, in vitro transcription methods, preferably an in vitro transcription method as described here, optionally using the modified RNA according to the invention.
- Modifications with nucleotides as described here in an antibody-coding RNA according to the invention can occur on at least one (modifiable) nucleotide of the RNA sequence according to the invention, preferably on at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 (modifiable) nucleotides, more preferably on at least 10-20 (modifiable) nucleotides, even more preferably on at least 10-100 (modifiable) nucleotides and most preferably on at least 10-200, 10 to 1,000 or 10 to 10,000 or more (modifiable), e.g. all, nucleotides.
- modifications in an antibody-coding RNA according to the invention can occur on at least one (modifiable) nucleotide of the RNA sequence according to the invention, preferably on at least 10% of all the (modifiable) nucleotides, more preferably on at least 25% of all the (modifiable) nucleotides, even more preferably on at least 50% of all the (modifiable) nucleotides, even more preferably on at least 75% of all the (modifiable) nucleotides and most preferably on 100% of the (modifiable) nucleotides contained in the RNA sequence according to the invention.
- a “modifiable nucleotide” is any (preferably naturally occurring (native) and therefore non-modified) nucleotide which is to be exchanged for a nucleotide modified as described here.
- all the nucleotides of the RNA sequence can be modified, or only certain selected nucleotides of the RNA sequence. If all the nucleotides of the RNA sequence are to be modified, 100% of the “modifiable nucleotides” of the RNA sequence are all the nucleotides of the RNA sequence used.
- the selected nucleotides are, for example, adenosine, cytidine, guanosine or uridine.
- an adenosine of the native sequence can be exchanged for a modified adenosine, a cytidine for a modified cytidine, a uridine for a modified uridine and a guanosine for a modified guanosine.
- 100% of the “modifiable nucleotides” of the RNA sequence are 100% of the adenosines, cytidines, guanosines and/or uridines in the RNA sequence used.
- the antibody-coding RNA according to the invention can contain, for example, a GC content which has been modified compared with the native, i.e. non-modified (precursor) RNA sequence.
- the G/C content for the coding region of the RNA according to the invention is greater than the G/C content for the coding region of the native RNA sequence, the coded amino acid sequence of the antibody or antibody fragment being unchanged compared with the wild-type, i.e. the antibody or antibody fragment amino acid sequence coded by the native RNA sequence.
- the composition and the sequence of the various nucleotides plays a major role.
- sequences having an increased G (guanine)/C (cytosine) content are more stable than sequences having an increased A (adenine)/U (uracil) content.
- the codons are therefore varied compared with the wild-type RNA, while retaining the translated amino acid sequence, such that they include an increased amount of G/C nucleotides. Since several codons code for one and the same amino acid (degeneration of the genetic code), the most favourable codons for the stability can be determined (alternative codon usage).
- codons which contain A and/or U nucleotides are modified by substitution of other codons which encode the same amino acids but contain no A and/or U. Examples are:
- substitutions listed above can of course be used individually or also in all possible combinations to increase the G/C content of the antibody-coding RNA according to the invention compared with the native RNA sequence (and nucleic acid sequence, respectively).
- all the codons for Thr occurring in the native RNA sequence can be modified to ACC (or ACG).
- combinations of the above substitution possibilities are used, e.g.: substitution of all codons coding for Thr in the native RNA sequence by ACC (or ACG) and substitution of all codons originally coding for Ser by UCC (or UCG or AGC);
- the G/C content of the coding region of the antibody-coding RNA according to the invention is increased compared with the G/C content of the coding region of the native RNA such that at least 5%, at least 10%, at least 15%, at least 20%, at least 25% or more preferably at least 30%, at least 35%, at least 40%, at least 45%, at least 50% or at least 55%, even more preferably at least 60%, at least 65%, at least 70% or at least 75% and most preferably at least 80%, at least 85%, at least 90%, at least 95% or at least 100% of the possible modifiable codons of the coding region of the native RNA (and nucleic acid, respectively) are modified.
- a second alternative of the antibody-coding RNA according to the invention with modifications is based on the knowledge that the translation efficiency of the RNA is also determined by a different frequency in the occurrence of tRNAs in cells. Thus, if so-called “rare” codons are present in an RNA sequence to an increased extent, the corresponding RNA is translated to a significantly poorer degree than in the case where codons which code for relatively “frequent” tRNAs are present.
- the coding region of the RNA according to the invention is therefore modified compared with the coding region of the native RNA such that at least one codon of the native RNA which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is relatively frequent in the cell and which carries the same amino acid as the relatively rare tRNA.
- the sequence of the antibody-coding RNA according to the invention is modified such that codons for which frequently occurring tRNAs are available are inserted. Which tRNAs occur relatively frequently in the cell and which, in contrast, are relatively rare is known to a person skilled in the art; cf. e.g. Akashi, Curr. Opin. Genet. Dev. 2001, 11(6): 660-666.
- RNA sequence according to the invention which encodes an antibody (for example for a pharmaceutical composition according to the invention).
- RNA DSE destabilizing sequence elements
- the antibody-coding RNA it is of course also preferable, where appropriate, to eliminate from the RNA DSEs present in the untranslated regions (3′ and/or 5′ UTR).
- Such destabilizing sequences are, for example, AU-rich sequences (“AURES”), which occur in 3′ UTR sections of numerous unstable RNAs (Caput et al., Proc. Natl. Acad. Sci. USA 1986, 83: 1670 to 1674).
- the antibody-coding RNA according to the invention is therefore preferably modified compared with the native RNA such that this no longer contains such destabilizing sequences.
- sequence motifs which are recognized by possible endonucleases, for example the sequence GAACAAG, which is contained in the 3′ UTR segment of the gene which codes for the transferrin receptor (Binder et al., EMBO J. 1994, 13: 1969 to 1980).
- sequence motifs are also preferably eliminated in the antibody-coding RNA according to the invention.
- RNAs i.e. substitution of codons in the antibody-coding RNA according to the invention.
- the total antibody-coding RNA according to the invention can be synthesized chemically using standard techniques such as are familiar to a person skilled in the art.
- base substitutions are preferably introduced using a DNA template for the preparation of the antibody-coding RNA according to the invention with the aid of techniques of the usual targeted mutagenesis (see, for example, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 3rd ed., Cold Spring Harbor, N.Y., 2001).
- a corresponding DNA molecule is therefore transcribed in vitro (see below).
- This DNA template optionally has a suitable promoter, for example a T3, T7 or SP6 promoter, for the in vitro transcription, which is followed by the desired nucleotide sequence for the antibody-coding RNA according to the invention to be prepared and a termination signal for the in vitro transcription.
- a suitable promoter for example a T3, T7 or SP6 promoter
- the DNA molecule which forms the template of the antibody-coding RNA construct to be prepared can be prepared by fermentative proliferation and subsequent isolation as part of a plasmid which can be replicated in bacteria.
- Plasmids which may be mentioned as suitable for this are, for example, the plasmids pT7 Ts (GenBank accession number U26404; Lai et al., Development 1995, 121: 2349 to 2360), pGEM® series, for example pGEM®-1 (GenBank accession number X65300; from Promega) and pSP64 (GenBank accession number X65327); cf. also Mezei and Storts, Purification of PCR Products, in: Griffin and Griffin (ed.), PCR Technology: Current Innovation, CRC Press, Boca Raton, Fla., 2001.
- RNA or DNA oligonucleotides which contain short single-stranded transitions at the cleavage sites formed, or genes prepared by chemical synthesis
- the desired nucleotide sequence can thus be cloned into a suitable plasmid by molecular biology methods with which a person skilled in the art is familiar (cf. Maniatis et al., (2001) supra).
- the RNA or DNA molecule is then cut out of the plasmid, in which it can be present in one or several copies, by digestion with restriction endonucleases.
- the antibody-coding (modified) RNA according to the invention described above can moreover have a 5′ cap structure (a modified guanosine nucleotide).
- a 5′ cap structure a modified guanosine nucleotide.
- cap structures which may be mentioned, without being restricted thereto, are m7G(5′)ppp (5′(A,G(5′)ppp(5′)A and G(5′)ppp(5′)G.
- the antibody-coding (modified) RNA according to the invention contains, especially if the RNA is in the form of mRNA, a poly-A tail on the 3′ terminus of typically about 10 to 200 adenosine nucleotides, preferably about 10 to 100 adenosine nucleotides, more preferably about 20 to 70 adenosine nucleotides or even more preferably about 20 to 60 adenosine nucleotides.
- the antibody-coding (modified) RNA according to the invention contains, especially if the RNA is in the form of mRNA, a poly-C tail on the 3′ terminus of typically about 10 to 200 cytosine nucleotides (SEQ ID NO: 54), preferably about 10 to 100 cytosine nucleotides (SEQ ID NO: 55), more preferably about 20 to 70 cytosine nucleotides (SEQ ID NO: 56) or even more preferably about 20 to 60 (SEQ ID NO: 57) or even 10 to 40 cytosine nucleotides (SEQ ID NO: 58).
- the poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
- the antibody-coding (modified) RNA according to the invention can additionally contain a nucleic acid section which codes a tag for purification.
- tags include, but without being limited thereto, e.g. a hexahistidine tag (SEQ ID NO: 59) (His tag, polyhistidine tag), a streptavidin tag (Strep tag), an SBP tag (streptavidin-binding tag) a GST (glutathione S transferase) tag etc.
- the antibody-coding (modified) RNA according to the invention can furthermore encode a tag for purification via an antibody epitope (antibody-binding tag), e.g. a Myc tag, an Swal 1 epitope, a FLAG tag, an HA tag etc., i.e. via recognition of the epitope via the (immobilized) antibody.
- the antibody-coding (modified) RNA according to the invention can therefore have an increased A/U content around the ribosome binding site, preferably an A/U content which is increased by 5 to 50%, more preferably one increased by 25 to 50% or more, compared with the native RNA.
- an IRES internal ribosomal entry site
- An IRES can thus function as the sole ribosome binding site, but it can also serve to provide an antibody-coding (modified) RNA according to the invention which codes for several antibodies or antibody fragments or for at least one antibody or antibody fragment which are to be translated by the ribosomes independently of one another (“multicistronic RNA”).
- Such an RNA can code, for example, a complete sequence of an antibody, the corresponding coding regions of the heavy and light chain being linked (functionally) with one another by an IRES sequence.
- the heavy and light chain to be encoded by the inventive RNA may also be located in one single “cistron”.
- the IRES sequences described are employed in particular for (virtually) simultaneous and uniform expression of the light and the heavy chains of the antibody coded by the RNA according to the invention.
- Examples of IRES sequences which can be used according to the invention are those from picornaviruses (e.g.
- FMDV pestiviruses
- CFFV pestiviruses
- PV polioviruses
- ECMV encephalomyocarditis viruses
- FMDV foot and mouth disease viruses
- HCV hepatitis C viruses
- CSFV classical swine fever viruses
- MLV murine leukoma virus
- SIV simian immunodeficiency viruses
- CrPV cricket paralysis viruses
- the antibody-coding (modified) RNA according to the invention has, in the 5′ and/or 3′ untranslated regions, stabilizing sequences which are capable of increasing the half-life of the RNA in the cytosol.
- stabilizing sequences can have a 100% sequence homology to naturally occurring sequences which occur in viruses, bacteria and eukaryotes, but can also be partly or completely synthetic in nature.
- the untranslated sequences (UTR) of the ⁇ -globin gene for example from Homo sapiens or Xenopus laevis , may be mentioned as an example of stabilizing sequences which can be used in the present invention.
- stabilizing sequence has the general formula (C/U)CCAN x CCC(U/A)Py x UC(C/U)CC (SEQ ID NO: 17), which is contained in the 3′ UTR of the very stable RNA which codes for ⁇ -globin, ⁇ -(I)-collagen, 15-lipoxygenase or for tyrosine hydroxylase (cf. Holcik et al., Proc. Natl. Acad. Sci. USA 1997, 94: 2410 to 2414).
- Such stabilizing sequences can of course be used individually or in combination with one another and also in combination with other stabilizing sequences known to a person skilled in the art.
- the antibody-coding (modified) RNA according to the invention can encode a secretory signal peptide, in addition to the antibodies as described here.
- signal peptides are (signal) sequences which conventionally comprise a length of from 15 to 30 amino acids and are preferably localized on the N-terminus of the coded antibody.
- Signal peptides typically render possible transport of a protein or peptide fused therewith (here e.g. an antibody) to or into a defined cell compartment, preferably the cell surface, the endoplasmic reticulum or the endosomal-lysosomal compartment. Examples of signal sequences which can be used according to the invention are e.g.
- signal sequences of conventional and non-conventional MHC molecules cytokines, immunoglobulins, the invariant chain, Lamp1, tapasin, Erp57, calreticulin and calnexin, and all further membrane-located, endosomally-lysosomally or endoplasmic reticulum-associated proteins.
- the signal peptide of the human MHC class I molecule HLA-A*0201 is preferably used.
- Sequences which render possible transport of a protein or peptide fused therewith to or into a defined cell compartment, preferably the cell surface, the nucleus, the nucleus region, the plasma membrane, the cytosol, the endoplasmic reticulum, the organelles, the mitochondria, the Golgi apparatus or the endosomal-lysosomal compartment, also include, without being limited thereto, so-called routing signals, sorting signals, retention signals or salvage signals and membrane topology-stop transfer signals (cf. Pugsley, A. P., Protein Targeting, Academic Press, Inc. (1989)) at the level of the RNA according to the invention.
- routing signals sorting signals
- retention signals or salvage signals cf. Pugsley, A. P., Protein Targeting, Academic Press, Inc. (1989)
- localization sequences include nucleic acid sequences which encode e.g. signals, i.e. amino acid sequences, such as, for example, KDEL (SEQ ID NO: 18) (Munro, et al., Cell 48:899-907 (1987)) DDEL (SEQ ID NO: 19), DEEL (SEQ ID NO: 20), QEDL (SEQ ID NO: 21) and RDEL (SEQ ID NO: 22) (Hangejorden, et al., J. Biol. Chem. 266:6015 (1991)) for the endoplasmic reticulum; PKKKRKV (SEQ ID NO: 23) (Lanford, et al.
- KDEL SEQ ID NO: 18
- DDEL SEQ ID NO: 19
- DEEL SEQ ID NO: 20
- QEDL SEQ ID NO: 21
- RDEL SEQ ID NO: 22
- PQKKIKS SEQ ID NO: 24
- QPKKP SEQ ID NO: 25
- RKKR SEQ ID NO:26
- RKKRRQRRRAHQ SEQ ID NO: 27
- RQARRNRRRRWRERQR SEQ ID NO: 28
- an antibody to the plasma membrane, or to certain various sub-cell compartments, such as the nucleus region, the organelles, the mitochondria and the Golgi apparatus.
- Corresponding amino acid sequences which are coded by a corresponding codon sequence of the RNA according to the invention are given below.
- the sequence MLFNLRXXLNNAAFRHGHNFMVRNFRCGQPLX (SEQ ID NO: 31) can be used to lead the antibody to the mitochondrial matrix (Pugsley, supra). See Tang, et al., J. Bio. Chem.
- GCVCSSNP SEQ ID NO: 32
- GQTVTTPL SEQ ID NO: 33
- GQELSQHE SEQ ID NO: 34
- GNSPSYNP SEQ ID NO: 35
- GVSGSKGQ SEQ ID NO: 36
- GQTITTPL SEQ ID NO: 37
- GQTLTTPL SEQ ID NO: 38
- GQIFSRSA SEQ ID NO: 39
- GQIHGLSP SEQ ID NO: 40
- GARASVLS SEQ ID NO: 41
- GCTLSAEE SEQ ID NO: 42
- the modifications described here can be introduced into the antibody-coding RNA sequence according to the invention in a suitable manner by a person skilled in the art.
- the optimum modified RNA according to the invention can be determined by methods known to the person skilled in the art, e.g. the G/C content can be adapted manually and/or by means of an automated method as disclosed in WO 02/098443.
- the RNA sequences can be adapted with the various additional optimization aims described here: On the one hand, the adaptation can be carried out with the highest possible G/C content, and on the other hand taking into the best possible account the frequency of the tRNAs according to codon usage.
- RNA (or DNA) sequence is carried out in order to generate the corresponding amino acid sequence.
- a virtual reverse translation is carried out, which on the basis of the degenerated genetic code provides selection possibilities for the corresponding codons.
- corresponding selection lists and optimization algorithms are used for selection of the suitable codons.
- the algorithm is typically implemented on a computer with the aid of suitable software.
- the optimized RNA sequence is established in this way and can be displayed, for example, with the aid of an appropriate display device and compared with the original (wild-type) sequence. The same also applies to the frequency of the individual nucleotides.
- RNA stabilized in accordance with natural sequence motifs are furthermore read in.
- a secondary structure analysis which can analyse stabilizing and destabilizing properties or, respectively, regions of the RNA with the aid of structure calculations can likewise be envisaged.
- RNA (mRNA) according to the invention includes, for example, complexing (or binding) of the RNA according to the invention with a (poly)cationic polymer, polyplexes, protein(s), in particular polycationic protein(s), or peptide(s).
- a RNA (mRNA) according to the invention is complexed or condensed with at least one cationic or polycationic agent.
- such a cationic or polycationic agent is an agent which is chosen from the group consisting of protamine, poly-L-lysine, poly-L-arginine, nucleolin, spermin and histones, nucleolin or derivatives thereof.
- protamine as a polycationic, nucleic acid-binding protein is particularly preferred.
- This procedure for stabilizing RNA is described, for example, in EP-A-1083232, the disclosure content of which in this respect is included in its full scope in the present invention.
- the antibody-coding (modified) RNA according to the invention can contain a lipid modification.
- a RNA modified with a lipid typically comprises an antibody-coding RNA, as defined here, according to the invention, at least one linker covalently linked with this RNA and at least one lipid covalently linked with the particular linker.
- the (modified) RNA according to the invention modified with a lipid comprises (at least) one (modified) RNA, as defined here, according to the invention and at least one (bifunctional) lipid covalently linked with this RNA.
- the (modified) RNA according to the invention modified with a lipid comprises a (modified) RNA, as defined here, according to the invention, at least one linker covalently linked with this RNA and at least one lipid linked covalently with the particular linker and at least one (bifunctional) lipid covalently linked (without a linker) with this (modified) RNA according to the invention.
- the lipid employed for lipid modification of the antibody-coding (modified) RNA according to the invention is typically a lipid or a lipophilic residue, which is preferably biologically active per se.
- lipids preferably include natural substances, or compounds, such as e.g. vitamins, e.g. ⁇ -tocopherol (vitamin E), including RRR- ⁇ -tocopherol (formerly D- ⁇ -tocopherol), L- ⁇ -tocopherol, the racemate D,L- ⁇ -tocopherol, vitamin E succinate (VES) or vitamin A and derivatives thereof, e.g. retinic acid, retinol, vitamin D and derivatives thereof, e.g.
- vitamin D and ergosterol precursors thereof vitamin E and derivatives thereof, vitamin K and derivatives thereof, e.g. vitamin K and related quinone or phytol compounds, or steroids, such as bile acids, for example cholic acid, deoxycholic acid, dehydrocholic acid, cortisone, digoxygenin, testosterone, cholesterol or thiocholesterol.
- bile acids for example cholic acid, deoxycholic acid, dehydrocholic acid, cortisone, digoxygenin, testosterone, cholesterol or thiocholesterol.
- Further lipids or lipophilic residues in the context of the present invention include, without being limited thereto, polyalkylene glycols, (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533), aliphatic groups, such as e.g.
- C 1 -C 20 -alkanes such as, for example, dodecanediol, hexadecanol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 111; Kabanov et al., FEBS Lett., 1990, 259, 327; Svinarchuk et al., Biochimie, 1993, 75, 49), phospholipids, such as e.g.
- phosphatidylglycerol diacylphosphatidylglycerol, phosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, dihexadecyl-racglycerol, sphingolipids, cerebrosides, gangliosides, or triethylammonium 1,2-di-O-hexadecylrac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651; Shea et al., Nucl.
- polyamines or polyalkylene glycols such as e.g. polyethylene glycol (PEG) (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969), hexaethylene glycol (HEG), palmitin, or palmityl residues (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229), octadecylamines, or hexylaminocarbonyloxycholesterol residues (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923), and waxes, terpenes, alicyclic hydrocarbons, saturated or mono- or polyunsaturated fatty acid residues etc.
- PEG polyethylene glycol
- HEG hexaethylene glycol
- HEG hexaethylene glycol
- palmitin or palmityl residues
- palmityl residues oc
- the linking between the lipid and the antibody-coding (modified) RNA according to the invention can in principle take place on any nucleotide, on the base or the sugar residue of any nucleotide, on the 3′ and/or 5′ end, and/or on the phosphate backbone of the antibody-coding (modified) RNA according to the invention.
- a terminal lipid modification of the (modified) RNA according to the invention on the 3′ and/or 5′ end thereof is particularly preferred.
- a terminal modification has several advantages over modifications within the sequence. On the one hand, modifications within the sequence can influence the hybridization properties, which may have an adverse effect in the case of sterically demanding residues.
- the linking takes place between the antibody-coding (modified) RNA according to the invention and at least one lipid via a linker (linked covalently with the (modified) RNA).
- Linkers in the context of the present invention typically contain at least two and optionally 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30 or more reactive groups, chosen from e.g. a hydroxyl group, an amino group, an alkoxy group etc.
- One reactive group preferably serves to bond the antibody-coding (modified) RNA according to the invention described here. This reactive group can be in a protected form, e.g.
- an antibody-coding (modified) RNA can therefore bond at least one lipid via the covalently bonded linker, e.g.
- the bonded lipids can be bonded separately from one another at various positions of the antibody-coding (modified) RNA according to the invention, but can also be in the form of a complex at one or more positions of the (modified) RNA.
- An additional reactive group of the linker can be used for direct or indirect (cleavable) bonding to a carrier material, e.g. a solid phase.
- Preferred linkers according to the present invention are e.g.
- glycerol or glycerol derivatives (C 3 anchor) or a 2-aminobutyl-1,3-propanediol derivative/matrix (C 7 anchor) are particularly preferably used as linkers.
- a glycerol derivative (C 3 anchor) as a linker is particularly preferred if the lipid modification can be introduced via an ether bond.
- the bond formed between the linker and the antibody-coding (modified) RNA according to the invention is preferably such that it is compatible with the conditions and chemicals of amidite chemistry, that is to say it is preferably neither acid-nor base-labile.
- bonds which are readily accessible synthetically and are not hydrolysed by the ammoniacal cleavage procedure of a nucleic acid synthesis process are preferred.
- Possible bonds are in principle all appropriately suitable bonds, preferably ester bonds, amide bonds, urethane bonds and ether bonds.
- the ether bond is particularly preferred in this context because of its relatively high biological stability to enzymatic hydrolysis.
- the linking of (at least one) (modified) RNA according to the invention takes place directly with at least one (bifunctional) lipid as described here, i.e. without using a linker as described here.
- the (bifunctional) lipid according to the invention preferably contains at least two reactive groups, or optionally 3, 4, 5, 6, 7, 8, 9, 10 or more reactive groups, a first reactive group serving for direct or indirect bonding of the lipid to a carrier material described here and at least one further reactive group serving for bonding of the (modified) RNA.
- an antibody-coding (modified) RNA according to the invention can therefore preferably bond at least one lipid (directly without a linker), e.g. 1, 2, 3, 4, 5, 5-10, 10-20, 20-30 or more lipid(s), particularly preferably at least 3-8 or more lipids per (modified) RNA.
- the bonded lipids can be bonded separately from one another at various positions of the antibody-coding (modified) RNA according to the invention, but can also be in the form of a complex at one or more positions of the (modified) RNA.
- at least one antibody-coding (modified) RNA e.g.
- RNAs can be bonded to a lipid as described above via reactive groups thereof.
- Lipids which can be used for this second embodiment particularly preferably include such (bifunctional) lipids which render possible a coupling (preferably on their termini or optionally intramolecularly), such as e.g. polyethylene glycol (PEG) and derivatives thereof, hexaethylene glycol (HEG) and derivatives thereof, alkanediols, aminoalkanes, thioalkanols etc.
- PEG polyethylene glycol
- HEG hexaethylene glycol
- alkanediols aminoalkanes
- thioalkanols thioalkanols etc.
- the bond between a (bifunctional) lipid and an antibody-coding (modified) RNA according to the invention as described above is preferably such as is described for the first preferred embodiment.
- the linking between the antibody-coding (modified) RNA according to the invention and at least one lipid as described here takes place via both of the abovementioned embodiments simultaneously.
- the antibody-coding (modified) RNA according to the invention can be linked at one position of the RNA with at least one lipid via a linker (analogously to the 1st embodiment) and at another position of the (modified) RNA directly with at least one lipid without using a linker (analogously to the 2nd embodiment).
- At least one lipid as described here can be linked covalently with the RNA at the 3′ end of the (modified) RNA via a linker, and a lipid as described here can be linked covalently with the RNA at the 5′ end of the (modified) RNA without a linker.
- at least one lipid as described here can be linked covalently with the (modified) RNA at the 5′ end of an antibody-coding (modified) RNA according to the invention via a linker, and a lipid as described here can be linked covalently with the (modified) RNA at the 3′ end of the (modified) RNA without a linker.
- Covalent linkings can likewise take place not only on the termini of the antibody-coding (modified) RNA according to the invention, but also intramolecularly, as described above, e.g. on the 3′ end and intramolecularly, on the 5′ end and intramolecularly, on the 3′ and 5′ end and intramolecularly, exclusively intramolecularly etc.
- the (modified) RNA according to the invention described here can be prepared by preparation processes known in the prior art, e.g. automatically or manually via known nucleic acid syntheses (see, for example, Maniatis et al. (2001) supra) or also via molecular biology methods, for example with subsequent purification, for example via chromatography methods.
- the antibody-coding (modified) RNA according to the invention can be used for the preparation of a pharmaceutical composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or optionally monogenetic diseases, e.g. in gene therapy.
- a pharmaceutical composition in the context of the present invention comprises an antibody-coding (modified) RNA as described here and optionally a pharmaceutically suitable carrier and/or further auxiliary substances and additives.
- the pharmaceutical composition employed according to the present invention typically comprises a safe and effective amount of a (modified) RNA as described here.
- safe and effective amount means an amount of the antibody-coding (modified) RNA according to the invention such as is sufficient to induce significantly, by expression of the coded antibody, a positive change of a state to be treated, e.g. a tumour disease or cancer disease, a cardiovascular disease or an infectious disease, as described in the following.
- a “safe and effective amount” is low enough to avoid serious side effects in the therapy of these diseases, that is to say to render possible a reasonable ratio of advantage and risk. Determination of these limits typically lies within the range of reasonable medical judgement.
- the concentration of the antibody-coding (modified) RNA according to the invention in such pharmaceutical compositions can therefore vary, for example, without being limited thereto, within a wide range of from e.g. 0.1 ng to 1,000 mg/ml.
- Such a “safe and effective amount” of an antibody-coding (modified) RNA according to the invention can vary in connection with the particular state to be treated and the age and the physical state of the patient to be treated, the severity of the state, the duration of the treatment, the nature of the concomitant therapy, of the particular pharmaceutically suitable carrier used and similar factors within the knowledge and experience of the treating doctor.
- the pharmaceutical composition described here can be employed for human and also for veterinary medicine purposes.
- the pharmaceutical composition according to the invention described here can optionally comprise a pharmaceutically suitable carrier (and/or vehicle).
- pharmaceutically suitable carrier (and/or vehicle) used here preferably includes one or more compatible solid or liquid carriers or vehicles, (e.g. fillers, or diluents or encapsulating compounds) which are suitable for administration to a person.
- compatible means that the constituents of the composition are capable of being mixed together with the antibody-coding (modified) RNA according to the invention and the auxiliary substance optionally contained in the composition, as such and with one another in a manner such that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the composition under usual condition of use, such as e.g. would reduce the pharmaceutical activity of the coded antibody or even suppress or impair expression of the coded antibody.
- Pharmaceutically suitable carrier must of course have a sufficiently high purity and a sufficiently low toxicity to render them suitable for administration to a person to be treated.
- compositions may be typically distinguished into solid or liquid carriers or vehicles, wherein a specific determination may depend on the viscosity of the respective carrier or vehicle to be used.
- solid carriers and vehicles typically include e.g., but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, and salts, if provided in solid form, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, or polyvinyl pyrrolidone, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars, such as, for example, lactose, glucose and sucrose; starches, such as, for example, corn starch or potato starch; or cellulose-based substances, e.g.
- cellulose and its derivatives such as, for example, sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; pulverized tragacanth; malt; gelatine; tallow; solid lubricants, such as, for example, stearic acid, magnesium stearate; calcium sulfate; wetting agents, such as, for example, sodium lauryl sulfate; colouring agents; flavouring agents; drug (active agent) carriers; tablet-forming agents; stabilizers; antioxidants; preservatives; etc.
- solid lubricants such as, for example, stearic acid, magnesium stearate; calcium sulfate; wetting agents, such as, for example, sodium lauryl sulfate; colouring agents; flavouring agents; drug (active agent) carriers; tablet-forming agents; stabilizers; antioxidants; preservatives; etc.
- Liquid carriers or vehicles typically include, but are not limited to, e.g., water; pyrogen-free water; solutions of ion exchangers, alumina, aluminum stearate, lecithin, or serum proteins, such as human serum albumin; alginic acid; isotonic saline solutions or phosphate-buffered solutions, Ringer's solution, isotonic sodium chloride solution, etc. or salts or electrolytes, if provided in solubilized form, such as protamine sulfate, phosphates, e.g.
- liquid carriers or vehicles may also contain or comprise a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents, or commonly used surfactants or emulsifiers, such as Tween®, Spans and other emulsifying agents or bioavailability enhancers, etc., if provided in a liquid form.
- a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents, or commonly used surfactants or emulsifiers, such as Tween®, Spans and other emulsifying agents or bioavailability enhancers, etc.
- a pharmaceutically suitable carrier as described above is determined in particular by the mode in which the pharmaceutical composition according to the invention is administered.
- the pharmaceutical composition according to the invention can be administered, for example, systemically.
- Administration routes include e.g. transdermal, oral, parenteral, including subcutaneous or intravenous injections, topical and/or intranasal routes.
- the suitable amount of the pharmaceutical composition according to the invention which is to be used can be determined by routine experiments using animal models. Such models include, but without being limited thereto, models of the rabbit, sheep, mouse, rat, dog and non-human primate models.
- Preferred unit dose forms for injection include sterile solutions of water, physiological saline solution or mixtures thereof. The pH of such solutions should be adjusted to about 7.4.
- Suitable carriers for injection include hydrogels, devices for controlled or delayed release, polylactic acid and collagen matrices.
- Pharmaceutically suitable carriers which can be used here include those which are suitable for use in lotions, creams, gels and the like. If the compound is to be administered perorally, tablets, capsules and the like are the preferred unit dose form.
- the pharmaceutically suitable carriers for the preparation of unit dose forms which can be used for oral administration are well-known in the prior art. Their choice will depend on secondary considerations, such as flavour, cost and storage stability, which are not critical for the purposes of the present invention and can be implemented without difficulties by a person skilled in the art.
- the pharmaceutical composition according to the invention can furthermore comprise an injection buffer, which preferably improves the transfection and also the translation of the antibody-coding RNA according to the invention in cells or an organism.
- the pharmaceutical composition according to the invention can comprise, for example, an aqueous injection buffer which contains, with respect to the total pharmaceutical composition, if this is in liquid form, a sodium salt, preferably at least 50 mM sodium salt, a calcium salt, preferably at least 0.01 mM calcium salt, and optionally a potassium salt, preferably at least 3 mM potassium salt.
- the sodium salts, calcium salts and optionally potassium salts contained in such an injection buffer are in the form of halides, e.g.
- the injection buffer can also contain organic anions of the abovementioned cations.
- such an injection buffer contains as salts sodium chloride (NaCl), calcium chloride (CaCl 2 ) and optionally potassium chloride (KCl), it also being possible for other anions to be present in addition to the chlorides.
- the injection buffer can be in the form of both hypertonic and isotonic or hypotonic injection buffers.
- the injection buffer is hypertonic, isotonic or hypotonic with respect to the particular reference medium, i.e.
- the injection buffer has either a higher, the same or a lower salt content compared with the particular reference medium, such concentrations of the abovementioned salts which do not lead to damage to the cells caused by osmosis or other concentration effects preferably being employed.
- Reference media are, for example, liquids which occur in “in vivo” methods, such as, for example, blood, lymph fluid, cytosol fluids or other fluids which occur in the body, or liquids or buffers conventionally employed in “in vitro” methods. Such liquids and buffers are known to a person skilled in the art.
- the injection buffer optionally contained in the pharmaceutical composition according to the invention can also contain further components, for example sugars (mono-, di-, tri- or polysaccharides), in particular glucose or mannitol. In a preferred embodiment, however, no sugars are present in the injection buffer used. It is also preferable for the injection buffer precisely to contain no non-charged components, such as, for example, sugars.
- the injection buffer typically contains exclusively metal cations, in particular from the group consisting of the alkali or alkaline earth metals, and anions, in particular the anions described above.
- the pH of the injection buffer used is preferably between 1 and 8.5, preferably between 3 and 5, more preferably between 5.5 and 7.5, in particular between 5.5 and 6.5.
- the injection buffer can also contain a buffer system which fixes the injection buffer at a buffered pH. This can be, for example, a phosphate buffer system, HEPES or Na 2 HPO 4 /NaH 2 PO 4 .
- the injection buffer used very particularly preferably contains none of the abovementioned buffer systems or contains no buffer system at all.
- the injection buffer optionally contained in the pharmaceutical composition according to the invention can contain, in addition to or as an alternative to the monovalent and divalent cations described, divalent cations, in particular from the group consisting of alkaline earth metals, such as, for example, magnesium (Mg 2+ ), or also iron (Fe 2+ ), and monovalent cations, in particular from the groups consisting of alkali metals, such as, for example, lithium (Lit).
- These monovalent cations are preferably in the form of their salts, e.g. in the form of halides, e.g. chlorides, iodides or bromides, or in the form of their hydroxides, carbonates, bicarbonates or sulfates.
- lithium salt LiCl, Lii, LiBr, Li 2 CO 3 , LiHCO 3 , Li 2 SO 4 for the magnesium salt MgCl 2 , MgI 2 , MgBr 2 , MgCO 3 , MgSO 4 , and Mg(OH) 2
- iron salt FeCl 2 , FeBr 2 , FeI 2 , FeF 2 , Fe 2 O 3 , FeCO 3 , FeSO 4 , Fe(OH) 2 All the combinations of di- and/or monovalent cations, as described above, are likewise included.
- Such injection buffers which contain only divalent, only monovalent or di- and monovalent cations can thus be used in the pharmaceutical composition according to the invention.
- Such injection buffers which contain only one type of di- or monovalent cations, particularly preferably e.g. only Ca 2+ cations, or a salt thereof, e.g. CaCl 2 , can likewise be used.
- the molarities given above for Ca 2+ (as a divalent cation) and Na 1+ (as a monovalent cation) (that is to say typically concentrations of at least 50 mM Nat, at least 0.01 mM Ca 2+ and optionally at least 3 mM K + ) in the injection buffer can also be taken into consideration if another di- or monovalent cation, in particular other cations from the group consisting of the alkaline earth metals and alkali metals, are employed instead of some or all the Ca 2+ or, respectively, Na 1+ in the injection buffer used according to the invention for the preparation of the injection solution.
- All the Ca 2+ or Na 1+ can indeed be replaced by other di- or, respectively, monovalent cations in the injection buffer used, for example also by a combination of other divalent cations (instead of Ca 2+ ) and/or a combination of other monovalent cations (instead of Na 1+ ) (in particular a combination of other divalent cations from the group consisting of the alkaline earth metals or, respectively, of other monovalent cations from the group consisting of the alkali metals), but it is preferable to replace at most some of the Ca 2+ or Na 1+ , i.e.
- the injection buffer optionally contained in the pharmaceutical composition according to the invention contains exclusively Ca 2+ as a divalent cation and Na 1+ as a monovalent cation, that is to say, with respect to the total pharmaceutical composition, Ca 2+ represents 100% of the total molarity of divalent cations, just as Na 1+ represents 100% of the total molarity of monovalent cations.
- the aqueous solution of the injection buffer can contain, with respect to the total pharmaceutical composition, up to 30 mol % of the salts contained in the solution, preferably up to 25 mol %, preferably up to 20 mol %, furthermore preferably up to 15 mol %, more preferably up to 10 mol %, even more preferably up to 5 mol %, likewise more preferably up to 2 mol % of insoluble or sparingly soluble salts.
- Salts which are sparingly soluble in the context of the present invention are those of which the solubility product is ⁇ 10 ⁇ 4 .
- Salts which are readily soluble are those of which the solubility product is >10 ⁇ 4 .
- the injection buffer optionally contained in the pharmaceutical composition according to the invention is from 50 mM to 800 mM, preferably from 60 mM to 500 mM, more preferably from 70 mM to 250 mM, particularly preferably 60 mM to 110 mM in sodium chloride (NaCl), from 0.01 mM to 100 mM, preferably from 0.5 mM to 80 mM, more preferably from 1.5 mM to 40 mM in calcium chloride (CaCl 2 ) and optionally from 3 mM to 500 mM, preferably from 4 mM to 300 mM, more preferably from 5 mM to 200 mM in potassium chloride (KCl).
- KCl potassium chloride
- Organic anions can also occur as further anions in addition to the abovementioned inorganic anions, for example halides, sulfates or carbonates.
- succinate, lactobionate, lactate, malate, maleate etc. which can also be present in combination.
- An injection buffer optionally contained in the pharmaceutical composition according to the invention preferably contains lactate. If it contains an organic anion, such an injection buffer particularly preferably contains exclusively lactate as the organic anion.
- Lactate in the context of the invention can be any desired lactate, for example L-lactate and D-lactate.
- Lactate salts which occur in connection with the present invention are typically sodium lactate and/or calcium lactate, especially if the injection buffer contains only Na + as a monovalent cation and Ca 2+ as a divalent cation.
- An injection buffer optionally used in the pharmaceutical composition according to the invention and as described above preferably contains, with respect to the total pharmaceutical composition, from 15 mM to 500 mM, more preferably from 15 mM to 200 mM, and even more preferably from 15 mM to 100 mM lactate.
- an injection buffer with the components described above, optionally with or without lactate in the following: “RL injection buffer” if it does not contain the component lactate, or “RL injection buffer with lactate” if it does contain the component lactate) for RNA injection solutions (i.e. injection solutions which contain RNA and are suitable for injection of this RNA) significantly increases both the transfer and the translation of the RNA into/in the cells/tissue of a host organism (mammal) compared with other injection buffers conventionally used in the prior art.
- the pharmaceutical composition used here can also be provided as a passive vaccine (for passive immunization).
- passive immunization is based on the introduction of an antibody-coding (modified) RNA as described here into an organism, in particular into a cell, the coded antibody then being expressed, i.e. translated.
- binding of such molecules e.g. nucleic acids or antigens, for which the coded antibody is specific can take place.
- Passive vaccines in connection with the present invention typically comprise a composition as described above for a pharmaceutical composition, the composition of such passive vaccines used being determined in particular by the mode in which they are administered.
- the passive vaccines according to the invention are administered systemically or in some cases non-systemically.
- Administration routes of such passive vaccines according to the invention typically include transdermal, oral, parenteral, including subcutaneous, intravenous, or intraarterial injections, topical and/or intranasal routes.
- Passive vaccines according to the invention are therefore preferably formulated in a liquid or solid form.
- the antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention is used for treatment of indications mentioned by way of example in the following.
- diseases or states for example, such as e.g.
- cervix carcinoma cervical cancer
- the antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can likewise be used for treatment of, for example, viral infectious diseases chosen from, without being limited thereto, AIDS, condyloma acuminata, molluscum contagiosum, dengue fever, three-day fever, Ebola virus, colds, early summer meningoencephalitis (ESME), influenza, shingles, hepatitis, herpes simplex type I, herpes simplex type II, herpes zoster, influenza, Japanese encephalitis, Lassa fever, Marburg virus, measles, foot and mouth disease, mononucleosis, mumps, Norwalk virus infection, Pfeiffer's glandular fever, smallpox, polio (poliomyelitis), pseuodcroup, infectious erythema, rabies, warts, West Nile fever, chicken-pox, cytomegalovirus (CMV), caused by viruses
- HIV orthopox variola virus, orthopox alastrim virus, parapox ovis virus, molluscum contagiosum virus, herpes simplex virus 1, herpes simplex virus 2, herpes B virus, varicella zoster virus, pseudorabies virus, human cytomegaly virus, human herpes virus 6, human herpes virus 7, Epstein-Barr virus, human herpes virus 8, hepatitis B virus, chikungunya virus, O'nyong'nyong virus, rubivirus, hepatitis C virus, GB virus C, West Nile virus, dengue virus, yellow fever virus, louping ill virus, St.
- the antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can also be used for treatment of cardiovascular diseases chosen from, without being limited thereto, coronary heart disease, arteriosclerosis, apoplexy and hypertension, and neuronal diseases chosen from Alzheimer's disease, amyotrophic lateral sclerosis, dystonia, epilepsy, multiple sclerosis and Parkinson's disease etc.
- the antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can furthermore be used for treatment of autoimmune diseases chosen from, without being limited thereto, autoimmune type I diseases or autoimmune type II diseases or autoimmune type III diseases or autoimmune type IV diseases, such as, for example, multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I (diabetes mellitus), systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergy type I diseases, allergy type II diseases, allergy type III diseases, allergy type IV diseases, fibromyalgia, hair loss, Bechterew's disease, Crohn's disease, myasthenia gravis, neurodermatitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter's syndrome, rheumatic
- Diseases in the context of the present invention likewise include monogenetic diseases, i.e. (hereditary) diseases which are caused by an individual gene defect and are inherited according to Mendel's rules.
- Monogenetic diseases in the context of the present invention are preferably chosen from the group consisting of autosomally recessive hereditary diseases, such as, for example, adenosine deaminase deficiency, familial hypercholesterolaemia, Canavan's syndrome, Gaucher's disease, Fanconi's anaemia, neuronal ceroid lipofuscinoses, mucoviscidosis (cystic fibrosis), sickle cell anaemia, phenylketonuria, alcaptonuria, albinism, hypothyroidism, galactosaemia, alpha-1 antitrypsin deficiency, xeroderma pigmentosum, Ribbing's syndrome, mucopolysaccharidoses, cleft lip, jaw, palate, Laurence-Moo
- RNA according to the invention which encodes an antibody as described here can be used on monogenetic diseases in the context of the present invention, the coded antibody being able to intervene in a regulatory manner, and also as a therapy, for example by regulation of undesirable metabolism products, trapping of specific gene products, interference with undesired certain interactions of proteins, e.g. inhibiting certain undesired ligand/receptor interactions etc.
- a (modified) RNA according to the invention which encodes an antibody can be employed in various ways for treatment of the abovementioned indications.
- cancer diseases for example, can be treated by immunotherapy in addition or as an alternative to known therapies.
- an RNA according to the invention which codes for a bispecific antibody can be employed, the antibody recognizing on the one hand a surface antigen, such as e.g. CD3, on T cells and on the other hand a tumour antigen, such as e.g. Her2/neu, C20, EGFR or CA-125.
- a surface antigen such as e.g. CD3
- tumour antigen such as e.g. Her2/neu, C20, EGFR or CA-125.
- RNA according to the invention which codes for a bispecific antibody which recognizes on the one hand a stem cell antigen, such as e.g. CD45, and on the other hand an antigen of the target tissue, such as e.g. myosin light chain, in order to increase the concentration of stem cells in the heart muscle (see also Reusch et al. Anti-CD3 ⁇ anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006).
- a stem cell antigen such as e.g. CD45
- an antigen of the target tissue such as e.g. myosin light chain
- RNA according to the invention which codes bispecific antibodies e.g. two different cell types can be brought into contact or spatially close by the coded antibodies.
- This is advantageous, for example, in order to concentrate a cell in a tissue or to bring two proteins, e.g. antigens, into contact with or spatially close to one another, e.g. ligand and receptor or proteins which must dimerize/oligomerize in order to become activated.
- RNAs according to the invention as described here which code for intrabodies can also be employed for use on the abovementioned diseases, in particular infectious diseases, autoimmune diseases and neuronal diseases and also on monogenetic diseases.
- intrabodies can be used in order to inhibit, as e.g. bispecific intracellularly expressed antibodies, cytoplasmic proteins (be it proteins originating from the pathogenic organism or be it proteins from the host organism), as described above.
- RNAs according to the invention which code for intrabodies can be employed in order to inhibit IL-2R (receptor of IL-2) or ErbB2 (Her2/neu) by the coded antibodies.
- RNAs according to the invention which code for intrabodies are also suitable for use on virus diseases, such as e.g. HIV-1.
- RNAs according to the invention which code for intrabodies can furthermore be employed in order to bind and preferably to neutralize, by the coded antibodies, intracellularly expressed factors as described here, such as e.g. antigens, nucleic acids etc. (see above).
- the invention therefore also provides the use of an antibody-coding (modified) RNA according to the invention or of a pharmaceutical composition according to the invention, e.g. a passive vaccine according to the invention, for treatment of indications and diseases described here.
- This also includes, in particular, the use of the antibody-coding (modified) RNA according to the invention for passive immunization and, respectively, the use of the pharmaceutical composition described according to the invention as a passive vaccine.
- the use of the antibody-coding (modified) RNA according to the invention for the preparation of a pharmaceutical composition or a passive vaccine, as described here, for treatment of the indications described here is likewise included.
- the use of the antibody-coding (modified) RNA according to the invention for the preparation of a passive vaccine, as described here, for passive immunization against the abovementioned indications is also included.
- the invention therefore likewise provides the use of an antibody-coding (modified) RNA according to the invention, of the antibody thereby coded, of the pharmaceutical composition described here or of the passive vaccine according to the invention for therapeutic use or for inhibition/neutralization of a protein function in one of the indications described here.
- a protein function is preferably suppressed (neutralizing antibodies).
- any of the antibodies coded by the RNA according to the invention and described here simultaneously also has a neutralizing action by binding of its specific substrate. Examples include e.g. anti-CD4 antibodies for prevention of rejection of transplants, Avastin (see above), Herceptin (see above) etc.
- the invention therefore also furthermore provides the use of an antibody-coding (modified) RNA according to the invention, of the antibody thereby coded or of the pharmaceutical composition described here for therapeutic use for passive immunization by triggering an immunological effector function in the sense of a monoclonal antibody.
- an antibody-coding (modified) RNA according to the invention, of the antibody thereby coded or of the pharmaceutical composition described here for therapeutic use for passive immunization by triggering an immunological effector function in the sense of a monoclonal antibody.
- therapy of tumour cells or pathogens such as viruses or bacteria
- the immune defense of the host is supported by the inventive RNA by triggering the innate, cellular or humoral immune system.
- Antibodies may be directed against immune suppressing factors or they may simulate the function of certain immunologically active cytokines by e.g. activating cytokine receptors.
- an antibody-coding (modified) RNA according to the invention or the pharmaceutical composition according to the invention described here or the passive vaccine according to the invention can also be used as an immunosuppressant in the indications described above.
- an antibody-coding (modified) RNA according to the invention or the pharmaceutical composition according to the invention described here or the passive vaccine according to the invention can also be used as an immunosuppressant in the indications described above.
- Such (modified) RNAs according to the invention which encode an antibody, the coded antibodies of which can bind to surface antigens or generally to surface factors of cells, such as e.g.
- the invention also additionally provides the use of an antibody-coding (modified) RNA according to the invention or of the pharmaceutical composition described here for therapeutic use for expansion of (certain) cells in vitro or in vivo.
- CD4- and CD25-positive cells and regulatory T cells can be stimulated to expansion by expression of the superantagonistic CD28 antibody.
- Regulatory T cells which can be multiplied by expression of the superantagonistic CD28 antibody play a role above all in autoimmune diseases (Beyersdorf N, Hanke T, Kerkau T, Hunig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. 2005 November; 64).
- An antibody-coding (modified) RNA according to the invention or the pharmaceutical composition described here can likewise be used on rheumatoid arthritis for prevention of inflammation reactions by antibodies against e.g. TNF ⁇ or other factors exacerbating the undesired immune response against e.g. the patients' proteins, as for the treatment of autoimmune diseases.
- a (modified) RNA according to the invention which encodes anti-CD18 antibodies or the pharmaceutical composition described here or the passive vaccine according to the invention can furthermore also be used for reduction of inflammations by inhibition of leukocytes, e.g. in the abovementioned indications.
- the present invention furthermore also provides a method for treatment and/or prevention of the abovementioned diseases and, respectively, for (preventive) passive immunization against the abovementioned diseases, which comprises administration of the pharmaceutical composition according to the invention described, the passive vaccine according to the invention or, respectively, the RNA according to the invention to a patient, in particular a human.
- Such methods also relate to treatment of indications which are connected with the intra- and extracellular processes described above, with neutralization functions of antibodies, the abovementioned inhibition of certain (cell) functions by antibodies etc.
- the present invention also provides an in vitro transcription method for the preparation of an antibody-coding (modified) RNA, comprising the following steps:
- a nucleic acid as described in step a) of the in vitro transcription method according to the invention can be any nucleic acid as described here (for example single- or double-stranded DNA, cDNA etc.) which encodes an antibody as described here.
- DNA sequences e.g. genomic DNA or fragments thereof, or plasmids which encode an antibody as described here, preferably in linearized form, are typically employed for this.
- the in vitro transcription can conventionally be carried out using a vector which has an RNA polymerase binding site. Any (expression) vectors known in the prior art, e.g. commercially obtainable (expression) vectors, can be used for this.
- Preferred (expression) vectors are, for example, those which have an SP6 or a T7 or T3 binding site upstream and/or downstream of the cloning site.
- the nucleic acid sequences used can thus be transcribed later as desired, depending on the RNA polymerase chosen.
- a nucleic acid sequence which is used for the in vitro transcription and codes for an antibody as described here is typically cloned into the (expression) vector, e.g. via a multiple cloning site of the vector used.
- the (expression) vector is typically cleaved with restriction enzymes at the site at which the future 3′ end of the RNA is to be found, using a suitable restriction enzyme, and the fragment is purified.
- RNA transcript of defined length is obtained.
- no restriction enzymes which generate overhanging ends such as e.g. Aat II, Apa I, Ban II, Bgl I, Bsp 1286, BstX I, Cfo I, Hae II, HgiA I, Hha I, Kpn I, Pst I, Pvu I, Sac I, Sac II, Sfi I, Sph I etc.
- the overhanging 3′ end is preferably filled up, e.g. with Klenow or T4 DNA polymerase.
- the nucleic acid can also be prepared as a transcription template by a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- one of the primers used typically contains the sequence of an RNA polymerase binding site.
- the 5′ end of the primer used preferably contains an extension of about 10-50 further nucleotides, more preferably of from 15 to 30 further nucleotides and most preferably of about 20 nucleotides.
- the nucleic acid e.g. the DNA or cDNA, template is typically purified and freed from RNase in order to ensure a high yield. Purification can be carried out with the aid of any method known in the prior art, for example using a caesium chloride gradient, ion exchange methods or by purification via agarose gel electrophoresis.
- the nucleic acid (used as the transcription template) is added to an in vitro transcription medium.
- a suitable in vitro transcription medium initially comprises a nucleic acid as provided under step a), for example about 0.1-10 ⁇ g, preferably about 1-5 ⁇ g, more preferably 2.5 ⁇ g and most preferably about 1 ⁇ g of such a nucleic acid.
- a suitable in vitro transcription medium furthermore optionally comprises a reducing agent, e.g. DTT, more preferably about 1-20 ⁇ l 50 mM DTT, even more preferably about 5 ⁇ l 50 mM DTT.
- the in vitro transcription medium furthermore comprises nucleotides, e.g.
- nucleotide mix in the case of the present invention comprising a mixture of (modified) nucleotides as defined here (typically about 0.1-10 mM per nucleotide, preferably 0.1 to 1 mM per nucleotide (preferably about 4 mM in total)) and optionally non-modified nucleotides.
- modified nucleotides as defined here about 1 mM per nucleotide, preferably about 4 mM in total
- pseudouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate etc. are employed, they are typically added in an amount such that the modified or base-modified nucleotides is completely replaced by the natural nucleotide.
- a suitable in vitro transcription medium likewise comprises an RNA polymerase, e.g. T7 RNA polymerase (for example T7-Opti mRNA Kit, CureVac, Tubingen, Germany), T3 RNA polymerase or SP6, typically about 10 to 500 U, preferably about 25 to 250 U, more preferably about 50 to 150 U, and most preferably about 100 U of RNA polymerase.
- T7 RNA polymerase for example T7-Opti mRNA Kit, CureVac, Tubingen, Germany
- T3 RNA polymerase or SP6 typically about 10 to 500 U, preferably about 25 to 250 U, more preferably about 50 to 150 U, and most preferably about 100 U of RNA polymerase.
- the in vitro transcription medium is furthermore preferably kept free from RNase in order to avoid degradation of the transcribed RNA.
- a suitable in vitro transcription medium therefore optionally additionally comprises an RNase inhibitor.
- the nucleic acid is incubated in the in vitro transcription medium in a step c) and is transcribed to an antibody-coding (modified) RNA.
- the incubation times are typically about 30 to 240 minutes, preferably about 40 to 120 minutes and most preferably about 90 minutes.
- the incubation temperatures are typically about 30-45° C., preferably 37-42° C.
- the incubation temperature depends on the RNA polymerase used, e.g. for T7 RNA polymerase it is about 37° C.
- the RNA obtained by the transcription is preferably an mRNA.
- the yields obtained in the in vitro transcription are, for the stated starting amounts employed in step b), typically in the region of about 30 ⁇ g of RNA per ⁇ g of template DNA used.
- the yields obtained in the in vitro transcription can be increased by linear up scaling.
- the stated starting amounts employed in step b) are preferably increased according to the yields required, e.g. by a multiplication factor of 5, 10, 50, 100, 500, 1,000, 5,000, 10,000, 50,000, 100,000 etc.
- a purification of the transcribed antibody-coding (modified) RNA can optionally take place in step d) of the in vitro transcription method according to the invention.
- Any suitable method known in the prior art e.g. chromatographic purification methods, e.g. affinity chromatography, gel filtration etc., can be used for this.
- non-incorporated, i.e. excess nucleotides and template DNA can be removed from the in vitro transcription medium and a clean (modified) RNA can be obtained.
- the reaction mixture containing the transcribed RNA can typically be digested with DNase in order to remove the DNA template still contained in the reaction mixture.
- the transcribed RNA can be subsequently or alternatively precipitated with LiCl. Purification of the transcribed RNA can then take place via IP RP-HPLC. This renders it possible in particular to separate longer and shorter fragments from one another effectively.
- the purification takes place via a method for purification of RNA on a preparative scale, which is distinguished in that the RNA is purified by means of HPLC using a porous reverse phase as the stationary phase (PURE Messenger).
- a reverse phase can be employed as the stationary phase for the HPLC purification.
- a non-polar compound typically serves as stationary phase
- a polar solvent such as mixtures of water, which is usually employed in the form of buffers, with acetonitrile and/or methanol, serves as the mobile phase for the elution.
- the porous reverse phase has a particle size of 8.0 ⁇ 2 ⁇ m, preferably ⁇ 1 ⁇ m, more preferably +/ ⁇ 0.5 ⁇ m.
- the reverse phase material can be in the form of beads.
- the purification can be carried out in a particularly favourable manner with a porous reverse phase having this particle size, optionally in the form of beads, particularly good separation results being obtained.
- the reverse phase employed is preferably porous since with stationary reverse phases which are not porous, such as are described e.g. by Azarani A. and Hecker K. H., pressures which are too high are built up, so that preparative purification of the RNA is possible, if at all, only with great difficulty.
- the reverse phase preferably has a pore size of from 200 ⁇ to 5,000 ⁇ , in particular a pore size of from 300 ⁇ to 4,000 ⁇ . Particularly preferred pore sizes for the reverse phases are 200-400 ⁇ , 800-1,200 ⁇ and 3,500-4,500 ⁇ . With a reverse phase having these pore sizes, particularly good results are achieved in respect of the purification of the RNA in process step d).
- the material for the reverse phase is preferably a polystyrene-divinylbenzene, and non-alkylated polystyrene-divinylbenzenes can be employed in particular. Stationary phases with polystyrene-divinylbenzene are known per se.
- the polystyrene-divinylbenzenes which are known per se and already employed for HPLC methods and are commercially obtainable can be used.
- a non-alkylated porous polystyrene-divinylbenzene which in particular has a particle size of 8.0 ⁇ 0.5 ⁇ m and a pore size of 250-300 ⁇ , 900-1,100 ⁇ or 3,500-4,500 ⁇ is very particularly preferably used for the purification in method step d).
- the advantages described above can be achieved in a particularly favourable manner with this material for the reverse phases.
- the HPLC purification can be carried out by the ion pair method, an ion having a positive charge being added to the mobile phase as a counter-ion to the negatively charged RNA.
- An ion pair having a lipophilic character which is slowed down by the non-polar stationary phase of the reverse phase system, is formed in this manner.
- the precise conditions for the ion pair method must be worked out empirically for each concrete separation problem.
- the size of the counter-ion, its concentration and the pH of the solution contribute greatly towards the result of the separation.
- alkylammonium salts such as triethylammonium acetate and/or tetraalkylammonium compounds, such as tetrabutylammonium
- 0.1 M triethylammonium acetate is added and the pH is adjusted to about 7.
- the choice of mobile phase depends on the nature of the desired separation. This means that the mobile phase found for a specific separation, such as can be known, for example, from the prior art, cannot be transferred readily to another separation problem with adequate prospect of success.
- the ideal elution conditions, in particular the mobile phase used must be determined for each separation problem by empirical experiments.
- a mixture of an aqueous solvent and an organic solvent can be employed as the mobile phase for elution of the RNA by the HPLC method.
- a buffer which has, in particular, a pH of about 7, for example 6.5-7.5, e.g. 7.0, is used as the aqueous solvent; preferably, the buffer triethylammonium acetate is used, particularly preferably a 0.1 M triethylammonium acetate buffer which, as described above, also acts as a counter-ion to the RNA in the ion pair method.
- the organic solvent employed in the mobile phase can be acetonitrile, methanol or a mixture of these two, very particularly preferably acetonitrile.
- the purification of the RNA in method step d) using an HPLC method as described is carried out in a particularly favourable manner with these organic solvents.
- the mobile phase is particularly preferably a mixture of 0.1 M triethylammonium acetate, pH 7, and acetonitrile. It has emerged to be likewise particularly favourable if the mobile phase contains 5.0 vol. % to 20.0 vol. % of organic solvent, based on the mobile phase, and the remainder to make up 100 vol. % is the aqueous solvent. It is very particularly favourable for the method according to the invention if the mobile phase contains 9.5 vol. % to 14.5 vol. % of organic solvent, based on the mobile phase, and the remainder to make up 100 vol.
- % is the aqueous solvent.
- Elution of the RNA can subsequently be carried out isocratically or by means of a gradient separation.
- elution of the RNA is carried out with a single eluting agent or a mixture of several eluting agents which remains constant, it being possible for the solvents described above in detail to be employed as the eluting agent.
- the present invention also provides an in vitro transcription and translation method for expression of an antibody, comprising the following steps:
- Steps a), b), c) and d) of the in vitro transcription and translation method according to the invention for expression of an antibody are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here.
- step e) of the in vitro transcription and translation method according to the invention for expression of an antibody the (modified) RNA transcribed in step c) (and optionally purified in step d) is added to a suitable in vitro translation medium.
- a suitable in vitro translation medium comprises, for example, reticulocyte lysate, wheat germ extract etc. Such a medium conventionally furthermore comprises an amino acid mix. The amino acid mix typically comprises (all) naturally occurring amino acids and optionally modified amino acids, e.g. 35 S-methionine (for example for monitoring the translation efficiency via autoradiography).
- a suitable in vitro translation medium furthermore comprises a reaction buffer.
- In vitro translation media are described, for example, in Krieg and Melton (1987) (P. A. Krieg and D. A. Melton (1987) In vitro RNA synthesis with SP6 RNA polymerase; Methods Enzymol 155:397-415), the disclosure content of which in this respect is included in its full scope in the present invention.
- a step f) of the in vitro transcription and translation method according to the invention for expression of an antibody the (modified) nucleic acid is incubated in the in vitro translation medium and the antibody coded by the (modified) nucleic acid is translated in vitro.
- the incubation typically lasts about 30 to 240 minutes, preferably about 40 to 120 minutes and most preferably about 90 minutes.
- the incubation temperature is typically in a range of about 20-40° C., preferably about 25 to 35° C. and most preferably about 30° C.
- Steps b) to f) of the in vitro transcription and translation method according to the invention for expression of an antibody or individual steps of steps b) to f) can be combined with one another, i.e. can be carried out together.
- all the necessary components are preferably added to the reaction medium together at the start or successively during the reaction in accordance with the sequence of the steps b) to f) described.
- the translated antibody obtained in step f) can be purified in an optional step g).
- a purification can be carried out with methods which are known to a person skilled in the art from the prior art, e.g. chromatography, such as, for example, affinity chromatography (HPLC, FPLC, etc.), ion exchange chromatography, gel chromatography, size exclusion chromatography, gas chromatography, or antibody detection, or biophysical methods, such as e.g. NMR analyses, etc. (see e.g. Maniatis et al. (2001) supra). Chromatography methods, including affinity chromatography methods, can employ tags in a suitable manner for the purification, as described above, e.g.
- a hexahistidine tag (SEQ ID NO: 59) (His tag, polyhistidine tag), a streptavidin tag (Strep tag), an SBP tag (streptavidin-binding tag), a GST (glutathione S transferase) tag etc.
- the purification can furthermore be carried out via an antibody epitope (antibody-binding tag), e.g. a Myc tag, an Swal 1 epitope, a FLAG tag, an HA tag etc., i.e. via recognition of the epitope via a corresponding (immobilized) antibody.
- the purification can likewise be carried out via the immobilized substrate of the specific antibody, i.e. by binding of the antibody to an immobilized antigen which is recognized and, respectively, bound specifically by the translated antibody.
- the present invention also provides an in vitro transcription and translation method for expression of an antibody in a host cell, comprising the following steps:
- Steps a), b), c) and d) of the in vitro transcription and translation method according to the invention for expression of an antibody in a host cell are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here and of the in vitro transcription and translation method according to the invention described here for expression of an antibody.
- step e′) of the in vitro transcription and translation method transfection of the (modified) RNA obtained in step c) (and optionally in step d)) into a host cell is carried out.
- the transfection is in general carried out via transfection methods known in the prior art (see, for example, Maniatis et al. (2001) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- Suitable transfection methods in the context of the present invention include, without being limited thereto, e.g. electroporation methods, including modified electroporation methods (e.g. nucleofection), calcium phosphate methods, e.g.
- the lipofection method e.g. the transferrin-mediated lipofection method, polyprene transfection, particle bombardment, nanoplexes, e.g. PLGA, polyplexes, e.g. PEI, protoplast fusion and the microinjection method, the lipofection method having emerged in particular as a suitable method.
- the (modified) RNA according to the invention can be in the naked or complexed form, as described above for the (modified) RNA according to the invention.
- a (suitable) host cell includes any cell which allows expression of the antibody coded by the (modified) RNA according to the invention, preferably any cultured eukaryotic cell (e.g. yeast cells, plant cells, animal cells and human cells) or prokaryotic cell (e.g. bacteria cells etc.).
- Cells of multicellular organisms are preferably chosen for expression of the antibody coded by the (modified) RNA according to the invention if posttranslational modifications, e.g. glycosylation of the coded protein, are necessary (N- and/or O-coupled).
- eukaryotic cells render possible posttranslational modification of the protein synthesized.
- the person skilled in the art knows a large number of such higher eukaryotic cells or cell lines, e.g. 293T (embryonal kidney cell line), HeLa (human cervix carcinoma cells), CHO (cells from the ovaries of the Chinese hamster) and further cell lines, including such cells and cell lines developed for laboratory purposes, such as, for example, hTERT-MSC, HEK293, Sf9 or COS cells.
- Suitable eukaryotic cells furthermore include cells or cell lines which are impaired by diseases or infections, e.g.
- cancer cells in particular cancer cells of any of the types of cancer mentioned here in the description, cells impaired by HIV, and/or cells of the immune system or of the central nervous system (CNS).
- Human cells or animal cells, e.g. of animals as mentioned here, are particularly preferred as eukaryotic cells.
- Suitable host cells can likewise be derived from eukaryotic microorganisms, such as yeast, e.g. Saccharomyces cerevisiae (Stinchcomb et al., Nature, 282:39, (1997)), Schizosaccharomyces pombe, Candida, Pichia , and filamentous fungi of the genera Aspergillus, Penicillium , etc.
- Suitable host cells likewise include prokaryotic cells, such as e.g. bacteria cells, e.g. from Escherichia coli or from bacteria of the genera Bacillus, Lactococcus, Lactobacillus, Pseudomonas, Streptomyces, Streptococcus, Staphylococcus , preferably E. coli , etc.
- prokaryotic cells such as e.g. bacteria cells, e.g. from Escherichia coli or from bacteria of the genera Bacillus, Lactococcus, Lactobacillus, Pseudomonas, Streptomyces, Streptococcus, Staphylococcus , preferably E. coli , etc.
- step f) of the in vitro transcription and translation method according to the invention for expression of an antibody in a host cell incubation of the (modified) RNA in the host cell and translation of the antibody coded by the (modified) RNA in the host cell are carried out.
- Expression mechanisms intrinsic to the host cell are preferably used for this, e.g. by translation of the RNA in the host cell via ribosomes and tRNAs.
- the incubation temperatures used in this context depend on the particular host cell systems used.
- the translated antibody obtained in step f) can be isolated and/or purified.
- an isolation of the translated (expressed) antibody typically comprises separating off the antibody from reaction constituents, and can be carried out by methods which are known to a person skilled in the art, for example by cell lysis, breakdown by ultrasound, or similar methods, including the abovementioned methods.
- a purification can therefore also be carried out by methods as described for step e) of the in vitro transcription and translation method according to the invention for expression of an antibody.
- the purification usually requires an involved breakdown of the bacteria and a difficult separating off of all the bacterial constituents which can act as endotoxins during a therapeutic use.
- expression systems for yeasts, insect cells, mammalian cells and plants can be employed according to the invention in such cases, the production preferably being carried out in suitable mammalian cells, such as e.g. hamster cells (CHO), as described here.
- the antibody coded by the (modified) RNA according to the invention can also be expressed by an in vitro translation method of steps (e′) to (g′), which is also subject matter of the present invention as such.
- the present invention also provides an in vitro transcription and in vivo translation method for expression of an antibody in an organism, comprising the following steps:
- Steps a), b), c) and d) of the in vitro transcription and in vivo translation method according to the invention for expression of an antibody in an organism are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here, of the in vitro transcription and translation method according to the invention described here for expression of an antibody and of the in vitro transcription and translation method according to the invention described here for expression of an antibody in a host cell.
- Host cells in the context of the present invention can also include autologous cells, i.e. cells which are taken from a patient and returned again (endogenous cells). Such autologous cells reduce the risk of rejection by the immune system in the case of in vivo uses.
- autologous cells (healthy or diseased) cells from the affected body regions/organs of the patient are preferably employed. Transfection methods are preferably those as described above for step e).
- transplanting of the host cell into an organism is carried out, additionally to step e).
- An organism or a being in connection with the present invention typically means mammals, i.e.
- the isolation and/or purification can be carried out according to steps f)/f) and/or g)/g′) and the translated (therapeutically active) protein can be administered subsequently to the being.
- the administration can be carried out as described for pharmaceutical compositions.
- step f′ translation of the antibody coded by the (modified) RNA is carried out in the organism.
- the translation is preferably carried out by means of systems specific to the host cell, depending on the host cell used.
- the transcribed (modified) RNA according to the invention can also be expressed by an in vitro translation method of steps (e′′) to (g′′), which is also subject matter of the present invention as such.
- RNA according to the invention transcribed according to steps a) to d) can be administered directly into the organism, e.g. human, e.g. by administration of the naked or complexed RNA according to the invention, for example using the transfection methods described above, optionally using certain stabilizing factors described here.
- the RNA is preferably transported into the cells, e.g. with localization or signal sequences as described here, and preferably translated into the coded antibody in the cells.
- the present invention describes in particular an antibody-coding RNA according to the invention.
- This can be modified or non-modified, where the definition of “modification” is to be understood in the broadest sense.
- a native RNA covalently bonded to another group for example a lipid or a sugar residue, is modified in the context of this invention.
- An RNA which contains non-natively occurring constituents, for example non-native nucleotides, or an RNA which is modified with respect to its precursor by exchange of nucleotides, regardless of whether these are native or non-native, is also modified in the context of the invention.
- the great advantage of such RNAs is that these do not have the negative actions of DNA transfections (with stable incorporation into the genome).
- the limited stability of the RNA coding for the antibodies or antibody fragments is moreover improved.
- the antibodies after administration to patients, in particular mammals, above all humans, the antibodies are therefore thus expressed in vivo for only an estimatable time beyond the treatment and therefore do not lead to harmful effects.
- the conventional intrabody DNAs can be integrated into the genome in a stable manner or at least expressed persistently, which can lead to uncontrollable events.
- the great advantage compared with administration of monoclonal antibodies in vivo is furthermore that with the use of an antibody-coding (modified) RNA as described here, no antibodies have to be prepared and purified in an involved manner and they are therefore considerably less expensive to prepare.
- the most essential advantage of the present invention is, however, that intracellularly expressed proteins can also be achieved with the antibodies coded by (modified) RNAs according to the invention, which is not possible with monoclonal antibodies known hitherto from the prior art.
- FIG. 1 illustrates the structure of an IgG antibody.
- IgG antibodies are built up from in each case two identical light and two heavy protein chains which are bonded to one another via disulfide bridges.
- the light chain comprises the N-terminal variable domain V L and the C-terminal constant domain C L .
- the heavy chain of an IgG antibody can be divided into an N-terminal variable domain V H and three constant domains C H 1, C H 2 and C H 3.
- FIGS. 2A-D show the gene cluster for the light and the heavy chains of an antibody:
- FIG. 3 illustrates in the form of a diagram the differences in the light and heavy chains of murine (i.e. obtained in the mouse host organism), chimeric, humanized and human antibodies.
- FIG. 4 shows an overview of the structure of various antibody fragments. The constituents of the antibody fragments are shown on a dark grey background.
- FIGS. 5A-C show various variants of antibodies and antibody fragments in FIGS. 5A, 5B and 5C :
- FIG. 6 shows a presentation of an antibody-coding (modified) RNA according to the invention as an expression construct.
- modified modified RNA
- FIG. 7 shows a diagram of the detection of an antibody coded by an RNA according to the invention by means of ELISA on the example of the antigen Her2.
- the total construct contains the following sequences and cleavage sites (see also alternative cleavage sites of FIG. 25 , SEQ ID No. 51):
- the total construct contains the following sequences and cleavage sites (see also alternative cleavage sites of FIG. 26 , SEQ ID No 52):
- the total construct contains the following sequences and cleavage sites (see also alternative cleavage sites of FIG. 27 , SEQ ID No. 53):
- FIG. 23 shows RNA-mediated antibody expression in cell culture.
- CHO or BHK cells were transfected with 20 ⁇ g of antibody-encoding mRNA according to the invention which was produced (RNA, G/C enriched, see above) or mock-transfected. 24 hours after transfection protein synthesis was analysed by Western blotting of cell lysates. Cells harboured about 0.5 ⁇ g of protein as assessed by Western Blot analysis. Each lane represents 10% of total lysate.
- Humanised antibodies served as control and for a rough estimate of protein levels.
- the detection antibody recognises both heavy and light chains; moreover, it shows some unspecific staining with cell lysates (three distinct bands migrating much slower than those of the antibodies).
- a comparison with control antibodies clearly demonstrates that heavy and light chains were produced in equal amounts.
- FIGS. 24A-E show that RNA-mediated antibody expression gives rise to a functional protein (antibody). Functional antibody formation was addressed by FACS staining of antigen-expressing target cells.
- FACS staining of antigen-expressing target cells.
- Humanised antibodies served as control and for a rough estimate of protein levels.
- Primary antibody used for cell staining a) humanised antibody; b) none; c,d) supernatant from RNA-transfected cells expressing the respective antibody; e) supernatant from mock-transfected CHO cells.
- RNA encoding antibodies may enter into cell, may be expressed within the cell and considerable amounts of RNA encoded antibodies are then secreted by the cell into the surrounding medium/extracellular space.
- Cell transfection in vivo or in vitro by the inventive RNA may therefore be used to provide antibodies acting e.g. therapeutically in the extracellular space.
- FIG. 25 shows an alternative sequence of the construct of FIG. 12 (antibody rituximab), wherein the restriction sites have been modified as compared to SEQ ID No. 5 of FIG. 12 (SEQ ID No.: 51).
- SEQ ID No. 5 of FIG. 12 SEQ ID No.: 51.
- FIG. 26 shows an alternative sequence of the construct of FIG. 17 (antibody cetuximab), wherein the restriction sites have been modified as compared to SEQ ID No. 10 of FIG. 17 (SEQ ID No.: 52). For closer information with regard to the description of various sequence elements it is referred to FIG. 17 .
- FIG. 27 shows an alternative sequence of the construct of FIG. 22 (antibody trastuzumab), wherein the restriction sites have been modified as compared to SEQ ID No. 15 of FIG. 22 (SEQ ID No.: 53).
- SEQ ID No.: 53 SEQ ID No. 15 of FIG. 22
- HeLa human cervix carcinoma cell line; Her2-positive
- HEK293 human embryonal kidney; Her2-negative
- BHK21 human hamster kidney; Her2-negative
- DMSZ Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH
- RPMI medium enriched with 2 mM L-glutamine (Bio Whittaker) and 10 ⁇ g/ml streptomycin and 10 U/ml of penicillin at 37° C. under 5% CO 2 .
- the GC-enriched and translation-optimized DNA sequences which code for a heavy chain and a light chain of an antibody (e.g. cetuximab (ERBITUX®), trastuzumab (HERCEPTIN®) and rituximab (RITUXAN®), cf.
- cetuximab e.g. cetuximab (ERBITUX®), trastuzumab (HERCEPTIN®) and rituximab (RITUXAN®
- cf e.g. cetuximab
- HERCEPTIN® trastuzumab
- RITUXAN® rituximab
- SEQ ID NO: 1-15 where SEQ ID NO: 1, 3, 6, 8, 11 and 13 represent the particular coding sequences which are not GC-optimized of the heavy and the light chains of these antibodies and SEQ ID NO: 2, 4, 5, 7, 9, 10, 12, 14 and 15 represent the coding GC-enriched sequences (see above)) were cloned into the pCV19 vector (CureVac GmbH) by standard molecular biology methods. To ensure equimolar expression of the two chains, an IRES (internal ribosomal entry site) was introduced. The mutated 3′ UTR (untranslated region) of the alpha-globin gene and a polyA-polyC tail at the 3′ end serve for additional stabilizing of the mRNA. The signal peptide of the HLA-A*0201 gene is coded for secretion of the antibody expressed. A His tag was additionally introduced for detection of the antibody. FIG. 6 shows the expression constructs used.
- T7 polymerase T7-Opti mRNA Kit, CureVac, Tubingen, Germany
- Pure MessengerTM CureVac, Tubingen, Germany
- a DNase digestion was first carried out, followed by an LiCl precipitation and thereafter an HPLC using a porous reverse phase as the stationary phase (PURE Messenger).
- a microtitre plate was loaded with a murine antibody (1) against a first antigen (HER-2).
- Cell lysate of antigen-expressing cells was then added to the plate.
- the antigen was bound here by the murine antigen-specific antibody (1).
- the supernatant of cells which were transfected with a modified mRNA according to the invention which codes for an HER-2-specific antibody was then added to the microtitre plate.
- the HER-2-specific antibody (2) contained in the supernatant likewise binds to the antibody-bound antigen, the two antibodies recognizing different domains of the antigen.
- anti-human IgG coupled to horseradish peroxidase (3-HRP) was added, the substrate TMB being converted and the result determined photometrically.
- An antibody-coding (m)RNA according to the invention as described above was injected intradermally or intramuscularly into BALB/c mice. 24 h thereafter, the corresponding tissues were removed and protein extracts were prepared. The expression of the antibody was detected by means of ELISA as described here.
- the expressed antibodies from the supernatant of cells which were transfected with a modified mRNA which codes for an antibody as described above were separated by means of a polyacrylamide gel electrophoresis and then transferred to a membrane. After incubation with anti-His tag antibody and a second antibody coupled to horseradish peroxidase, the antibody expressed was detected by means of chemoluminescence.
- SKOV-3 cells were injected subcutaneously into BALB/c mice. Within the following 28 days, eight portions of 10 ⁇ g of a modified mRNA which codes for an antibody as described above were injected into the tail vein of the mice. The tumour growth was monitored over a period of 5 weeks.
- RNA-based expression of humanised antibodies was done in either CHO-K1 or BHK-21 cells.
- RNA proteins from either cell culture supernatants or cell lysates were separated by a 12% SDS-PAGE and blotted onto a nitrocellulose membrane.
- Humanised antibodies Herceptin (Roche), Erbitux (Merck KGAA), and Mabthera Rituxan (Roche) were used as controls. After blotting was completed, membranes were consecutively incubated with biotinylated goat anti-human IgG (Dianova), streptavidin coupled to horseradish peroxidase (BD), and a chemiluminescent substrate (SuperSignal West Pico, Pierce). Staining was detected with a Fuji LAS-1000 chemiluminescence camera.
- target cells expressing the respective antigen were incubated with either control antibodies (Herceptin, Erbitux, Mabthera) or cell culture supernatants.
- control antibodies Herceptin, Erbitux, Mabthera
- cell culture supernatants For detection of bound antibodies, cells were stained with biotinylated goat anti-human IgG (Dianova) and PE-labelled streptavidin (Invitrogen). Cells were analysed on a FACSCalibur (BD).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.
Description
- This application is a continuation of U.S. application Ser. No. 12/522,214, filed Jan. 4, 2010, which is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/EP2008/000081, filed Jan. 8, 2008, the entire contents of each of which are incorporated herein by reference. International Application No. PCT/EP2008/000081 claims benefit of German Application No. 10 2007 001 370.3, filed Jan. 9, 2007.
- This application contains a Sequence Listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said Sequence Listing XML, created on Jul. 19, 2022, is named CRVCP0048USC11_ST26.xml and is 138,999 bytes in size.
- The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.
- The occurrence of tumours and cancer diseases is, alongside cardiovascular and infectious diseases, one of the most frequent causes of death in modern societies and is associated with usually considerable costs during the therapy and subsequent rehabilitation measures. The treatment of tumours and cancer diseases depends greatly, for example, on the nature of the tumour which occurs and at present conventionally is undertaken by using radio- or chemotherapy, in addition to invasive interventions. However, these therapies represent an exceptional burden on the immune system, and in some cases can be employed to only a limited extent. Furthermore, these therapy forms usually require long pauses between the individual treatments for regeneration of the immune system. In recent years, alongside these “conventional methods”, molecular biology programmes in particular have emerged as promising for the treatment or for assisting these therapies.
- An example of these molecular biology methods comprises the use of antibodies or immunoglobulins as essential effectors of the immune system. Antibodies or immunoglobulins can be generated either in vitro by using known molecular biology methods or by the immune system of the organism itself to be treated. The immune system of higher vertebrates thus has two separate functions of the immune system: the innate immune system, which reacts non-specifically to pathogens (e.g. by macrophage-mediated phagocytosis) and the adaptive immune system, which reacts specifically to pathogens by means of specialized effector cells (e.g. B and T cells). The antibodies or immunoglobulins which are secreted by plasma cells during an immune response are part of this adaptive immune system. Together with the complement system, they form the humoral branch of the immune response.
- Alongside their essential importance for the immune system in higher vertebrates, precisely because of their high affinity and specificity for a particular antigen antibodies are an outstanding means both in biochemical and molecular biology research and in diagnostics and medical uses. Thus, antibodies are capable of binding specifically to their target structures (e.g. antigens, which substantially comprise proteins, peptides, in some cases lipids, carbohydrates etc.) and of thereby blocking (inhibiting) or, where appropriate, labelling these. They can moreover activate the immune system by means of their Fc part, so that the labelled cells are destroyed. Over 100 therapeutic antibodies are currently to be found in clinical studies. Antibodies which can be employed in cancer therapy play by far the greatest role in this context. Most of the antibodies prepared for this at present are monoclonal antibodies which originate originally, for example, from the mouse. In order to prevent an immune reaction against such monoclonal antibodies, at present chiefly humanized or human antibodies are employed for therapy (cf. David Male; “Immunologie auf einen Blick [Immunology at a Glance]”, 1st German edition, 2005, Elsevier-Urban & Fischer Verlag; Charles A. Janeway, Paul Travers, Mark Walport and Mark Shlomchik, Immunobiology, 5th edition, 2001, Garland Publishing; Dissertation by Christian Klein, Monoklonale Antikörper and rekombinante Antikörperfragmente gegen sekundäre Arzneipflanzenmetabolite [Monoclonal Antibodies and Recombinant Antibody Fragments Against Secondary Medicinal Plant Metabolites], 2004; Andreas Schmiedl and Stefan Dübel, Rekombinante Antikörper & Phagen-Display [Recombinant Antibody & Phage Display], 2004, Molekulare Biotechnologie [Molecular Biotechnology] (Wiley-VCH)).
- Antibodies generally can be assigned to the group of immunoglobulins. These immunoglobulins can in turn be differentiated into five main classes of immunoglobulins on the basis of their heavy chain, the IgM (μ), IgD (δ), IgG (γ), IgA (α) and IgE (ε) antibodies, IgG antibodies making up the largest proportion. Immunoglobulins can moreover be differentiated into the isotypes κ and λ on the basis of their light chains.
- In spite of their different specificity, antibodies are structurally quite similar in construction. Thus, IgG antibodies typically are built up two identical light and two heavy protein chains which are bonded to one another via disulfide bridges. The light chain comprises the N-terminal variable domain VL and the C-terminal constant domain CL. The heavy chain of an IgG antibody can be divided into an N-terminal variable domain VH and three
constant domains C H1,C H2 and CH3 (cf.FIG. 1 ). While the amino acid sequence is largely the same in the region of the constant domains, wide differences in sequence are typically found within the variable domains. - The antibody repertoire of a human comprises about at least 1011 different antibody specificities. In higher vertebrates, the formation of antibodies takes place naturally in the immune system by somatic recombination. In this context, an organism is indeed theoretically capable of generating an antibody of appropriate specificity against any antigen. However, if each of these antibodies were to be coded by an endogenous gene, they would burst the human genome. Instead, in humans antibody genes are composed of a large number of individual gene segments. The part of the antibody gene which codes for the variable region of a light chain is formed from a V gene segment and a J gene segment. In this context, numerous different V and J segments are available, which can be combined with one another virtually as desired. In this context, the variable region of a heavy chain is composed of three different gene segments. In addition to the V and J segments, additional D segments are also found here. The VH, DH and JH segments can likewise be combined with one another virtually as desired to form the variable region of the heavy chain (cf.
FIG. 2 ). The mechanism by which the various gene segments are combined to form complete antibody genes is called immunoglobulin rearrangement or somatic recombination. It takes place exclusively in B lymphocytes at certain times of cell development. - In addition to pure gene rearrangement, further mechanisms for increasing the antibody diversity also exist. Two mechanisms which are accompanied by somatic recombination are first to be mentioned in this context: The junctional diversity in this context describes controlled imprecise joining together of the rearranged gene segments, as a result of which random removal and insertion of nucleotides occurs at the cleavage sites. A further combinatorial diversity results from the possibility of combining a particular rearranged light chain with a particular rearranged heavy chain. Finally, the diversity of antibodies is also additionally increased after successful rearrangement and later activation of B cells, in that an affinity maturation of antibodies occurs due to an increased rate of mutation in the region of the variable regions of activated B cells (somatic hypermutation).
- In addition to the formation of antibodies which takes place naturally by the immune system of the particular organism, antibodies can also be generated by molecular biology methods. However, in order to utilize the system elaborated for specification of antibody formation and specification thereof for particular antigens or nucleic acids, the formation of antibodies is at present typically induced in selected organisms by injection of a particular antigen, and the antibody is then isolated from the organism for further use. In this context, the B lymphocytes of the organism are conventionally purified selectively and fused with an immortal myeloma cell to form a hybridoma cell. Those cells which secrete the corresponding antigen-specific antibodies are then determined by selection methods.
- In addition to use of hybridoma cells, recombinant preparation of these antibodies with the desired specificity is also possible after isolation and sequencing. Cells which provide the required posttranslational modifications are typically used for this. On the basis of the immune reaction with formation of human anti-mouse antibodies in the human organism in the case of native antibodies produced in the mouse (or in other hosts), chimeric, humanized or human antibodies are preferably prepared here.
- After expression, these antibodies, optionally prepared by recombinant methods, can be employed as agents both in biochemical and molecular biology research, and in diagnostics and for medical uses.
- In medical uses, however, in many cases antibodies can be employed directly only with difficulty, since these usually have only a very short half-life in vivo and therefore, possibly, cannot reach their target antigen or their target nucleic acid at all. This requires either high active compound concentrations of the desired antibody, or alternative methods which are suitable for providing large amounts of antibodies in vivo.
- Such methods include, e.g. molecular medicine methods of gene therapy and genetic vaccination which, when used generally in the therapy and prevention of diseases, have considerable effects on medical practice. Both methods are based on the introduction of nucleic acids into cells or into tissue of the patient and on subsequent processing by the cells or, respectively, tissue of the information coded by the nucleic acids introduced, i.e. expression of the desired polypeptides, e.g. antibodies, in the cells or respectively, the tissue.
- The conventional procedure of methods of gene therapy and of genetic vaccination to date is based on the use of DNA to sluice the required genetic information into the cell. Various methods for introducing DNA into cells have been developed in this connection, such as, for example, calcium phosphate transfection, polyprene transfection, protoplast fusion, electroporation, microinjection, lipofection and the use of gene canons, lipofection in particular having emerged as a suitable method.
- A further method which has been proposed in particular in the case of genetic vaccination methods is the use of DNA viruses as DNA vehicles. Such viruses have the advantage that because of their infectious properties a very high transfection rate can be achieved. The viruses used are genetically modified, so that no functional infectious particles are formed in the transfected cell. The use of DNA viruses as DNA vehicles, however, has been criticized in recent years because of the risk of recombination of non-active viruses to give active viruses.
- The use of DNA as an agent in gene therapy and genetic vaccination or for passive immunization (by passive vaccines), e.g. by using coding sequences for antibodies, may, however, also be less advantageous from some points of view. DNA is degraded only relatively slowly in the bloodstream, so that when (foreign) DNA is used as the coding sequence for a desired protein, a formation of anti-DNA antibodies may occur, which has been confirmed in an animal model in the mouse (Gilkeson et al., J. Clin. Invest. 1995, 95: 1398-1402). The possible persistence of (foreign) DNA in the organism can thus lead to a hyperactivation of the immune system, which as is known results in splenomegaly in mice (Montheith et al., Anticancer Drug Res. 1997, 12(5): 421-432). Furthermore, (foreign) DNA can interact with the host genome, and in particular cause mutations by integration into the host genome. Thus, for example, the (foreign) DNA introduced may be inserted into an intact gene, which represents a mutation which can impede or even completely switch off the function of the endogenous gene. On the one hand enzyme systems which are vital for the cell may be destroyed by such integration events, and on the other hand there is also the danger of a transformation of the cell modified in this way into a degenerated state if a gene which is decisive for regulation of cell growth is modified by the integration of the foreign DNA. With the methods to date of gene therapy and genetic vaccination and also of passive immunization, a risk of development of cancer therefore cannot necessarily be ruled out when (foreign) DNA is used. In this context, passive immunization (by so-called “passive vaccines”) is to be strictly differentiated from so-called active immunization. In active immunization, an antigen (“active vaccine”) is typically administered, after which the organism forms antibodies against this antigen. Active immunization thus creates a permanent immunization of the organism against the particular antigen, which can be associated with the disadvantages described above. In passive immunization, in contrast, only an antiserum or the purified antibody itself (“passive vaccine”) is administered to the organism. The coding sequence for the antibody can likewise be administered, as described above, as a so-called passive vaccine for passive immunization.
- Summarizing, in the prior art there is an increased demand for and a considerable interest in agents which are suitable for employing antibodies effectively in vivo, in particular for providing increased active compound amounts of antibodies in vivo, without the risks hitherto associated with the use of DNA.
- This object is achieved according to the invention by the use of an RNA (sequence) for intracellular expression of an antibody, wherein the RNA (sequence) codes for an antibody or contains at least one coding region, which codes for at least one antibody, respectively. In connection with the present invention, an antibody-coding RNA according to the invention includes any RNA which encodes an antibody. More generally, the RNA of the present invention (directed to intracellular expression) contains at least one coding region, wherein the at least one coding region codes for at least one antibody. If more than one coding region is contained in the RNA molecule of the invention, the second, third etc. coding region may code for antibodies as well, which may be the same or distinct from the first antibody coding region. In a preferred embodiment, the inventive RNA contains at least two coding regions, all of them coding for identical or distinct antibodies. In still another embodiment of the present invention, an inventive RNA may code for more than one antibody within the same coding region. In summary, the inventive RNA may be mono-, bi- or multicistronic, codes for at least one antibody.
- The antibody-coding RNA according to the invention can be single-stranded or double-stranded, linear or circular, or in particular in the form of mRNA. The antibody-coding RNA according to the invention is particularly preferably in the form of single-stranded RNA, even more preferably in the form of mRNA.
- An antibody-coding RNA according to the invention preferably has a length of from 50 to 15,000 nucleotides, more preferably a length of from 50 to 10,000 nucleotides, even more preferably a length of from 500 to 10,000 nucleotides and most preferably a length of from 500 to 7,000, 500 to 5,000 or 700 to 3,000 nucleotides.
- In connection with the present invention, the antibodies coded by the RNA according to the invention can be chosen from all antibodies, e.g. from all antibodies which are generated by recombinant methods or are naturally occurring and are known to a person skilled in the art from the prior art, in particular antibodies which are (can be) employed for therapeutic purposes or for diagnostic or for research purposes or have been found with particular diseases, e.g. cancer diseases, infectious diseases etc.
- In the context of the present invention, antibodies which are coded by an RNA according to the invention typically include all antibodies (described above) which are known to a person skilled in the art, e.g. naturally occurring antibodies or antibodies generated in a host organism by immunization, antibodies prepared by recombinant methods which have been isolated and identified from naturally occurring antibodies or antibodies generated in a host organism by (conventional) immunization or have been generated with the aid of molecular biology methods, as well as chimeric antibodies, human antibodies, humanized antibodies, bispecific antibodies, intrabodies, i.e. antibodies expressed in cells and possibly localized in particular cell compartments, and fragments of the abovementioned antibodies. Insofar, the term antibody is to be understood in its broadest meaning. In this context, antibodies in general typically comprise a light chain and a heavy chain, both of which have variable and constant domains. The light chain comprises the N-terminal variable domain VL and the C-terminal constant domain CL. The heavy chain of an IgG antibody, in contrast, can be divided into an N-terminal variable domain VH and three
constant domains C H1,C H2 and CH3 (cf.FIG. 1 ). - RNA molecules according to the invention can also be prepared on the basis of polyclonal antibodies or, as an antibody-coding RNA cocktail, can have a polyclonal character. In the context of this invention, polyclonal antibodies are typically mixtures of antibodies against a specific antigen or immunogen or epitope of a protein which have been generated by immunization of a host organism, for example mammals, i.e. animals, including cattle, pigs, dogs, cats, donkeys, monkeys, including rodents, e.g. mice, hamsters, rabbits etc., and man. Polyclonal antibodies conventionally recognize different epitopes or regions of the same specific antigen, each of these epitopes in turn being capable of generating a clone of B lymphocytes which produces an antibody against this epitope. From such polyclonal antibodies or from the antibody sera obtained from the host organism, the individual antibodies specific against the particular epitopes can be obtained by individualization to monoclonal antibodies. The present invention accordingly also provides RNA which codes for a monoclonal antibody obtained by individualization of polyclonal antibodies.
- Monoclonal antibodies in the context of this invention are therefore typically antibodies which are specific for a particular antigen or epitope (of a protein), i.e. bind this antigen or epitope (of a protein) with a high affinity, and conventionally are expressed by a hybridoma cell. For the preparation of such monoclonal antibodies, the corresponding antigen or immunogen or epitope of a protein is typically injected at least once, but typically several times, into a host organism as described here, as a result of which the immune system of the host organism, in the presence of suitable adjuvants, is preferably stimulated to antibody production via activation of correspondingly specific B cells. The B lymphocytes are then conventionally selectively purified from the spleen or other organs or fluids suitable for this from an animal immunized in this manner, and are fused with an immortal myeloma cell to give the so-called hybridoma cell. After selection methods and cloning of the hybridomas or hybridoma cells formed, those clones which secernate, i.e. express and secrete, antibodies of the desired specificity can be determined. These clones can be isolated and sequenced with known molecular biology methods. The data obtained from such a sequencing can serve further in a nucleic acid synthesis for generation of synthetic DNA sequences or for screening a cDNA library and isolation of the cDNA fragments and generation of a DNA or nucleic acid template for in vitro or in vivo synthesis of the RNA according to the invention which codes for an antibody. Where appropriate, the RNA contained in the hybridomas can also be isolated, for example by fractionation, and subsequently the RNA molecules according to the invention which code for the hybridoma antibody can be purified by methods known to the person skilled in the art.
- Nevertheless, RNA molecules which code for non-human monoclonal or polyclonal antibody, e.g. murine monoclonal antibodies or monoclonal antibodies from other, as described here, non-human host organisms or hybridoma cells are of only limited suitability for therapeutic use in humans, since in the human organism itself they conventionally cause an immune reaction with formation of human anti-antibodies directed against these non-human host antibodies. As a result, such non-human monoclonal or polyclonal antibodies as a rule can be administered to a person only a single time. To by-pass this problem, RNA molecules which code for chimeric, humanized and human antibodies can also be provided according to the invention.
- Chimeric antibodies in the context of the present invention are preferably antibodies in which the constant domains of an antibody as described here have been replaced by human sequences.
- Preferably, chimeric antibodies are formed from monoclonal or polyclonal antibodies as described here.
- Humanized antibodies in the context of the present invention are antibodies in which the constant and variable domains described above of the non-human monoclonal or polyclonal antibodies, with the exception of the hypervariable regions, have been replaced by human sequences.
- RNA molecules which code for human antibodies, i.e. antibodies which have completely human sequences, that is to say in the constant and variable domains, including the hypervariable regions, can furthermore be used in the context of the present invention. Such RNA molecules which code for human antibodies can be isolated from human tissue or originate from immunized host organisms as described here, e.g. mice, which are then transgenic for the human IgG gene locus. RNA molecules which code for human antibodies and have been isolated by means of phage display and cloned with the aid of molecular biology methods are furthermore provided (see below).
- Antibodies which are coded by RNAs according to the invention particularly preferably include so-called full length antibodies, i.e. antibodies which comprise both the complete heavy and the complete light chains, as described above.
- RNAs which alternatively code for one or more antibody fragment(s) of the antibodies described above, instead of the corresponding full length antibody, can furthermore be provided in the context of the present invention. Examples of such antibody fragments are any antibody fragments known to a person skilled in the art, e.g. Fab, Fab′, F(ab′)2, Fc, Facb, pFc′, Fd, and Fv fragments of the abovementioned antibodies etc. A diagram of the structure of such antibody fragments is shown by way of example in
FIG. 4 . Protein fragments consisting of the minimal binding subunit of antibodies known as single-chain antibodies (scFvs) have excellent binding specificity and affinity for their ligands. In contrast to antibodies, scFvs lack the non-binding regions. Accordingly, RNA encoding scFvs are also encompassed by the present invention. - For example, an Fab (fragment antigen binding) fragment typically comprises the variable and a constant domain of a light and a heavy chain, e.g. the
C H1 and the VH domain of the heavy chain and the complete light chain. The two chains are bonded to one another via a disulfide bridge. An Fab fragment thus conventionally contains the complete antigen-binding region of the original antibody and usually has the same affinity for the antigen, the immunogen or an epitope of a protein. Antibody fragments, as also described above for antibodies, can be prepared with the aid of molecular biology methods. In this context, the DNA sequences which code for the various domains of the antibody fragment are cloned into a specific expression vector. The RNA which codes for these antibody fragments can then be expressed e.g. in suitable host cells. Suitable host cells in connection with the present invention include, inter alia, E. coli, yeasts, transgenic plants or mammalian cells etc. (see below). In contrast, an scFv fragment (single chain variable fragment) typically comprises the variable domain of the light and of the heavy chain, which are bonded to one another via an artificial polypeptide linker. In the cloning of such scFv fragments, RNAs which code for a VH and VL, these being linked to one another by a polypeptide linker, are preferably provided. As a rule, a polypeptide built up from 15-25 glycine, proline and/or serine residues (cf.FIG. 5 ) or the associated nucleotide sequence is used at the RNA level for the provision of this component. - Furthermore, RNA molecules which code for bispecific antibodies can also be provided in the context of the present invention. Bispecific antibodies in the context of the present invention are preferably antibodies which can act as adaptors between an effector and a corresponding target, e.g. for recruiting effector molecules (e.g. toxins, active compounds (drugs), cytokines etc.), targeting of effector cells (e.g. CTL, NK cells, macrophages, granulocytes etc. (see, for example, review by Kontermann R. E., Acta Pharmacol. Sin, 2005, 26(1): 1-9). In this context, bispecific antibodies are in principle built up such as is described here in general for antibodies, these bispecific antibodies e.g. recognizing two different antigens, immunogens or epitopes, or active compounds, cells, or other molecules (or structures) as mentioned above, i.e. the antigen-binding regions of the antibody are specific for two different molecules (or structures). The various antigens, immunogens or epitopes etc., for example, can thus be brought spatially close. Furthermore, by the binding e.g. of a binding domain or other specificities, the function of the antibody can be extended specifically, e.g. of a binding protein, an immunotoxin etc. Such bispecific antibodies can also be single-chain antibodies (e.g. scFv fragments etc.). Bispecific antibodies can be used, for example, to bring two reaction partners, e.g. two cells, two proteins, a protein and the substrate thereof etc., spatially close in order to promote an interaction between these (e.g. protein-protein interactions, substrate conversions, modifications etc.). Bispecific antibodies are used above all to bring effector cells (such as, for example, T cells, NK cells, macrophages etc.) and target cells (e.g. tumour cells, infected cells etc.) spatially close. Examples of bispecific antibodies can include, without being limited thereto, e.g. those antibodies or antibody fragments which bind on the one hand a surface factor as described here, and on the other hand an antigen as described here, preferably a tumour antigen as described here. This includes e.g. CD28 and a tumour antigen (Grosse-Hovest L. et al., 2003, Eur. Immunol. 33(5); 1334-40, (A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing)), CD19 and CD3 (CD19 tumour antigen of B cell lymphoma) etc.
- Without being limited thereto, according to the present invention RNAs which code for antibodies inter alia code for those antibodies which bind antigens or specific nucleic acids. Antigens in the context of the present invention are typically molecules which are recognized as exogenous by the immune system and conventionally cause an immune reaction or immune response with the formation of antibodies directed specifically against them. However, antigens can also include, especially in the case of autoimmune diseases, endogenous molecules or structures which are incorrectly recognized as exogenous by the immune system and thereby trigger an immune reaction. Alternatively formulated, antigens are therefore all molecules which are recognized by an antibody in the context of the present invention. Antigens substantially comprise proteins, peptides or epitopes of these proteins or peptides. In this context, epitopes (also called “antigenic determinants”) are typically small regions (molecular sections) lying on the surface of such protein or peptide structures and having a length of from 5 to 15, in rare case also to 25, preferably 6 to 9 amino acids. Antigens can furthermore also include lipids, carbohydrates etc. In the context of the present invention, antigens also include, for example, so-called immunogens, i.e. antigens which lead to an immunity of the organism transfected therewith. Antigens by way of example include, without being limited thereto, surface antigens of cells, tumour antigens etc. For example, according to the present invention antibodies can bind the following antigens (which typically occur in vertebrates), e.g. tumour-specific surface antigens (TSSA), e.g. 5T4, α5β1-integrin, 707-AP, AFP, ART-4, B7H4, BAGE, β-catenin/m, Bcr-abl, MN/C IX-antigen, CA125, CAMEL, CAP-1, CASP-8, CD4, CD19, CD20, CD22, CD25, CDC27/m, CD 30, CD33, CD52, CD56, CD80, CDK4/m, CEA, CT, Cyp-B, DAM, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ETV6-AML1, G250, GAGE, GnT-V, Gp100, HAGE, HER-2/neu, HLA-A*0201-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT), iCE, IGF-1R, IL-2R, IL-5, KIAA0205, LAGE, LDLR/FUT, MAGE, MART-1/Melan-A, MART-2/Ski, MC1R, myosin/m, MUC1, MUM-1, -2, -3, NA88-A, NY-ESO1, PAP, proteinase-3, p190 minor bcr-abl, Pml/RARα, PRAME, PSA, PSM, PSMA, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, survivin, TEL/AML1, TGFβ, TPI/m, TRP-1, TRP-2, TRP-2/INT2, VEGF and WT1, or sequences, such as e.g. NY-Eso-1 or NY-Eso-B. Tumour antigens can, for example, typically be responsible for metastasing, that is to say dissolving of tumour cells out of their native tissue, transfer into the vascular system (lymph or blood vessel system), exit from the vascular system and colonization in a new tissue. In this context, such tumour antigens which cause modified cell-cell interactions compared with the native state are of interest in particular.
- Antibodies encoded by the inventive RNA may also be directed against tumour antigens listed by Table 1 or Table 2. In particular, RNA encoding those antibodies may be used to treat (or, may be used to prepare a medicament to treat, respectively) the cancer diseases given in the last column of Tables 1 and 2.
-
TABLE 1 Antigens expressed in cancer diseases Name of Cancers or cancer Tumor tumor diseases related antigen antigen thereto 5T4 colorectal cancer, gastric cancer, ovarian cancer 707-AP 707 melanoma alanine 9D7 proline renal cell carcinoma AFP alpha- hepatocellular fetoprotein carcinoma, gallbladder cancer, testicular cancer, ovarian cancer, bladder cancer AlbZIP prostate cancer HPG1 alpha- 5beta1- Integrin alpha- colon cancer 5beta6- Integrin alpha- prostate cancer methylacyl- coenzyme A racemase ART-4 adeno- lung cancer, carcinoma head and neck antigen cancer, leukemia, recognized esophageal cancer, by T cells 4 gastric cancer, cervical cancer, ovarian cancer, breast cancer, squamous cell carcinoma B7H4 ovarian cancer BAGE-1 B antigen bladder cancer, head and neck cancer, lung cancer, melanoma, squamous cell carcinoma BCL-2 leukemia BING-4 melanoma CA 15-3/ breast cancer, CA 27-29 ovary cancer, lung cancer, prostate cancer CA 19-9 gastric cancer, pancreatic cancer, liver cancer, breast cancer, gallbladder cancer, colon cancer, ovary cancer, lung cancer CA 72-4 ovarian cancer CA125 ovarian cancer, colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, uterus cancer, cervix carcinoma, colon cancer, breast cancer, lung cancer calreticulin bladder cancer CAMEL CTL- melanoma recognized antigen on melanoma CASP-8 caspase-8 head and neck cancer cathepsin breast cancer B cathepsin breast cancer L CD19 B-cell malignancies CD20 CD22 CD25 CD30 CD33 CD4 CD52 CD55 CD56 CD80 CEA carcino- gut carcinoma, embryonic colorectal cancer, colon antigen cancer, hepatocellular cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, liver cancer cervix cancer, bladder cancer, melanoma CLCA2 calcium- lung cancer activated chloride channel-2 CML28 leukemia Coactosin- pancreatic cancer like protein Collagen prostate cancer XXIII COX-2 ovarian cancer, breast cancer, colorectal cancer CT-9/ bromodomain BRD6 testis- specific protein Cten C-terminal prostate cancer tensin- like protein cyclin B1 cyclin D1 ovarian cancer cyp-B cyclophilin B bladder cancer, lung cancer, T-cell leukemia, squamous cell carcinoma, CYPB1 cytochrom leukemia P450 1B1 DAM-10/ differentiation melanoma, skin tumors, MAGE-B1 antigen ovarian cancer, melanoma 10 lung cancer DAM-6/ differentiation melanoma, skin tumors, MAGE-B2 antigen ovarian cancer, melanoma 6 lung cancer EGFR/ lung cancer, ovarian cancer, head and Her1 neck cancer, colon cancer, pancreatic cancer, breast cancer EMMPRIN tumor cell- lung cancer, breast cancer, bladder associated cancer, ovarian cancer, brain extracellular cancer, lymphoma matrix metalloproteinase inducer/ EpCam epithelial cell ovarian cancer, breast cancer, adhesion colon cancer, lung cancer molecule EphA2 ephrin type- glioma A receptor 2 EphA3 ephrin type- melanoma, sarcoma, lung cancer A receptor 2 ErbB3 breast cancer EZH2 (enhancer of Zeste endometrium cancer, melanoma, homolog 2) prostate cancer, breast cancer FGF-5 fibroblast growth renal cell carcinoma, breast cancer, factor-5 prostate cancer FN fibronectin melanoma Fra-1 Fos-related breast cancer, esophageal cancer, antigen-1 renal cell carcinoma, thyroid cancer G250/ glycoprotein 250 leukemia, renal cell CAIX carcinoma, head and neck cancer, colon cancer, ovarian cancer, cervical cancer GAGE-1 G antigen 1 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-2 G antigen 2 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-3 G antigen 3 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-4 G antigen 4 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-5 G antigen 5 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-6 G antigen 6 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-7b G antigen 7b bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GAGE-8 G antigen 8 bladder cancer, lung cancer, sarcoma, melanoma, head and neck cancer GDEP gene differentially prostate cancer expressed in prostate GnT-V N-acetylgluco- glioma, melanoma saminyl- transferase V gp100 glycoprotein melanoma 100 kDa GPC3 glypican 3 hepatocellular carcinoma, melanoma HAGE helicase antigen bladder cancer HAST-2 human signet ring tumor-2 hepsin prostate Her2/neu/ human epidermal breast cancer, bladder ErbB 2 receptor-2/ cancer, melanoma, ovarian neurological cancer, pancreas cancer, gastric cancer HERV- melanoma K-MEL HNE human neutrophil leukemia elastase homeobox prostate cancer NKX 3.1 HOM- ovarian cancer TES- 14/SCP-1 HOM- TES-85 HPV-E6 cervical cancer HPV-E7 cervical cancer HST-2 gastric cancer hTERT human telomerase breast cancer, melanoma, lung reverse cancer, ovarian cancer, transcriptase sarcoma, Non-Hodgkin- lymphoma, acute leukemia iCE intestinal carboxyl renal cell carcinoma esterase IGF-1R colorectal cancer IL-13Ra2 interleukin 13 glioblastoma receptor alpha 2 chain IL-2R colorectal cancer IL-5 immature renal cell carcinoma laminin receptor kallikrein 2 prostate cancer kallikrein 4 prostate cancer Ki67 prostate cancer, breast cancer, Non- Hodgkin-lymphoma, melanoma KIAA0205 bladder cancer KK-LC-1 Kita-kyushu lung lung cancer cancer antigen 1 KM-HN-1 tongue cancer, hepatocellular carcinomas, melanoma, gastric cancer, esophageal, colon cancer, pancreatic cancer LAGE-1 L antigen bladder cancer, head and neck cancer, melanoma livin bladder cancer, melanoma MAGE-A1 melanoma bladder cancer, head and neck cancer, antigen-A1 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE- melanoma bladder cancer, head and neck cancer, A10 antigen-A10 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE- melanoma bladder cancer, head and neck cancer, A12 antigen-A12 melanoma, colon cancer, lung cancer, sarcoma, leukemia, prostate cancer, myeloma, brain tumors MAGE-A2 melanoma bladder cancer, head and neck cancer, antigen-A2 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE-A3 melanoma bladder cancer, head and neck cancer, antigen-A3 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE-A4 melanoma bladder cancer, head and neck cancer, antigen-A4 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE-A6 melanoma bladder cancer, head and neck cancer, antigen-A6 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE-A9 melanoma- bladder cancer, head and neck cancer, antigen-A9 melanoma, colon cancer, lung cancer, sarcoma, leukemia MAGE-B1 melanoma- melanoma antigen-B1 MAGE- melanoma- melanoma B10 antigen-B10 MAGE- melanoma- melanoma B16 antigen-B16 MAGE- melanoma- melanoma B17 antigen-B17 MAGE-B2 melanoma- melanoma antigen-B2 MAGE-B3 melanoma- melanoma antigen-B3 MAGE-B4 melanoma- melanoma antigen-B4 MAGE-B5 melanoma- melanoma antigen-B5 MAGE-B6 melanoma- melanoma antigen-B6 MAGE-C1 melanoma- bladder cancer, melanoma antigen-C1 MAGE-C2 melanoma- melanoma antigen-C2 MAGE-C3 melanoma- melanoma antigen-C3 MAGE-D1 melanoma- melanoma antigen-D1 MAGE-D2 melanoma- melanoma antigen-D2 MAGE-D4 melanoma- melanoma antigen-D4 MAGE-E1 melanoma- bladder cancer, melanoma antigen-E1 MAGE-E2 melanoma- melanoma antigen-E2 MAGE-F1 melanoma- melanoma antigen-F1 MAGE-H1 melanoma- melanoma antigen-H1 MAGEL2 MAGE-like 2 melanoma mamma- breast cancer globin A MART-1/ melanoma antigen melanoma Melan-A recognized by T cells- 1/melanoma antigen A MART-2 melanoma antigen melanoma recognized by T cells-2 matrix bladder cancer protein 22 MC1R melanocortin melanoma 1 receptor M-CSF macrophage ovarian cancer colony- stimulating factor gene mesothelin ovarian cancer MG50/ breast cancer, glioblastoma, PXDN melanoma MMP 11 M-phase leukemia phosphoprotein 11 MN/CA renal cell carcinoma IX-antigen MRP-3 multidrug lung cancer resistance- associated protein 3 MUC1 mucin 1 breast cancer MUC2 mucin 2 breast cancer, ovarian cancer, pancreatic cancer NA88-A NA cDNA clone melanoma of patient M88 N-acetyl- glucos- aminyl- transferase- V Neo-PAP Neo-poly(A) polymerase NGEP prostate cancer NMP22 bladder cancer NPM/ALK nucleophosmin/ anaplastic lymphoma kinase fusion protein NSE neuron-specific small cell cancer of lung, enolase neuroblastoma, Wilm' tumor, melanoma, thyroid cancer, kidney cancer, testicle cancer, pancreas cancer NY-ESO-1 New York bladder cancer, head and neck cancer, esophageous 1 melanoma, sarcoma, B-lymphoma, hepatoma, pancreatic cancer, ovarian cancer, breast cancer NY-ESO-B OA1 ocular albinism melanoma type 1 protein OFA-iLRP oncofetal antigen- leukemia immature laminin receptor OGT O-linked N- acetylglucosamine transferase gene OS-9 osteocalcin prostate cancer osteopontin prostate cancer, breast cancer, ovarian cancer p15 protein 15 p15 melanoma p190 minor bcr-abl p53 PAGE-4 prostate prostate cancer GAGE-like protein-4 PAI-1 plasminogen breast cancer acitvator inhibitor 1 PAI-2 plasminogen breast cancer acitvator inhibitor 2 PAP prostate acic prostate cancer phosphatase PART-1 prostate cancer PATE prostate cancer PDEF prostate cancer Pim-1- Kinase Pin1 Propyl isomerase prostate cancer POTE prostate cancer PRAME preferentially melanoma, lung cancer, leukemia, expressed antigen head and neck cancer, of melanoma renal cell carcinoma, sarcoma prostein prostate cancer proteinase- 3 PSA prostate-specific prostate cancer antigen PSCA prostate cancer PSGR prostate cancer PSM PSMA prostate-specific prostate cancer membrane antigen RAGE-1 renal antigen bladder cancer, renal cancer, sarcoma, colon cancer RHAMM/ receptor for leukemia CD168 hyaluronic acid mediated motility RU1 renal ubiquitous 1 bladder cancer, melanoma, renal cancer RU2 renal ubiquitous 1 bladder cancer, melanoma, sarcoma, brain tumor, esophagel cancer, renal cancer, colon cancer, breast cancer S-100 melanoma SAGE sarcoma antigen SART-1 squamous antigen esophageal cancer, head and neck rejecting tumor 1 cancer, lung cancer, uterine cancer SART-2 squamous antigen head and neck cancer, lung cancer, rejecting tumor 1 renal cell carcinoma, melanoma, brain tumor SART-3 squamous antigen head and neck cancer, lung cancer, rejecting tumor 1 leukemia, melanoma, esophageal cancer SCC squamous cell lung cancer carcinoma antigen Sp17 sperm protein 17 multiple myeloma SSX-1 synovial sarcoma hepatocellular cell carcinom, X breakpoint 1 breast cancer SSX-2/ synovial sarcoma breast cancer HOM- X breakpoint 2 MEL-40 SSX-4 synovial sarcoma bladder cancer, hepatocellular X breakpoint 4 cell carcinoma, breast cancer STAMP-1 prostate cancer STEAP six prostate cancer transmembrane epithelial antigen prostate survivin bladder cancer survivin-2B intron 2-retaining bladder cancer survivin TA-90 melanoma TAG-72 prostate carcinoma TARP prostate cancer TGFb TGFbeta TGFbRII TGFbeta receptor II TGM-4 prostate-specific prostate cancer transglutaminase TRAG-3 taxol resistant breast cancer, leukemia, and associated melanoma protein 3 TRG testin-related gene TRP-1 tyrosine related melanoma protein 1 TRP-2/6b TRP-2/novel melanoma, glioblastoma exon 6b TRP-2/ TRP-2/intron 2 melanoma, glioblastoma INT2 Trp-p8 prostate cancer Tyrosinase melanoma UPA urokinase-type breast cancer plasminogen activator VEGF vascular endothelial growth factor VEGFR-2/ vascular FLK-1 endothelial growth factor receptor-2 WT1 Wilm' tumor gene gastric cancer, colon cancer, lung cancer, breast cancer, ovarian cancer, leukemia -
TABLE 2 Mutant antigens expressed in cancer diseases Mutant Name of Cancers or cancer antigen mutant antigen diseases related thereto alpha- lung carcinoma actinin-4/m ARTC1/m melanoma bcr/abl breakpoint CML cluster region- Abelson fusion protein beta- beta-Catenin melanoma Catenin/m BRCA1/m breast cancer BRCA2/m breast cancer CASP-5/m colorectal cancer, gastric cancer, endometrial carcinoma CASP-8/m head and neck cancer, squamous cell carcinoma CDC27/m cell-division- cycle 27 CDK4/m cyclin- melanoma dependent kinase 4 CDKN2A/ melanoma m CML66 CML COA-1/m colorectal cancer DEK-CAN fusion AML protein EFTUD2/m melanoma ELF2/m Elongation lung squamous factor 2 cell carcinoma ETV6- Ets variant ALL AML1 gene6/acute myeloid leukemia 1 gene fusion protein FN1/m fibronectin 1 melanoma GPNMB/m melanoma HLA-A* arginine to renal cell carcinoma 0201- isoleucine R170I exchange at residue 170 of the alpha-helix of the alpha2- domain in the HLA-A2 gene HLA-A11/m melanoma HLA-A2/m renal cell carcinoma HSP70-2M heat shock renal cell protein 70-2 carcinoma, melanoma, mutated neuroblastoma KIAA0205/ bladder tumor m K-Ras/m pancreatic carcinoma, colorectal carcinoma LDLR-FUT LDR-Fucosyl- melanoma transferase fusion protein MART2/m melanoma ME1/m non-small cell lung carcinoma MUM-1/m melanoma melanoma ubiquitous mutated 1 MUM-2/m melanoma melanoma ubiquitous mutated 2 MUM-3/m melanoma melanoma ubiquitous mutated 3 Myosin melanoma class I/m neo-PAP/m melanoma NFYC/m lung squamous cell carcinoma N-Ras/m melanoma OGT/m colorectal carcinoma OS-9/m melanoma p53/m Pml/RARa promyelocytic APL, PML leukemia/ retinoic acid receptor alpha PRDX5/m melanoma PTPRK/m receptor-type melanoma protein-tyrosine phosphatase kappa RBAF600/ melanoma m SIRT2/m melanoma SYT-SSX-1 synaptotagmin sarcoma I/synovial sarcoma X fusion protein SYT-SSX-2 synaptotagmin sarcoma I/synovial sarcoma X fusion protein TEL- translocation AML AML1 Ets-family leukemia/ acute myeloid leukemia 1 fusion protein TGFbRII TGFbeta colorectal receptor II carcinoma TPI/m triosephosphate melanoma isomerase - In a preferred embodiment according to the invention, antibodies encoded by the inventive RNA are directed against the following (protein) antigens (whereby the RNA molecules may be used for the preparation of a medicament, e.g. a pharmaceutical composition or more preferably a (passive) vaccine in the meaning of the present inventino), are selected from the group consisting of 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, alpha-5-beta-1-integrin, alpha-5-beta-6-integrin, alpha-actinin-4/m, alpha-methylacyl-coenzyme A racemase, ART-4, ARTC1/m, B7H4, BAGE-1, BCL-2, bcr/abl, beta-catenin/m, BING-4, BRCA1/m, BRCA2/m, CA 15-3/CA 27-29, CA 19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8/m, cathepsin B, cathepsin L, CD19, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDC27/m, CDK4/m, CDKN2A/m, CEA, CLCA2, CML28, CML66, COA-1/m, coactosin-like protein, collage XXIII, COX-2, CT-9/BRD6, Cten, cyclin B1, cyclin D1, cyp-B, CYPB1, DAM-10, DAM-6, DEK-CAN, EFTUD2/m, EGFR, ELF2/m, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1, EZH2, FGF-5, FN, Frau-1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB/m, HAGE, HAST-2, hepsin, Her2/neu, HERV-K-MEL, HLA-A*0201-R17I, HLA-A11/m, HLA-A2/m, HNE, homeobox NKX3.1, HOM-TES-14/SCP-1, HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1R, IL-13Ra2, IL-2R, IL-5, immature laminin receptor, kallikrein-2, kallikrein-4, Ki67, KIAA0205, KIAA0205/m, KK-LC-1, K-Ras/m, LAGE-A1, LDLR-FUT, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-B1, MAGE-B2, MAGE-B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B16, MAGE-B17, MAGE-C1, MAGE-C2, MAGE-C3, MAGE-D1, MAGE-D2, MAGE-D4, MAGE-E1, MAGE-E2, MAGE-F1, MAGE-H1, MAGEL2, mammaglobin A, MART-1/melan-A, MART-2, MART-2/m, matrix protein 22, MC1R, M-CSF, ME1/m, mesothelin, MG50/PXDN, MMP11, MN/CA IX-antigen, MRP-3, MUC-1, MUC-2, MUM-1/m, MUM-2/m, MUM-3/m, myosin class I/m, NA88-A, N-acetylglucosaminyltransferase-V, Neo-PAP, Neo-PAP/m, NFYC/m, NGEP, NMP22, NPM/ALK, N-Ras/m, NSE, NY-ESO-1, NY-ESO-B, OA1, OFA-iLRP, OGT, OGT/m, OS-9, OS-9/m, osteocalcin, osteopontin, p15, p190 minor bcr-abl, p53, p53/m, PAGE-4, PAI-1, PAI-2, PART-1, PATE, PDEF, Pim-1-Kinase, Pin-1, Pml/PARalpha, POTE, PRAME, PRDX5/m, prostein, proteinase-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK/m, RAGE-1, RBAF600/m, RHAMM/CD168, RU1, RU2, S-100, SAGE, SART-1, SART-2, SART-3, SCC, SIRT2/m, Sp17, SSX-1, SSX-2/HOM-MEL-40, SSX-4, STAMP-1, STEAP, survivin, survivin-2B, SYT-SSX-1, SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1, TGFbeta, TGFbetaRII, TGM-4, TPI/m, TRAG-3, TRG, TRP-1, TRP-2/6b, TRP/INT2, TRP-p8, tyrosinase, UPA, VEGF, VEGFR-2/FLK-1, and WT1.
- In a particularly preferred embodiment, the RNA codes for antibodies which are directed against protein antigens selected from the group consisting of MAGE-A1, MAGE-A6, melan-A, GP100, tyrosinase, survivin, CEA, Her-2/neu, WT1, PRAME, EGFRI (epidermal growth factor receptor 1), mucin-1 and SEC61G, hTERT, 5T4, NY-Eso1, and TRP-2, more preferably from sequences of group consisting of MAGE-A1 [accession number M77481], MAGE-A6 [accession number NM_005363], melan-A [accession number NM_005511], GP100 [accession number M77348], tyrosinase [accession number NM_000372], survivin [accession number AF077350], CEA [accession number NM_004363], Her-2/neu [accession number M11730], WT1 [accession number NM_000378], PRAME [accession number NM_006115], EGFRI (epidermal growth factor receptor 1) [accession number AF288738], mucin-1 [accession number NM_002456] and SEC61G [accession number NM_014302], hTERT [accession number NM_198253], 5T4 [accession number NM_006670], NY-Eso1 [accession number NM_001327], and TRP-2 [accession number NM_001922].
- Antibodies (and therefore also the RNAs according to the invention on which these antibodies are based) which bind the antigens described here and, possibly, other antigens or nucleic acids can be identified e.g. by means of the method of phage display developed by George P. Smith. In this context, antibodies or antibody fragments are typically expressed on the surface of filamentous phages (Smith, G. P., 1985, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface”, Science 228; 1315-1317). For this there are conventionally 3 to 5 copies of the surface protein gpIII on the proximal end of the phage, with the aid of which the phage infects bacteria cells via the F pilus thereof. In phage display, for example, the DNA for an antibody fragment which codes the antigen-binding variable domain is then cloned in-frame before the gpIII gene. In protein biosynthesis, a fusion protein is formed therefrom, which is expressed on the virus surface without the phage losing its infectiousness. With the aid of the phage display technique, it is possible to generate large antibody libraries, each phage expressing a different antibody fragment on the surface. To this extent, the underlying RNA is therefore also available. A particular antibody fragment can be isolated from such a library by a method called “phage panning”. For this, the corresponding antigen is bound to a matrix and incubated with the phage suspension. The phages which present an appropriate antibody fragment interact with the fixed antigen, while the other phages are removed by a washing step. The phages isolated are multiplied, for example, in E. coli. The DNA is isolated accordingly and the gene sequence is determined. Expression constructs which contain the cDNA coding for the entire antibody or antibody fragments can then be developed with the aid of genetic engineering methods. An RNA (mRNA) which codes for the antibody can be generated from this cDNA by means of in vitro transcription (see below). Nucleic acids or, respectively, mRNA coding for monoclonal antibodies which are entirely of human origin are obtained in this manner.
- In the context of the present invention, RNA according to the invention which codes for antibodies as described above is also suitable for coding so-called intrabodies or for rendering possible an expression of intrabodies. Intrabodies in the context of the present invention can include any of the antibodies or antibody fragments described here. Intrabodies are intracellularly expressed antibodies, i.e. antibodies which are coded by nucleic acids localized in the cell and are expressed there. For this, an RNA according to the invention which encodes the antibodies or antibody fragments as described above is introduced into cells beforehand, for example with the aid of transfection methods according to the invention or other suitable transfection methods (see below) and, where appropriate, thereafter transplanted into an organism or being or introduced directly as nucleic acids into an organism or being. In this context (irrespective of whether an intrabody or a secreted antibody shall be introduce into the cell), the RNA according to the invention (or a corresponding nucleic acid) can be introduced in the naked form or as a complex with suitable carriers (e.g. liposomes) into the organism or the being or can have such modifications (of the RNA) which, where appropriate together with one of the transfection methods mentioned, lead to a better cell uptake, e.g. any of the RNA modifications mentioned here, such as, for example, lipid modifications of the RNA according to the invention. An organism or a being in connection with the present invention typically means mammals, i.e. animals, including cattle, pig, dog, cat, donkey, monkey, rodents, e.g. mouse, hamster, rabbit etc., and humans. Intrabodies can be localized and expressed at certain sites in the cell. For example, intrabodies can be expressed in the cytoplasm, the formation of disulfide bridges usually being decreased under the reducing conditions of the cytoplasm. It has been possible to demonstrate, however, that cytoplasmic intrabodies, and in particular scFv fragments, can be functional. Cytoplasmic expression by the RNA according to the invention opens up the possibility of also inhibiting cytoplasmic proteins. This is not possible with treatment with monoclonal antibodies from the prior art, since these antibodies can reach only secreted and membrane-located (extracellular) proteins due to their secretion from the cell after intracellular expression (which represents the major difference between antibodies and intrabodies). By expression of a signal peptide, intrabodies can be transported into the endoplasmic reticulum (ER) and then secreted as with regular antibodies. In this case, typically only secreted or membrane-located proteins are a target for these antibodies. By additional coding of a C-terminal ER retention signal (for example KDEL (SEQ ID NO: 18)) by the RNA according to the invention, the intrabody can remain in the ER (where it may bind to specific antigen located in the ER) and prevent secretion of its antigen and/or transport of its antigen or its target molecule to the plasma membrane. Depending on the requirement, intrabodies can include full length antibodies or antibody fragments as described above. Intrabodies in the context of the present invention preferably initially include full length antibodies, which are retained in the cell and not secreted from the cell (by whatever technique, e.g. retention signal sequences etc.). However, if e.g. intracellular expression of full length antibodies is technically not possible or not appropriate, antibody fragments as described above can also be employed as intrabodies.
- Antibodies which are coded by the RNA according to the invention furthermore also include those antibodies or antibody fragments which have a sequence identity to one of the antibodies or antibody fragments described here of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the coding nucleic acid or amino acid sequence of an antibody or antibody fragment as described here. Preferably, such antibodies or antibody fragments have the same biological function as or, respectively, the specific activity of the corresponding full length antibody, e.g. the specific binding of particular antigens or nucleic acids. Accordingly, it is preferred, if the hypervariable region(s) are conserved or are modified by merely conservative mutations.
- The biological function of antibodies described here which are coded by the RNA according to the invention includes e.g. neutralization of antigens, complement activation or opsonization. In the case of neutralization of antigens, the antibody can bind to an antigen and thereby neutralize this. The antibody is conventionally blocked by the binding of the antigen, and can therefore display its action only against one antigen, or two antigens in the case of bispecific antibodies. scFv antibody fragments are suitable above all for this (neutralization) function of an antibody, since they do not include the functions of the constant domains of an antibody. In the case of complement activation, the complex system of complement proteins which are dependent upon the Fc part of the antibody can be activated via binding of antibodies. End products of the complement cascade typically lead to lysis of cells and to the creation of a phlogistic (inflammatory) milieu. In the case of opsonization, pathogens or foreign particles are rendered accessible to phagocytes by binding by an antibody via the constant domains of the antibody. Alternatively, the opsonized cells, which are recognized as foreign, can be lysed via an antibody-dependent, cell-mediated cytotoxicity (ADCC). In this context, NK cells in particular can perform lytic functions in this manner via activation of their Fc receptors.
- In connection with the present invention, the term “identity” means that the sequences are compared with one another as follows. In order to determine the percentage identity of two nucleic acid sequences, the sequences can first be aligned with respect to one another in order subsequently to make a comparison of these sequences possible. For this e.g. gaps can be inserted into the sequence of the first nucleic acid sequence and the nucleotides can be compared with the corresponding position of the second nucleic acid sequence. If a position in the first nucleic acid sequence is occupied by the same nucleotide as is the case at a position in the second sequence, the two sequences are identical at this position. The percentage identity between two sequences is a function of the number of identical positions divided by the number of all the positions compared in the sequences investigated. If e.g. a specific sequence identity is assumed for a particular nucleic acid (e.g. a nucleic acid which codes for a protein, as described above) in comparison with a reference nucleic acid (e.g. a nucleic acid from the prior art) of defined length, this percentage identity is stated relatively with reference to this reference nucleic acid. Starting therefore, for example, from a nucleic acid which has a sequence identity of 50% to a reference
nucleic acid 100 nucleotides long, this nucleic acid can be anucleic acid 50 nucleotides long which is completely identical to a 50 nucleotides long section of the reference nucleic acid. Indeed, it can also be anucleic acid 100 nucleotides long which has 50% identity, i.e. in thiscase 50% identical nucleic acids, with the reference nucleic acid over the entire length thereof. Alternatively, this nucleic acid can be a nucleic acid 200 nucleotides long which is completely identical in a 100 nucleotides long section of the nucleic acid to the referencenucleic acid 100 nucleotides long. Other nucleic acids of course equally meet these criteria. The identity statements described for nucleic acids apply equally to the antibodies and antibody fragments coded by the RNA according to the invention. The same holds for the determination of the sequence identity between two (poly)peptides, based on the comparison/alignment of the respective amino acid sequences. - The percentage identity of two sequences can be determined with the aid of a mathematical algorithm. A preferred, but not limiting, example of a mathematical algorithm which can be used for comparison of two sequences is the algorithm of Karlin et al. (1993), PNAS USA, 90:5873-5877. Such an algorithm is integrated in the NBLAST program, with which sequences which have a desired identity to the sequences of the present invention can be identified. In order to obtain a gapped alignment, as described here, the “Gapped BLAST” program can be used, as is described in Altschul et al. (1997), Nucleic Acids Res, 25:3389-3402. If BLAST and Gapped BLAST programs are used, the preset parameters of the particular program (e.g. NBLAST) can be used. The sequences can be aligned further using version 9 of GAP (global alignment program) of the “Genetic Computing Group” using the preset (BLOSUM62) matrix (values −4 to +11) with a gap open penalty of −12 (for the first zero of a gap) and a gap extension penalty of −4 (for each additional successive zero in the gap). After the alignment, the percentage identity is calculated by expressing the number of agreements as a percentage content of the nucleic acids in the sequence claimed. The methods described for determination of the percentage identity of two nucleic acid sequences can also be used correspondingly, if necessary, on the coded amino acid sequences, e.g. the antibodies described here.
- According to a preferred embodiment, the antibody-coding RNA according to the invention contains according regions which codes for one of the antibodies listed in Table 3. The antibody encoding RNA may be used to treat (or, may be used to provide a pharmaceutical composition to treat) one of the diseases, disorders, pathologies listed in the right-hand column of Table 3.
-
TABLE 3 Name Target Clinical application Oregovomab CA125 (MUC- Ovarian Cancer, (OvaRex) 16) Fallopian Tube Cancer, Peritoneal Cavity Cancer Cantuzumab CanAg (MUC-1) Colon Cancer, Gastric Cancer, Pancreatic Cancer, NSCLC HuC242-DM4 CanAg (MUC-1) Colon Cancer, Gastric Cancer, Pancreatic Cancer PAM4 CanAg (MUC-1) Pancreatic Cancer (IMMU-107) HuC242-DM4 CanAg (MUC-1) Colorectal Cancer; Pancreatic Cancer HuHMFG1 CanAg (MUC-1) Breast Cancer WX-G250 Carbonische Renal Cell (Rencarex) Anhydrase IX Carcinoma (G250) MT103 CD19 Non-Hodgkin- Lymphoma Ibritumomab CD20 Non-Hodgkin- (Zevalin) Lymphoma, Lymphoma Rituximab CD20 Non-Hodgkin- (Rituxan, Lymphoma, MabThera) Lymphoma, Chronic Lymphocytic Leukemia Tositumomab CD20 Non-Hodgkin- (Bexxar) Lymphoma, Lymphoma, Myeloma Ofatumamab CD20 Lymphoma, B-Cell (HuMax-CD20) Chronic Lymphocytic Leukemia Epratuzumab CD22 Non-Hodgkin- (LymphoCide) Lymphoma, Leukemia MDX-060 CD30 Hodgkin-Lymphoma, Lymphoma SGN-30 CD30 Hodgkin-Lymphoma, Lymphoma Gemtuzumab CD33 Leukemia (Mylotarg) Zanolimumab CD4 T-Cell-Lymphoma (HuMax-CD4) SGN-40 CD40 Non-Hodgkin- Lymphoma, Myeloma, Leukemia, Chronic Lymphocytic Leukemia Alemtuzumab CD52 T-Cell-Lymphoma, (MabCampath) Leukemia HuN901-DM1 CD56 Myeloma Galiximab CD80 Non-Hodgkin- Lymphoma Labetuzumab CEA Colon Cancer, Pancreatic Cancer, Ovarian Cancer Ipilimumab CTLA4 Sarcoma, Melanoma, (MDX-010) Lung cancer, Ovarian Cancer leucemia, Lymphoma, Brain and Central Nervous System Tumors, Testicular Cancer, Prostate Cancer, Pancreatic Cancer, Breast Cancer Cetuximab EGFR Colon Cancer, Head (Erbitux) and Neck Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Myeloma, Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Oropharyngeal Neoplasms, Hepatocellular Carcinoma, Squamous Cell Carcinoma, Sarcoma, Larynx Cancer; Hypopharynx Cancer Panitumumab EGFR Colon Cancer, Lung (Vectibix) Cancer, Breast Cancer; Bladder Cancer; Ovarian Cancer Nimotuzumab EGFR Solid Tumors, Lung (TheraCim) Cancer Matuzumab EGFR Lung Cancer, Cervical Cancer, Esophageal Cancer Zalutumumab EGFR Head and Neck Cancer, Squamous Cell Cancer Pertuzumab EGFR und Breast Cancer, Ovarian Cancer, Lung Cancer, (Omnitarg) HER2/neu Prostate Cancer Catumaxomab EpCam Ovarian Cancer, (Removab) Fallopian Tube Neoplasms, Peritoneal Neoplasms MORab-003 GP-3 Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer MORab-009 GP-9 Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer Ertumaxomab HER2/neu Breast Cancer Trastuzumab HER2/neu Breast Cancer, (Herceptin) Endometrial Cancer, Solid Tumors AMG 102 HGF Advanced Renal Cell Carcinoma Apolizumab HLA-DR- Solid Tumors, (Remitogen) Antigen Leukemia, Non-Hodgkin- Lymphoma, Lymphoma CNTO 95 Integrin- Melanoma Rezeptor ID09C3 MHCII Non-Hodgkin- Lymphoma Denosumab RANKL Myeloma, Giant Cell (AMG-102) Tumor of Bone, Breast Cancer, Prostate Cancer GC1008 TGFbeta Advanced Renal Cell Carcinoma; Malignant Melanoma Mapatumumab TRAIL-R1 Colon Cancer, Myeloma Bevacizumab VEGF Colon Cancer, Breast (Avastin) Cancer, Brain and Central Nervous System Tumors, Lung Cancer, Hepatocellular Carcinoma, Kidney Cancer, Breast Cancer, Pancreatic Cancer, Bladder Cancer, Sarcoma, Melanoma, Esophageal Cancer; Stomach Cancer, Metastatic Renal Cell Carcinoma; Kidney Cancer, Glioblastoma, Liver Cancer MEDI 522 VLA3 Solid Tumors, (alpha5beta3- Leukemia, Integrin) Lymphoma, Small Volociximab VLA5 Renal Cell (alpha5beta1- Carcinoma, Integrin) Pancreatic Cancer, Melanoma Hematology: Name Target Application Eculizumab C5 Komple- Paroxysmale (Alexion) mentfaktor nächtliche Hämoglobinurie (PNH) Mepolizumab Interleukin-5 Hypereosinophilie- Syndrom Dentology: Name Target Application CaroRx (CaroRx) Streptococcus Zahnkaries mutans Autoimmune Diseases und allergic Diseases: Name Target Application Efalizumab CD11a Psoriasis (Raptiva) (Schuppenflechte) Epratuzumab CD22 Autoimmune Diseases, Non-Hodgkin- (LymphoCide) Lymphom Lumiliximab CD23 Allergies Daclizumab CD25 Schubförmige Multiple Sclerosis Natalizumab CD49d Multiple Sclerosis (Tysabri) Omalizumab IgE (Fc-Teil) Schweres Asthma (Xolair) bronchiale Mepolizumab Interleukin-5 Asthma, Hypereosinophilic Syndrome, Eosinophilic Gastroenteritis, Churg- Strauss Syndrome, Eosinophilic Esophagitis Tocilizumab Interleukin-6 Rheumatoid Arthritis (Actemra) Adalimumab TNFα Rheumatoid (Humira) Arthritis, Psoriasis- Arthritis, Morbus Bechterew Infliximab TNFα Morbus Crohn, (Remicade) Rheumatoide Arthritis, Morbus Bechterew, Psoriasis-Arthritis, Colitis ulcerosa, Psoriasis (Schuppenflechte) Golimumab TNFα Rheumatoid Arthritis (CNTO 148) Mapatumumab TRAIL-R1 Myeloma Rituximab CD20 Urticaria, Rheumatoid (Rituxan, Arthritis, MabThera) Ulcerative Colitis, Chronic Focal Encephalitis Epratuzumab CD22 Autoimmune (LymphoCide) diseases, Systemic Lupus Erythematosus Neurodegenerative Diseases: Name Target Application R1450 Amyloid-beta Alzheimer Ophthalmology: Name Target Application Ranibizumab VEGF-A Feuchte Macular (Lucentis) Degeneration Bevacizumab VEGF Macular (Avastin) Degeneration Infektious Diseases: Name Target Application Palivizumab Component of RSV Prevention of RSV- (Synagis) (Respiratory Pneumonia bei Syncytial Virus) Frühgeborenen Cardiovascular Diseases: Name Target Application Abciximab GPIIb/Iia Verhinderung eines (ReoPro) Gefäβverschlusses nach PTCA Other Diseases: Name Target Application Denosumab RANKL Osteoporosis (AMG-102) GC1008 TGFbeta Pulmonary Fibrosis Bevacizumab VEGF Proliferative (Avastin) Diabetic Retinopathy - According to a preferred embodiment, the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 2 and the light chains according to SEQ ID NO: 4. According to an even more preferred embodiment, the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 5 or SEQ ID NO: 51, respectively.
- According to another preferred embodiment, the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 7 and the light chains according to SEQ ID NO: 9. According to an even more preferred embodiment, the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 10 or SEQ ID NO: 52, respectively.
- According to a further preferred embodiment, the antibody-coding RNA according to the invention contains or has a sequence which codes for the heavy chains according to SEQ ID NO: 12 and the light chains according to SEQ ID NO: 14. According to an even more preferred embodiment, the antibody-coding RNA according to the invention contains or has a coding sequence according to SEQ ID NO: 15 or SEQ ID NO: 53, respectively.
- Antibodies which are coded by the RNA according to the invention can furthermore also encode such antibodies which have a sequence identity to one of the coding sequences of the antibodies described here, e.g. as described by Table 3 or by SEQ ID NO: 5 (51), 10 (52) or 15 (53), of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the nucleic acid sequence or amino acid sequence of an antibody as described here, e.g. as described by Table 3 or by SEQ ID NO: 5 (51), 10 (52) or 15 (53).
- Such antibodies which are coded by the RNA according to the invention likewise include antibodies according to SEQ ID NO: 5 (51), 10 (52) or 15 (53) or according to Table 3 which contain or have, in one of the heavy chains described here according to SEQ ID NO: 2, 7 or 12 and/or in one of the light chains described here according to SEQ ID NO: 4, 9 or 14, a nucleic acid or amino acid sequence identity of at least 70%, 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% over the entire length of the coding sequence for the particular light and/or heavy chain, with an otherwise unchanged coding antibody sequence of SEQ ID NO: 5 (51), 10 (52) or 15 (53) or e.g antibodies of Table 3.
- Overall, a novel route for carrying out antibody therapies on the basis of RNA, in particular mRNA, is thus provided with the aid of the present invention. In such a manner, clinically tested antibodies, for example angiogenesis inhibitors based on antibodies, for example bevacizumab (monoclonal immunoglobulin Gi antibody which binds to the vascular growth factor VEGF (vascular endothelial growth factor); or trastuzumab (Herceptin), an indirect inhibitor which inhibits the action of tumour proteins on receptors, or for example rituximab or cetuximab (directed against the epidermal growth factor receptor (EGFR)), based on RNA, can be provided, so that the inventive RNA contains at least one coding region which codes for at least one of these antibodies.
- In a preferred embodiment, the antibody-coding RNA according to the invention typically additionally has at least one of the following modifications, which are preferably suitable for increasing the stability of the coding RNA, improving the expression of the antibody thereby coded, increasing the cell permeability, rendering possible localization of the antibody on or in certain cell compartments etc. Each of these modifications of the RNA according to the invention described here (modified RNA) which are mentioned in the following can be combined with one another in a suitable manner, such modifications which do not interfere with one another or adversely influence the stability or cell permeability of the antibody-coding, modified RNA according to the invention or the expression of the antibody thereby coded preferably being combined with one another. For the entire present invention, the nomenclature “modified” is equated with the content of “optionally modified”.
- Modifications of the RNA according to the invention described here (modified RNA) can include, for example, modifications of the nucleotides of the RNA. An RNA (modified RNA) according to the invention can thus include, for example, backbone modifications, sugar modifications or base modifications. In this context, the antibody-coding RNA according to the invention typically first contains nucleotides which can be chosen from all naturally occurring nucleotides and analogues thereof (modified nucleotides), such as e.g. ribonucleotides and/or deoxyribonucleotides. Nucleotides in the context of the present invention therefore include, without being limited thereto, for example purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and as modified nucleotides analogues or derivatives of purines and pyrimidines, such as e.g. 1-methyl-adenine, 2-methyl-adenine, 2-methylthio-N6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine, inosine, 1-methyl-inosine, pseudouracil (5-uracil), dihydro-uracil, 2-thio-uracil, 4-thio-uracil, 5-carboxymethylaminomethyl-2-thio-uracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5-bromo-uracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil, 5-methyl-uracil, N-uracil-5-oxyacetic acid methyl ester, 5-methylaminomethyl-uracil, 5-methoxyaminomethyl-2-thio-uracil, 5′-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 1-methyl-pseudouracil, queosine, ß-D-mannosyl-queosine, wybutoxosine, and phosphoramidates, phosphorothioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine. The preparation of such analogues is known to a person skilled in the art e.g. from the U.S. Pat. Nos. 4,373,071, 4,401,796, 4,415,732, 4,458,066, 4,500,707, 4,668,777, 4,973,679, 5,047,524, 5,132,418, 5,153,319, 5,262,530 and 5,700,642, the disclosure of which is included here in its full scope by reference.
- In particular, an antibody-coding RNA according to the invention can contain RNA backbone modifications. In connection with the present invention, a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are modified chemically. In this context, such backbone modifications typically include, without being limited thereto, modifications from the group consisting of methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g. cytidine 5′-O-(1-thiophosphate)), boranophosphates, positively charged guanidinium groups etc., which means by replacing the phosphodiester linkage by other anionic, cationic or neutral groups.
- An antibody-coding RNA according to the invention can likewise also contain sugar modifications. A sugar modification in connection with the present invention is a chemical modification of the sugar of the nucleotides it contains and typically includes, without being limited thereto, sugar modifications chosen from the group consisting of 2′-deoxy-T-fluoro-oligoribonucleotide (2′-fluoro-2′-deoxycytidine 5′-triphosphate, 2′-fluoro-2′-deoxyuridine 5′-triphosphate), 2′-deoxy-2′-deamine-oligoribonucleotide (2′-amino-2′-deoxycytidine 5′-triphosphate, 2′-amino-2′-deoxyuridine 5′-triphosphate), 2′-O-alkyloligoribonucleotide, 2′-deoxy-T-C-alkyloligoribonucleotide (2′-O-methylcytidine 5′-triphosphate, 2′-methyluridine 5′-triphosphate), 2′-C-alkyloligoribonucleotide, and isomers thereof (2′-aracytidine 5′-triphosphate, 2′-arauridine 5′-triphosphate), or azidotriphosphates (2′-azido-2′-deoxycytidine 5′-triphosphate, 2′-azido-2′-deoxyuridine 5′-triphosphate).
- Preferably, however, the modified RNA sequence according to the invention contains no sugar modifications or backbone modifications if e.g. an in vitro transcription is necessary. The reason for this preferred exclusion lies in the problem that certain backbone modifications and sugar modifications of RNA sequences on the one hand can prevent or at least greatly reduce in vitro transcription thereof. Thus, an in vitro transcription of eGFP carried out by way of example functions, for example, only with the
sugar modifications 2′-amino-2′-deoxyuridine 5′-phosphate, 2′-fluoro-2′-deoxyuridine 5′-phosphate and 2′-azido-T-deoxyuridine 5′-phosphate. In addition, the translation of the protein, i.e. the protein expression, in vitro or in vivo typically can be reduced considerably by backbone modifications and, independently thereof, by sugar modifications of RNA sequences. It was possible to demonstrate this, for example, for eGFP in connection with the backbone modifications and sugar modifications selected above. - An antibody-coding RNA according to the invention can likewise also contain modifications of the bases of the nucleotides it contains (base modifications). Thus, for example, the antibody-coding RNA according to the invention can be modified such that only one or several of the nucleotides of the modified RNA are exchanged for nucleotides having base modifications, which are preferably suitable for increasing the expression of the antibody coded by the RNA significantly compared with the non-modified, i.e. native RNA sequence. In this case, significant means an increase in the expression of the antibody on the basis of the modified RNA sequence compared with the native RNA sequence by at least 20%, preferably at least 30%, 40%, 50% or 60%, even more preferably by at least 70%, 80%, 90% or even 100% and most preferably by at least 150%, 200% or even 300%. In connection with the present invention, a modified nucleotide which contains a base modification is called a base-modified nucleotide and, without being limited thereto, is preferably chosen from the group consisting of: 2-amino-6-chloropurine riboside 5′-triphosphate, 2-aminoadenosine 5′-triphosphate, 2-thiocytidine 5′-triphosphate, 2-thiouridine 5′-triphosphate, 4-thiouridine 5′-triphosphate, 5-aminoallylcytidine 5′-triphosphate, 5-aminoallyluridine 5′-triphosphate, 5-bromocytidine 5′-triphosphate, 5-bromouridine 5′-triphosphate, 5-iodocytidine 5′-triphosphate, 5-iodouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate, 5-methyluridine 5′-triphosphate, 6-azacytidine 5′-triphosphate, 6-azauridine 5′-triphosphate, 6-chloropurine riboside 5′-triphosphate, 7-deazaadenosine 5′-triphosphate, 7-deazaguanosine 5′-triphosphate, 8-azaadenosine 5′-triphosphate, 8-azidoadenosine 5′-triphosphate, benzimidazole riboside 5′-triphosphate, N1-methyladenosine 5′-triphosphate, N1-methylguanosine 5′-triphosphate, N6-methyladenosine 5′-triphosphate, O6-methylguanosine 5′-triphosphate, pseudouridine 5′-triphosphate, puromycin 5′-triphosphate or xanthosine 5′-triphosphate. Nucleotides for base modifications are particularly preferably chosen from the group of base-modified nucleotides consisting of 5-methylcytidine 5′-triphosphate and pseudouridine 5′-triphosphate.
- Without being restricted thereto, in this connections the inventors attribute an increase in the expression of the antibody coded by the (base)-modified RNA according to the invention to, inter alia, the improvement in the stabilizing of secondary structures and, where appropriate, to the “more rigid” structure formed in the RNA and the increased base stacking. Thus, for example, it is known of pseudouridine 5′-triphosphate that this occurs naturally in structural RNAs (tRNA, rRNA and snRNA) in eukaryotes as well as in prokaryotes. In this connection, it is assumed that pseudouridine is necessary in rRNA for stabilizing secondary structures. In the course of evolution, the content of pseudouridine in RNA has increased, and it has been possible to demonstrate, surprisingly, that the translation depends on the presence of pseudouridine in the tRNA and rRNA, the interaction between tRNA and mRNA presumably being intensified in this context. The conversion of uridine into pseudouridine takes place posttranscriptionally by pseudouridine synthase. A posttranscriptional modification of RNA likewise takes place in the case of 5-methylcytidine 5′-triphosphate, and is catalysed by methyltransferases. A further increase in the content of pseudouridine and the base modification of other nucleotides is assumed to lead to similar effects, which, in contrast to the naturally occurring increased contents of pseudouridine in the sequence, can be carried out in a targeted manner and with a considerably wider variability. For 5-methylcytidine 5′-triphosphate and the further base modifications mentioned here, a similar mechanism to that for pseudouridine 5′-triphosphate is therefore assumed, i.e. an improved stabilizing of secondary structures, and on the basis of this an improved translation efficiency. In addition to this structurally based increase in expression, however, a positive effect on the translation is presumed, independently of the stabilizing of secondary structures and a “more rigid” structure of the RNA. Further causes of the increase in expression are also to be found, possibly, in the lower degradation rate of the RNA sequences by RNAses in vitro or in vivo.
- The modifications of the antibody-coding RNA according to the invention which are described above can be introduced into the RNA with the aid of methods known to a person skilled in the art. Possible methods for this are, for example, synthesis methods using (automatic or semi-automatic) oligonucleotide synthesis apparatuses, biochemical methods, such as e.g. in vitro transcription methods, etc. Preferably, in this connection, for (shorter) sequences which in general do not exceed a length of 50-100 nucleotides, synthesis methods using (automatic or semi-automatic) oligonucleotide synthesis apparatuses and also in vitro transcription methods can be employed. For (longer) sequences, e.g. sequences which have a length of more than 50 to 100 nucleotides, biochemical methods are preferred, such as, for example, in vitro transcription methods, preferably an in vitro transcription method as described here, optionally using the modified RNA according to the invention.
- Modifications with nucleotides as described here in an antibody-coding RNA according to the invention can occur on at least one (modifiable) nucleotide of the RNA sequence according to the invention, preferably on at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 (modifiable) nucleotides, more preferably on at least 10-20 (modifiable) nucleotides, even more preferably on at least 10-100 (modifiable) nucleotides and most preferably on at least 10-200, 10 to 1,000 or 10 to 10,000 or more (modifiable), e.g. all, nucleotides. Worded alternatively, modifications in an antibody-coding RNA according to the invention can occur on at least one (modifiable) nucleotide of the RNA sequence according to the invention, preferably on at least 10% of all the (modifiable) nucleotides, more preferably on at least 25% of all the (modifiable) nucleotides, even more preferably on at least 50% of all the (modifiable) nucleotides, even more preferably on at least 75% of all the (modifiable) nucleotides and most preferably on 100% of the (modifiable) nucleotides contained in the RNA sequence according to the invention. In this connection, a “modifiable nucleotide” is any (preferably naturally occurring (native) and therefore non-modified) nucleotide which is to be exchanged for a nucleotide modified as described here. In this context, all the nucleotides of the RNA sequence can be modified, or only certain selected nucleotides of the RNA sequence. If all the nucleotides of the RNA sequence are to be modified, 100% of the “modifiable nucleotides” of the RNA sequence are all the nucleotides of the RNA sequence used. On the other hand, if only certain selected nucleotides of the RNA sequence are to be modified, the selected nucleotides are, for example, adenosine, cytidine, guanosine or uridine. Thus, for example, an adenosine of the native sequence can be exchanged for a modified adenosine, a cytidine for a modified cytidine, a uridine for a modified uridine and a guanosine for a modified guanosine. In this case, 100% of the “modifiable nucleotides” of the RNA sequence are 100% of the adenosines, cytidines, guanosines and/or uridines in the RNA sequence used.
- According to another very preferred embodiment of the present invention, the antibody-coding RNA according to the invention can contain, for example, a GC content which has been modified compared with the native, i.e. non-modified (precursor) RNA sequence. According to a first alternative of the antibody-coding RNA according to the invention, the G/C content for the coding region of the RNA according to the invention is greater than the G/C content for the coding region of the native RNA sequence, the coded amino acid sequence of the antibody or antibody fragment being unchanged compared with the wild-type, i.e. the antibody or antibody fragment amino acid sequence coded by the native RNA sequence. In this context, the composition and the sequence of the various nucleotides plays a major role. In particular, sequences having an increased G (guanine)/C (cytosine) content are more stable than sequences having an increased A (adenine)/U (uracil) content. According to the invention, the codons are therefore varied compared with the wild-type RNA, while retaining the translated amino acid sequence, such that they include an increased amount of G/C nucleotides. Since several codons code for one and the same amino acid (degeneration of the genetic code), the most favourable codons for the stability can be determined (alternative codon usage).
- Depending on the amino acid to be coded by the antibody-coding RNA according to the invention, there are various possibilities for modification of the native sequence of the RNA according to the invention. In the case of amino acids which are coded by codons which contain exclusively G or C nucleotides, no modification of the codon is necessary. Thus, the codons for Pro (CCC or CCG), Arg (CGC or CGG), Ala (GCC or GCG) and Gly (GGC or GGG) require no modification, since no A or U is present.
- In the following cases, the codons which contain A and/or U nucleotides are modified by substitution of other codons which encode the same amino acids but contain no A and/or U. Examples are:
-
- the codons for Pro can be modified from CCU or CCA to CCC or CCG;
- the codons for Arg can be modified from CGU or CGA or AGA or AGG to CGC or CGG;
- the codons for Ala can be modified from GCU or GCA to GCC or GCG;
- the codons for Gly can be modified from GGU or GGA to GGC or GGG.
- In other cases, although A or U nucleotides cannot be eliminated from the codons, it is however possible to decrease the A and U content by using codons which contain fewer A and/or U nucleotides. For example:
-
- the codons for Phe can be modified from UUU to UUC;
- the codons for Leu can be modified from UUA, CUU or CUA to CUC or CUG;
- the codons for Ser can be modified from UCU or UCA or AGU to UCC, UCG or AGC;
- the codon for Tyr can be modified from UAU to UAC;
- the stop codon UAA can be modified to UAG or UGA;
- the codon for Cys can be modified from UGU to UGC;
- the codon for His can be modified from CAU to CAC;
- the codon for Gln can be modified from CAA to CAG;
- the codons for Ile can be modified from AUU or AUA to AUC;
- the codons for Thr can be modified from ACU or ACA to ACC or ACG;
- the codon for Asn can be modified from AAU to AAC;
- the codon for Lys can be modified from AAA to AAG;
- the codons for Val can be modified from GUU or GUA to GUC or GUG;
- the codon for Asp can be modified from GAU to GAC;
- the codon for Glu can be modified from GAA to GAG.
- In the case of the codons for Met (AUG) and Trp (UGG), on the other hand, there is no possibility of sequence modification.
- The substitutions listed above can of course be used individually or also in all possible combinations to increase the G/C content of the antibody-coding RNA according to the invention compared with the native RNA sequence (and nucleic acid sequence, respectively). Thus, for example, all the codons for Thr occurring in the native RNA sequence can be modified to ACC (or ACG). Preferably, however, combinations of the above substitution possibilities are used, e.g.: substitution of all codons coding for Thr in the native RNA sequence by ACC (or ACG) and substitution of all codons originally coding for Ser by UCC (or UCG or AGC);
-
- substitution of all codons coding for Ile in the native RNA sequence by AUC and substitution of all codons originally coding for Lys by AAG and substitution of all codons originally coding for Tyr by UAC;
- substitution of all codons coding for Val in the native RNA sequence by GUC (or GUG) and substitution of all codons originally coding for Glu by GAG and substitution of all codons originally coding for Ala by GCC (or GCG) and substitution of all codons originally coding for Arg by CGC (or CGG);
- substitution of all codons coding for Val in the native RNA sequence by GUC (or GUG) and substitution of all codons originally coding for Glu by GAG and substitution of all codons originally coding for Ala by GCC (or GCG) and substitution of all codons originally coding for Gly by GGC (or GGG) and substitution of all codons originally coding for Asn by AAC;
- substitution of all codons coding for Val in the native RNA sequence by GUC (or GUG) and substitution of all codons originally coding for Phe by UUC and substitution of all codons originally coding for Cys by UGC and substitution of all codons originally coding for Leu by CUG (or CUC) and substitution of all codons originally coding for Gln by CAG and substitution of all codons originally coding for Pro by CCC (or CCG);
- etc.
- Preferably, the G/C content of the coding region of the antibody-coding RNA according to the invention is increased compared with the G/C content of the coding region of the native RNA such that at least 5%, at least 10%, at least 15%, at least 20%, at least 25% or more preferably at least 30%, at least 35%, at least 40%, at least 45%, at least 50% or at least 55%, even more preferably at least 60%, at least 65%, at least 70% or at least 75% and most preferably at least 80%, at least 85%, at least 90%, at least 95% or at least 100% of the possible modifiable codons of the coding region of the native RNA (and nucleic acid, respectively) are modified.
- In this connection, it is particularly preferable to increase to the maximum the G/C content of the antibody-coding RNA according to the invention, in particular in the coding region, compared with the native RNA sequence.
- A second alternative of the antibody-coding RNA according to the invention with modifications is based on the knowledge that the translation efficiency of the RNA is also determined by a different frequency in the occurrence of tRNAs in cells. Thus, if so-called “rare” codons are present in an RNA sequence to an increased extent, the corresponding RNA is translated to a significantly poorer degree than in the case where codons which code for relatively “frequent” tRNAs are present.
- According to this second alternative of the antibody-coding RNA according to the invention, the coding region of the RNA according to the invention is therefore modified compared with the coding region of the native RNA such that at least one codon of the native RNA which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is relatively frequent in the cell and which carries the same amino acid as the relatively rare tRNA.
- By this modification, the sequence of the antibody-coding RNA according to the invention is modified such that codons for which frequently occurring tRNAs are available are inserted. Which tRNAs occur relatively frequently in the cell and which, in contrast, are relatively rare is known to a person skilled in the art; cf. e.g. Akashi, Curr. Opin. Genet. Dev. 2001, 11(6): 660-666.
- According to the invention, by this modification all codons of the sequence of the antibody-coding RNA according to the invention which code for a tRNA which is relatively rare in the cell can be exchanged for a codon which codes for a tRNA which is relatively frequent in the cell and which carries the same amino acid as the relatively rare tRNA.
- It is particularly preferable to link the increased, in particular maximum, sequential G/C content in the antibody-coding RNA according to the invention with the “frequent” codons without modifying the amino acid sequence coded by the RNA according to the invention. This preferred embodiment provides a particularly efficiently translated and stabilized RNA sequence according to the invention which encodes an antibody (for example for a pharmaceutical composition according to the invention).
- In the sequences of eukaryotic RNAs, there are typically destabilizing sequence elements (DSE) to which signal proteins bind and regulate the enzymatic degradation of the RNA in vivo. For further stabilization of the antibody-coding RNA according to the invention, one or more modifications compared with the corresponding region of the native RNA are therefore optionally carried out in the region coding for the protein, so that no destabilizing sequence elements are present. According to the invention, it is of course also preferable, where appropriate, to eliminate from the RNA DSEs present in the untranslated regions (3′ and/or 5′ UTR).
- Such destabilizing sequences are, for example, AU-rich sequences (“AURES”), which occur in 3′ UTR sections of numerous unstable RNAs (Caput et al., Proc. Natl. Acad. Sci. USA 1986, 83: 1670 to 1674). The antibody-coding RNA according to the invention is therefore preferably modified compared with the native RNA such that this no longer contains such destabilizing sequences. This also applies to those sequence motifs which are recognized by possible endonucleases, for example the sequence GAACAAG, which is contained in the 3′ UTR segment of the gene which codes for the transferrin receptor (Binder et al., EMBO J. 1994, 13: 1969 to 1980). These sequence motifs are also preferably eliminated in the antibody-coding RNA according to the invention.
- A person skilled in the art is familiar with various methods which are suitable in the present case for substitution of codons in RNAs, i.e. substitution of codons in the antibody-coding RNA according to the invention. In the case of relatively short coding regions (which code for antibodies or antibody fragments as described here), for example, the total antibody-coding RNA according to the invention can be synthesized chemically using standard techniques such as are familiar to a person skilled in the art.
- Nevertheless, base substitutions are preferably introduced using a DNA template for the preparation of the antibody-coding RNA according to the invention with the aid of techniques of the usual targeted mutagenesis (see, for example, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 3rd ed., Cold Spring Harbor, N.Y., 2001). In this method, for the preparation of the antibody-coding RNA according to the invention, a corresponding DNA molecule is therefore transcribed in vitro (see below). This DNA template optionally has a suitable promoter, for example a T3, T7 or SP6 promoter, for the in vitro transcription, which is followed by the desired nucleotide sequence for the antibody-coding RNA according to the invention to be prepared and a termination signal for the in vitro transcription. The DNA molecule which forms the template of the antibody-coding RNA construct to be prepared can be prepared by fermentative proliferation and subsequent isolation as part of a plasmid which can be replicated in bacteria. Plasmids which may be mentioned as suitable for this are, for example, the plasmids pT7 Ts (GenBank accession number U26404; Lai et al., Development 1995, 121: 2349 to 2360), pGEM® series, for example pGEM®-1 (GenBank accession number X65300; from Promega) and pSP64 (GenBank accession number X65327); cf. also Mezei and Storts, Purification of PCR Products, in: Griffin and Griffin (ed.), PCR Technology: Current Innovation, CRC Press, Boca Raton, Fla., 2001.
- Using short synthetic RNA or DNA oligonucleotides which contain short single-stranded transitions at the cleavage sites formed, or genes prepared by chemical synthesis, the desired nucleotide sequence can thus be cloned into a suitable plasmid by molecular biology methods with which a person skilled in the art is familiar (cf. Maniatis et al., (2001) supra). The RNA or DNA molecule is then cut out of the plasmid, in which it can be present in one or several copies, by digestion with restriction endonucleases.
- According to a particular embodiment of the present invention, the antibody-coding (modified) RNA according to the invention described above, especially if the RNA is in the form of mRNA, can moreover have a 5′ cap structure (a modified guanosine nucleotide). Examples of cap structures which may be mentioned, without being restricted thereto, are m7G(5′)ppp (5′(A,G(5′)ppp(5′)A and G(5′)ppp(5′)G.
- According to a further preferred embodiment of the present invention, the antibody-coding (modified) RNA according to the invention contains, especially if the RNA is in the form of mRNA, a poly-A tail on the 3′ terminus of typically about 10 to 200 adenosine nucleotides, preferably about 10 to 100 adenosine nucleotides, more preferably about 20 to 70 adenosine nucleotides or even more preferably about 20 to 60 adenosine nucleotides.
- According to another preferred embodiment of the present invention, the antibody-coding (modified) RNA according to the invention contains, especially if the RNA is in the form of mRNA, a poly-C tail on the 3′ terminus of typically about 10 to 200 cytosine nucleotides (SEQ ID NO: 54), preferably about 10 to 100 cytosine nucleotides (SEQ ID NO: 55), more preferably about 20 to 70 cytosine nucleotides (SEQ ID NO: 56) or even more preferably about 20 to 60 (SEQ ID NO: 57) or even 10 to 40 cytosine nucleotides (SEQ ID NO: 58). The poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
- According to a further embodiment, the antibody-coding (modified) RNA according to the invention can additionally contain a nucleic acid section which codes a tag for purification. Such tags include, but without being limited thereto, e.g. a hexahistidine tag (SEQ ID NO: 59) (His tag, polyhistidine tag), a streptavidin tag (Strep tag), an SBP tag (streptavidin-binding tag) a GST (glutathione S transferase) tag etc. The antibody-coding (modified) RNA according to the invention can furthermore encode a tag for purification via an antibody epitope (antibody-binding tag), e.g. a Myc tag, an
Swal 1 epitope, a FLAG tag, an HA tag etc., i.e. via recognition of the epitope via the (immobilized) antibody. - For efficient translation of RNA, in particular mRNA, effective binding of the ribosomes to the ribosome binding site (Kozak sequence: GCCGCCACCAUGG (SEQ ID NO: 16), the AUG forms the start codon) is necessary. In this respect, it has been found that an increased A/U content around this site renders possible a more efficient ribosome binding to the RNA. According to another preferred embodiment of the present invention, the antibody-coding (modified) RNA according to the invention can therefore have an increased A/U content around the ribosome binding site, preferably an A/U content which is increased by 5 to 50%, more preferably one increased by 25 to 50% or more, compared with the native RNA.
- According to one embodiment of the antibody-coding (modified) RNA according to the invention, it is furthermore possible to insert one or more so-called IRES (internal ribosomal entry site) into the RNA. An IRES can thus function as the sole ribosome binding site, but it can also serve to provide an antibody-coding (modified) RNA according to the invention which codes for several antibodies or antibody fragments or for at least one antibody or antibody fragment which are to be translated by the ribosomes independently of one another (“multicistronic RNA”). Such an RNA can code, for example, a complete sequence of an antibody, the corresponding coding regions of the heavy and light chain being linked (functionally) with one another by an IRES sequence. However, the heavy and light chain to be encoded by the inventive RNA may also be located in one single “cistron”. According to the invention, the IRES sequences described are employed in particular for (virtually) simultaneous and uniform expression of the light and the heavy chains of the antibody coded by the RNA according to the invention. Examples of IRES sequences which can be used according to the invention are those from picornaviruses (e.g. FMDV), pestiviruses (CFFV), polioviruses (PV), encephalomyocarditis viruses (ECMV), foot and mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukoma virus (MLV), simian immunodeficiency viruses (SIV), cricket paralysis viruses (CrPV) or an SIRES sequence.
- According to a further preferred embodiment of the present invention, the antibody-coding (modified) RNA according to the invention has, in the 5′ and/or 3′ untranslated regions, stabilizing sequences which are capable of increasing the half-life of the RNA in the cytosol. These stabilizing sequences can have a 100% sequence homology to naturally occurring sequences which occur in viruses, bacteria and eukaryotes, but can also be partly or completely synthetic in nature. The untranslated sequences (UTR) of the β-globin gene, for example from Homo sapiens or Xenopus laevis, may be mentioned as an example of stabilizing sequences which can be used in the present invention. Another example of a stabilizing sequence has the general formula (C/U)CCANxCCC(U/A)PyxUC(C/U)CC (SEQ ID NO: 17), which is contained in the 3′ UTR of the very stable RNA which codes for α-globin, α-(I)-collagen, 15-lipoxygenase or for tyrosine hydroxylase (cf. Holcik et al., Proc. Natl. Acad. Sci. USA 1997, 94: 2410 to 2414). Such stabilizing sequences can of course be used individually or in combination with one another and also in combination with other stabilizing sequences known to a person skilled in the art.
- In a further preferred embodiment, the antibody-coding (modified) RNA according to the invention can encode a secretory signal peptide, in addition to the antibodies as described here. Such signal peptides are (signal) sequences which conventionally comprise a length of from 15 to 30 amino acids and are preferably localized on the N-terminus of the coded antibody. Signal peptides typically render possible transport of a protein or peptide fused therewith (here e.g. an antibody) to or into a defined cell compartment, preferably the cell surface, the endoplasmic reticulum or the endosomal-lysosomal compartment. Examples of signal sequences which can be used according to the invention are e.g. signal sequences of conventional and non-conventional MHC molecules, cytokines, immunoglobulins, the invariant chain, Lamp1, tapasin, Erp57, calreticulin and calnexin, and all further membrane-located, endosomally-lysosomally or endoplasmic reticulum-associated proteins. The signal peptide of the human MHC class I molecule HLA-A*0201 is preferably used.
- Sequences which render possible transport of a protein or peptide fused therewith (here e.g. an antibody) to or into a defined cell compartment, preferably the cell surface, the nucleus, the nucleus region, the plasma membrane, the cytosol, the endoplasmic reticulum, the organelles, the mitochondria, the Golgi apparatus or the endosomal-lysosomal compartment, also include, without being limited thereto, so-called routing signals, sorting signals, retention signals or salvage signals and membrane topology-stop transfer signals (cf. Pugsley, A. P., Protein Targeting, Academic Press, Inc. (1989)) at the level of the RNA according to the invention. In this connection, localization sequences include nucleic acid sequences which encode e.g. signals, i.e. amino acid sequences, such as, for example, KDEL (SEQ ID NO: 18) (Munro, et al., Cell 48:899-907 (1987)) DDEL (SEQ ID NO: 19), DEEL (SEQ ID NO: 20), QEDL (SEQ ID NO: 21) and RDEL (SEQ ID NO: 22) (Hangejorden, et al., J. Biol. Chem. 266:6015 (1991)) for the endoplasmic reticulum; PKKKRKV (SEQ ID NO: 23) (Lanford, et al. Cell 46:575 (1986)) PQKKIKS (SEQ ID NO: 24) (Stanton, L. W., et al., Proc. Natl. Acad. Sci USA 83:1772 (1986); QPKKP (SEQ ID NO: 25) (Harlow, et al., Mol. Cell Biol. 5:1605 1985), and RKKR (SEQ ID NO:26) for the nucleus; and RKKRRQRRRAHQ (SEQ ID NO: 27) (Seomi, et al., J. Virology 64:1803 (1990)), RQARRNRRRRWRERQR (SEQ ID NO: 28) (Kubota, et al., Biochem. and Biophy, Res. Comm. 162:963 (1989)), and MPLTRRRPAASQALAPPTP (SEQ ID NO: 29) (Siomi, et al., Cell 55:197 (1988)) for the nucleus region; MDDQRDLISNNEQLP (SEQ ID NO: 30) (Bakke, et al., Cell 63:707-716 (1990)) for the endosomal compartment (see, for example, Letourneur, et al., Cell 69:1183 (1992) for the targeting of liposomes). Myristoylation sequences can furthermore be used in order to lead the expressed protein or peptide (here e.g. an antibody) to the plasma membrane, or to certain various sub-cell compartments, such as the nucleus region, the organelles, the mitochondria and the Golgi apparatus. Corresponding amino acid sequences which are coded by a corresponding codon sequence of the RNA according to the invention are given below. The sequence MLFNLRXXLNNAAFRHGHNFMVRNFRCGQPLX (SEQ ID NO: 31) can be used to lead the antibody to the mitochondrial matrix (Pugsley, supra). See Tang, et al., J. Bio. Chem. 207:10122, in respect of the localization of proteins (antibodies) to the Golgi apparatus; for the localization of proteins to the plasma membrane: GCVCSSNP (SEQ ID NO: 32), GQTVTTPL (SEQ ID NO: 33), GQELSQHE (SEQ ID NO: 34), GNSPSYNP (SEQ ID NO: 35), GVSGSKGQ (SEQ ID NO: 36), GQTITTPL (SEQ ID NO: 37), GQTLTTPL (SEQ ID NO: 38), GQIFSRSA (SEQ ID NO: 39), GQIHGLSP (SEQ ID NO: 40), GARASVLS (SEQ ID NO: 41), and GCTLSAEE (SEQ ID NO: 42); to the endoplasmic reticulum GQNLSTSN (SEQ ID NO: 43); to the nucleus GAALTILV (SEQ ID NO: 44) and GAALTLLG (SEQ ID NO: 45); to the endoplasmic reticulum and to the cytoplasm GAQVSSQK (SEQ ID NO: 46) and GAQLSRNT (SEQ ID NO: 47); to the Golgi apparatus, to the nucleus, to the cytoplasm and to the cytoskeleton: GNAAAAKK (SEQ ID NO: 48); to the cytoplasm and to the cytoskeleton GNEASYPL (SEQ ID NO: 49); and to the plasma membrane and to the cytoskeleton GSSKSKPK (SEQ ID NO: 50). Such sequences as described above are preferably used for RNAs which code for intrabodies, i.e antibodies which are retained in the cell and are not secreted.
- The modifications described here can be introduced into the antibody-coding RNA sequence according to the invention in a suitable manner by a person skilled in the art. For example, the optimum modified RNA according to the invention can be determined by methods known to the person skilled in the art, e.g. the G/C content can be adapted manually and/or by means of an automated method as disclosed in WO 02/098443. In this context, the RNA sequences can be adapted with the various additional optimization aims described here: On the one hand, the adaptation can be carried out with the highest possible G/C content, and on the other hand taking into the best possible account the frequency of the tRNAs according to codon usage. In this context, in the first step of the method a virtual translation of any desired RNA (or DNA) sequence is carried out in order to generate the corresponding amino acid sequence. Starting from the amino acid sequence, a virtual reverse translation is carried out, which on the basis of the degenerated genetic code provides selection possibilities for the corresponding codons. Depending on the optimization or modification required, corresponding selection lists and optimization algorithms are used for selection of the suitable codons. The algorithm is typically implemented on a computer with the aid of suitable software. The optimized RNA sequence is established in this way and can be displayed, for example, with the aid of an appropriate display device and compared with the original (wild-type) sequence. The same also applies to the frequency of the individual nucleotides. In this context, the changes compared with the original nucleotide sequence are preferably highlighted. According to a preferred embodiment, stable sequences which are known in nature and can provide the basis for an RNA stabilized in accordance with natural sequence motifs are furthermore read in. A secondary structure analysis which can analyse stabilizing and destabilizing properties or, respectively, regions of the RNA with the aid of structure calculations can likewise be envisaged.
- Furthermore, according to a preferred embodiment effective transfer of the antibody-coding (modified) RNA according to the invention into the cells to be treated or the organism to be treated can be improved by complexing the antibody-coding (modified) RNA according to the invention with a cationic peptide or protein or binding it thereto. Such a complexing/condensing of the RNA, in particular mRNA, includes, for example, complexing (or binding) of the RNA according to the invention with a (poly)cationic polymer, polyplexes, protein(s), in particular polycationic protein(s), or peptide(s). Preferably, an RNA (mRNA) according to the invention is complexed or condensed with at least one cationic or polycationic agent. Preferably, such a cationic or polycationic agent is an agent which is chosen from the group consisting of protamine, poly-L-lysine, poly-L-arginine, nucleolin, spermin and histones, nucleolin or derivatives thereof. The use of protamine as a polycationic, nucleic acid-binding protein is particularly preferred. This procedure for stabilizing RNA is described, for example, in EP-A-1083232, the disclosure content of which in this respect is included in its full scope in the present invention.
- According to a particular embodiment, the antibody-coding (modified) RNA according to the invention can contain a lipid modification. Such an RNA modified with a lipid typically comprises an antibody-coding RNA, as defined here, according to the invention, at least one linker covalently linked with this RNA and at least one lipid covalently linked with the particular linker. Alternatively, the (modified) RNA according to the invention modified with a lipid comprises (at least) one (modified) RNA, as defined here, according to the invention and at least one (bifunctional) lipid covalently linked with this RNA. According to a third alternative the (modified) RNA according to the invention modified with a lipid comprises a (modified) RNA, as defined here, according to the invention, at least one linker covalently linked with this RNA and at least one lipid linked covalently with the particular linker and at least one (bifunctional) lipid covalently linked (without a linker) with this (modified) RNA according to the invention.
- The lipid employed for lipid modification of the antibody-coding (modified) RNA according to the invention is typically a lipid or a lipophilic residue, which is preferably biologically active per se. Such lipids preferably include natural substances, or compounds, such as e.g. vitamins, e.g. α-tocopherol (vitamin E), including RRR-α-tocopherol (formerly D-α-tocopherol), L-α-tocopherol, the racemate D,L-α-tocopherol, vitamin E succinate (VES) or vitamin A and derivatives thereof, e.g. retinic acid, retinol, vitamin D and derivatives thereof, e.g. vitamin D and ergosterol precursors thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, e.g. vitamin K and related quinone or phytol compounds, or steroids, such as bile acids, for example cholic acid, deoxycholic acid, dehydrocholic acid, cortisone, digoxygenin, testosterone, cholesterol or thiocholesterol. Further lipids or lipophilic residues in the context of the present invention include, without being limited thereto, polyalkylene glycols, (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533), aliphatic groups, such as e.g. C1-C20-alkanes, C1-C20-alkenes, or C1-C20-alkanol compounds etc., such as, for example, dodecanediol, hexadecanol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 111; Kabanov et al., FEBS Lett., 1990, 259, 327; Svinarchuk et al., Biochimie, 1993, 75, 49), phospholipids, such as e.g. phosphatidylglycerol, diacylphosphatidylglycerol, phosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, dihexadecyl-racglycerol, sphingolipids, cerebrosides, gangliosides, or
triethylammonium 1,2-di-O-hexadecylrac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651; Shea et al., Nucl. Acids Res., 1990, 18, 3777), polyamines or polyalkylene glycols, such as e.g. polyethylene glycol (PEG) (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969), hexaethylene glycol (HEG), palmitin, or palmityl residues (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229), octadecylamines, or hexylaminocarbonyloxycholesterol residues (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923), and waxes, terpenes, alicyclic hydrocarbons, saturated or mono- or polyunsaturated fatty acid residues etc. - The linking between the lipid and the antibody-coding (modified) RNA according to the invention can in principle take place on any nucleotide, on the base or the sugar residue of any nucleotide, on the 3′ and/or 5′ end, and/or on the phosphate backbone of the antibody-coding (modified) RNA according to the invention. According to the invention, a terminal lipid modification of the (modified) RNA according to the invention on the 3′ and/or 5′ end thereof is particularly preferred. A terminal modification has several advantages over modifications within the sequence. On the one hand, modifications within the sequence can influence the hybridization properties, which may have an adverse effect in the case of sterically demanding residues. (Sterically demanding) modifications within the sequence very often also interfere in translation, which can frequently lead to an interruption in the protein synthesis. On the other hand, in the case of preparation by synthesis of a lipid-modified (modified) RNA according to the invention which is modified exclusively terminally, synthesis of this antibody-coding (modified) RNA according to the invention is carried out with monomers which are commercially available in large amounts, and synthesis protocols known in the prior art are used.
- According to a first preferred embodiment, the linking takes place between the antibody-coding (modified) RNA according to the invention and at least one lipid via a linker (linked covalently with the (modified) RNA). Linkers in the context of the present invention typically contain at least two and optionally 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30 or more reactive groups, chosen from e.g. a hydroxyl group, an amino group, an alkoxy group etc. One reactive group preferably serves to bond the antibody-coding (modified) RNA according to the invention described here. This reactive group can be in a protected form, e.g. as a DMT (dimethoxytrityl chloride) group, as an Fmoc group, as an MMT (monomethoxytrityl) group, as a TFA (trifluoroacetic acid) group etc. Sulfur groups can furthermore be protected by disulfides, e.g. alkylthiols, such as, for example, 3-thiopropanol, or with activated components, such as 2-thiopyridine. According to the invention, one or more further reactive groups serve for covalent bonding of one or more lipids. According to the first embodiment, an antibody-coding (modified) RNA according to the invention can therefore bond at least one lipid via the covalently bonded linker, e.g. 1, 2, 3, 4, 5, 5-10, 10-20, 20-30 or more lipid(s), particularly preferably at least 3-8 or more lipids per (modified) RNA. In this context, the bonded lipids can be bonded separately from one another at various positions of the antibody-coding (modified) RNA according to the invention, but can also be in the form of a complex at one or more positions of the (modified) RNA. An additional reactive group of the linker can be used for direct or indirect (cleavable) bonding to a carrier material, e.g. a solid phase. Preferred linkers according to the present invention are e.g. glycol, glycerol and glycerol derivatives, 2-aminobutyl-1,3-propanediol and 2-aminobutyl-1,3-propanediol derivatives/matrix, pyrrolidine linkers or pyrrolidine-containing organic molecules (in particular for a modification on the 3′ end) etc. According to the invention, glycerol or glycerol derivatives (C3 anchor) or a 2-aminobutyl-1,3-propanediol derivative/matrix (C7 anchor) are particularly preferably used as linkers. A glycerol derivative (C3 anchor) as a linker is particularly preferred if the lipid modification can be introduced via an ether bond. If the lipid modification is to be introduced e.g. via an amide or an urethane bond, e.g. a 2-aminobutyl-1,3-propanediol matrix (C7 anchor) is preferred. In this connection, the bond formed between the linker and the antibody-coding (modified) RNA according to the invention is preferably such that it is compatible with the conditions and chemicals of amidite chemistry, that is to say it is preferably neither acid-nor base-labile. In particular, those bonds which are readily accessible synthetically and are not hydrolysed by the ammoniacal cleavage procedure of a nucleic acid synthesis process are preferred. Possible bonds are in principle all appropriately suitable bonds, preferably ester bonds, amide bonds, urethane bonds and ether bonds. In addition to the good accessibility of the educts (few synthesis stages), the ether bond is particularly preferred in this context because of its relatively high biological stability to enzymatic hydrolysis.
- According to a second preferred embodiment, for the lipid modification of the (modified) RNA according to the invention the linking of (at least one) (modified) RNA according to the invention takes place directly with at least one (bifunctional) lipid as described here, i.e. without using a linker as described here. In this case, the (bifunctional) lipid according to the invention preferably contains at least two reactive groups, or optionally 3, 4, 5, 6, 7, 8, 9, 10 or more reactive groups, a first reactive group serving for direct or indirect bonding of the lipid to a carrier material described here and at least one further reactive group serving for bonding of the (modified) RNA. According to the second embodiment, an antibody-coding (modified) RNA according to the invention can therefore preferably bond at least one lipid (directly without a linker), e.g. 1, 2, 3, 4, 5, 5-10, 10-20, 20-30 or more lipid(s), particularly preferably at least 3-8 or more lipids per (modified) RNA. In this context, the bonded lipids can be bonded separately from one another at various positions of the antibody-coding (modified) RNA according to the invention, but can also be in the form of a complex at one or more positions of the (modified) RNA. Alternatively, according to the second embodiment, at least one antibody-coding (modified) RNA, e.g. optionally 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30 or more (modified) RNAs, according to the invention can be bonded to a lipid as described above via reactive groups thereof. Lipids which can be used for this second embodiment particularly preferably include such (bifunctional) lipids which render possible a coupling (preferably on their termini or optionally intramolecularly), such as e.g. polyethylene glycol (PEG) and derivatives thereof, hexaethylene glycol (HEG) and derivatives thereof, alkanediols, aminoalkanes, thioalkanols etc. The bond between a (bifunctional) lipid and an antibody-coding (modified) RNA according to the invention as described above is preferably such as is described for the first preferred embodiment.
- According to a third embodiment, for the lipid modification of the (modified) RNA according to the invention the linking between the antibody-coding (modified) RNA according to the invention and at least one lipid as described here takes place via both of the abovementioned embodiments simultaneously. Thus e.g. the antibody-coding (modified) RNA according to the invention can be linked at one position of the RNA with at least one lipid via a linker (analogously to the 1st embodiment) and at another position of the (modified) RNA directly with at least one lipid without using a linker (analogously to the 2nd embodiment). For example, at least one lipid as described here can be linked covalently with the RNA at the 3′ end of the (modified) RNA via a linker, and a lipid as described here can be linked covalently with the RNA at the 5′ end of the (modified) RNA without a linker. Alternatively, at least one lipid as described here can be linked covalently with the (modified) RNA at the 5′ end of an antibody-coding (modified) RNA according to the invention via a linker, and a lipid as described here can be linked covalently with the (modified) RNA at the 3′ end of the (modified) RNA without a linker. Covalent linkings can likewise take place not only on the termini of the antibody-coding (modified) RNA according to the invention, but also intramolecularly, as described above, e.g. on the 3′ end and intramolecularly, on the 5′ end and intramolecularly, on the 3′ and 5′ end and intramolecularly, exclusively intramolecularly etc.
- The (modified) RNA according to the invention described here can be prepared by preparation processes known in the prior art, e.g. automatically or manually via known nucleic acid syntheses (see, for example, Maniatis et al. (2001) supra) or also via molecular biology methods, for example with subsequent purification, for example via chromatography methods.
- According to further subject matter of the present invention, the antibody-coding (modified) RNA according to the invention can be used for the preparation of a pharmaceutical composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or optionally monogenetic diseases, e.g. in gene therapy.
- A pharmaceutical composition in the context of the present invention comprises an antibody-coding (modified) RNA as described here and optionally a pharmaceutically suitable carrier and/or further auxiliary substances and additives. The pharmaceutical composition employed according to the present invention typically comprises a safe and effective amount of a (modified) RNA as described here. As used here, “safe and effective amount” means an amount of the antibody-coding (modified) RNA according to the invention such as is sufficient to induce significantly, by expression of the coded antibody, a positive change of a state to be treated, e.g. a tumour disease or cancer disease, a cardiovascular disease or an infectious disease, as described in the following. At the same time, however, a “safe and effective amount” is low enough to avoid serious side effects in the therapy of these diseases, that is to say to render possible a reasonable ratio of advantage and risk. Determination of these limits typically lies within the range of reasonable medical judgement. The concentration of the antibody-coding (modified) RNA according to the invention in such pharmaceutical compositions can therefore vary, for example, without being limited thereto, within a wide range of from e.g. 0.1 ng to 1,000 mg/ml. Such a “safe and effective amount” of an antibody-coding (modified) RNA according to the invention can vary in connection with the particular state to be treated and the age and the physical state of the patient to be treated, the severity of the state, the duration of the treatment, the nature of the concomitant therapy, of the particular pharmaceutically suitable carrier used and similar factors within the knowledge and experience of the treating doctor. The pharmaceutical composition described here can be employed for human and also for veterinary medicine purposes.
- The pharmaceutical composition according to the invention described here can optionally comprise a pharmaceutically suitable carrier (and/or vehicle). The term “pharmaceutically suitable carrier (and/or vehicle)” used here preferably includes one or more compatible solid or liquid carriers or vehicles, (e.g. fillers, or diluents or encapsulating compounds) which are suitable for administration to a person. The term “compatible” as used here means that the constituents of the composition are capable of being mixed together with the antibody-coding (modified) RNA according to the invention and the auxiliary substance optionally contained in the composition, as such and with one another in a manner such that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the composition under usual condition of use, such as e.g. would reduce the pharmaceutical activity of the coded antibody or even suppress or impair expression of the coded antibody. Pharmaceutically suitable carrier must of course have a sufficiently high purity and a sufficiently low toxicity to render them suitable for administration to a person to be treated.
- Pharmaceutically suitable carriers or vehicles, that may be used in the inventive pharmaceutical composition, may be typically distinguished into solid or liquid carriers or vehicles, wherein a specific determination may depend on the viscosity of the respective carrier or vehicle to be used.
- In this context, solid carriers and vehicles typically include e.g., but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, and salts, if provided in solid form, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, or polyvinyl pyrrolidone, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars, such as, for example, lactose, glucose and sucrose; starches, such as, for example, corn starch or potato starch; or cellulose-based substances, e.g. cellulose and its derivatives, such as, for example, sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; pulverized tragacanth; malt; gelatine; tallow; solid lubricants, such as, for example, stearic acid, magnesium stearate; calcium sulfate; wetting agents, such as, for example, sodium lauryl sulfate; colouring agents; flavouring agents; drug (active agent) carriers; tablet-forming agents; stabilizers; antioxidants; preservatives; etc.
- Liquid carriers or vehicles, e.g. for aqueous or oleaginous suspensions, typically include, but are not limited to, e.g., water; pyrogen-free water; solutions of ion exchangers, alumina, aluminum stearate, lecithin, or serum proteins, such as human serum albumin; alginic acid; isotonic saline solutions or phosphate-buffered solutions, Ringer's solution, isotonic sodium chloride solution, etc. or salts or electrolytes, if provided in solubilized form, such as protamine sulfate, phosphates, e.g. disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, or (other) buffer substances including e.g. glycine, sorbic acid, potassium sorbate; liquid solutions of polyols, such as, for example, polyethylene glycol, polypropylene glycol, glycerol, 1,3-butanediol, sorbitol, Mannitol; sterile, fixed oils, any suitable bland fixed oil, e.g. including synthetic mono- or di-glycerides, partial glyceride mixtures of saturated vegetable fatty acids, fatty acids, such as oleic acid and its glyceride derivatives, natural pharmaceutically-acceptable oils, e.g. plant oils, such as, for example, groundnut oil, cottonseed oil, sesame oil, corn oil and oil from Theobroma; olive oil or castor oil, especially in their polyoxyethylated versions. These liquid carriers or vehicles may also contain or comprise a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents, or commonly used surfactants or emulsifiers, such as Tween®, Spans and other emulsifying agents or bioavailability enhancers, etc., if provided in a liquid form.
- The choice of a pharmaceutically suitable carrier as described above is determined in particular by the mode in which the pharmaceutical composition according to the invention is administered. The pharmaceutical composition according to the invention can be administered, for example, systemically. Administration routes include e.g. transdermal, oral, parenteral, including subcutaneous or intravenous injections, topical and/or intranasal routes. The suitable amount of the pharmaceutical composition according to the invention which is to be used can be determined by routine experiments using animal models. Such models include, but without being limited thereto, models of the rabbit, sheep, mouse, rat, dog and non-human primate models. Preferred unit dose forms for injection include sterile solutions of water, physiological saline solution or mixtures thereof. The pH of such solutions should be adjusted to about 7.4. Suitable carriers for injection include hydrogels, devices for controlled or delayed release, polylactic acid and collagen matrices. Pharmaceutically suitable carriers which can be used here include those which are suitable for use in lotions, creams, gels and the like. If the compound is to be administered perorally, tablets, capsules and the like are the preferred unit dose form. The pharmaceutically suitable carriers for the preparation of unit dose forms which can be used for oral administration are well-known in the prior art. Their choice will depend on secondary considerations, such as flavour, cost and storage stability, which are not critical for the purposes of the present invention and can be implemented without difficulties by a person skilled in the art.
- The pharmaceutical composition according to the invention can furthermore comprise an injection buffer, which preferably improves the transfection and also the translation of the antibody-coding RNA according to the invention in cells or an organism. The pharmaceutical composition according to the invention can comprise, for example, an aqueous injection buffer which contains, with respect to the total pharmaceutical composition, if this is in liquid form, a sodium salt, preferably at least 50 mM sodium salt, a calcium salt, preferably at least 0.01 mM calcium salt, and optionally a potassium salt, preferably at least 3 mM potassium salt. According to a preferred embodiment, the sodium salts, calcium salts and optionally potassium salts contained in such an injection buffer are in the form of halides, e.g. chlorides, iodides or bromides, or in the form of their hydroxides, carbonates, bicarbonates or sulfates. Examples which are to be mentioned here are, for the sodium salt NaCl, NaI, NaBr, Na2CO3, NaHCO3, Na2SO4, for the potassium salt optionally present KCl, KI, KBr, K2CO3, KHCO3, K2SO4, and for the calcium salt CaCl2, CaI2, CaBr2, CaCO3, CaSO4, Ca(OH)2. The injection buffer can also contain organic anions of the abovementioned cations. In a particularly preferred embodiment, such an injection buffer contains as salts sodium chloride (NaCl), calcium chloride (CaCl2) and optionally potassium chloride (KCl), it also being possible for other anions to be present in addition to the chlorides.
- These salts are typically present in the injection buffer optionally used in the pharmaceutical composition according to the invention, with respect to the total pharmaceutical composition (if this is in liquid form), in a concentration of at least 50 mM sodium chloride (NaCl), at least 3 mM potassium chloride (KCl) and at least 0.01 mM calcium chloride (CaCl2). The injection buffer can be in the form of both hypertonic and isotonic or hypotonic injection buffers. In connection with the present invention, in this context the injection buffer is hypertonic, isotonic or hypotonic with respect to the particular reference medium, i.e. the injection buffer has either a higher, the same or a lower salt content compared with the particular reference medium, such concentrations of the abovementioned salts which do not lead to damage to the cells caused by osmosis or other concentration effects preferably being employed. Reference media here are, for example, liquids which occur in “in vivo” methods, such as, for example, blood, lymph fluid, cytosol fluids or other fluids which occur in the body, or liquids or buffers conventionally employed in “in vitro” methods. Such liquids and buffers are known to a person skilled in the art.
- The injection buffer optionally contained in the pharmaceutical composition according to the invention can also contain further components, for example sugars (mono-, di-, tri- or polysaccharides), in particular glucose or mannitol. In a preferred embodiment, however, no sugars are present in the injection buffer used. It is also preferable for the injection buffer precisely to contain no non-charged components, such as, for example, sugars. The injection buffer typically contains exclusively metal cations, in particular from the group consisting of the alkali or alkaline earth metals, and anions, in particular the anions described above. The pH of the injection buffer used, with respect to the total pharmaceutical composition, if this is in liquid form, is preferably between 1 and 8.5, preferably between 3 and 5, more preferably between 5.5 and 7.5, in particular between 5.5 and 6.5. If appropriate, the injection buffer can also contain a buffer system which fixes the injection buffer at a buffered pH. This can be, for example, a phosphate buffer system, HEPES or Na2HPO4/NaH2PO4. However, the injection buffer used very particularly preferably contains none of the abovementioned buffer systems or contains no buffer system at all.
- The injection buffer optionally contained in the pharmaceutical composition according to the invention can contain, in addition to or as an alternative to the monovalent and divalent cations described, divalent cations, in particular from the group consisting of alkaline earth metals, such as, for example, magnesium (Mg2+), or also iron (Fe2+), and monovalent cations, in particular from the groups consisting of alkali metals, such as, for example, lithium (Lit). These monovalent cations are preferably in the form of their salts, e.g. in the form of halides, e.g. chlorides, iodides or bromides, or in the form of their hydroxides, carbonates, bicarbonates or sulfates. Examples which are to be mentioned here are, for the lithium salt LiCl, Lii, LiBr, Li2CO3, LiHCO3, Li2SO4, for the magnesium salt MgCl2, MgI2, MgBr2, MgCO3, MgSO4, and Mg(OH)2, and for the iron salt FeCl2, FeBr2, FeI2, FeF2, Fe2O3, FeCO3, FeSO4, Fe(OH)2. All the combinations of di- and/or monovalent cations, as described above, are likewise included. Such injection buffers which contain only divalent, only monovalent or di- and monovalent cations can thus be used in the pharmaceutical composition according to the invention. Such injection buffers which contain only one type of di- or monovalent cations, particularly preferably e.g. only Ca2+ cations, or a salt thereof, e.g. CaCl2, can likewise be used. The molarities given above for Ca2+ (as a divalent cation) and Na1+ (as a monovalent cation) (that is to say typically concentrations of at least 50 mM Nat, at least 0.01 mM Ca2+ and optionally at least 3 mM K+) in the injection buffer can also be taken into consideration if another di- or monovalent cation, in particular other cations from the group consisting of the alkaline earth metals and alkali metals, are employed instead of some or all the Ca2+ or, respectively, Na1+ in the injection buffer used according to the invention for the preparation of the injection solution. All the Ca2+ or Na1+, as mentioned above, can indeed be replaced by other di- or, respectively, monovalent cations in the injection buffer used, for example also by a combination of other divalent cations (instead of Ca2+) and/or a combination of other monovalent cations (instead of Na1+) (in particular a combination of other divalent cations from the group consisting of the alkaline earth metals or, respectively, of other monovalent cations from the group consisting of the alkali metals), but it is preferable to replace at most some of the Ca2+ or Na1+, i.e. for at least 20%, preferably at least 40%, even more preferably at least 60% and still more preferably at least 80% of the particular total molarities of the mono- and divalent cations in the injection buffer to be occupied by Ca2+ and, respectively, Na1+. However, it is very particularly preferable if the injection buffer optionally contained in the pharmaceutical composition according to the invention contains exclusively Ca2+ as a divalent cation and Na1+ as a monovalent cation, that is to say, with respect to the total pharmaceutical composition, Ca2+ represents 100% of the total molarity of divalent cations, just as Na1+ represents 100% of the total molarity of monovalent cations. The aqueous solution of the injection buffer can contain, with respect to the total pharmaceutical composition, up to 30 mol % of the salts contained in the solution, preferably up to 25 mol %, preferably up to 20 mol %, furthermore preferably up to 15 mol %, more preferably up to 10 mol %, even more preferably up to 5 mol %, likewise more preferably up to 2 mol % of insoluble or sparingly soluble salts. Salts which are sparingly soluble in the context of the present invention are those of which the solubility product is <10−4. Salts which are readily soluble are those of which the solubility product is >10−4. Preferably, the injection buffer optionally contained in the pharmaceutical composition according to the invention is from 50 mM to 800 mM, preferably from 60 mM to 500 mM, more preferably from 70 mM to 250 mM, particularly preferably 60 mM to 110 mM in sodium chloride (NaCl), from 0.01 mM to 100 mM, preferably from 0.5 mM to 80 mM, more preferably from 1.5 mM to 40 mM in calcium chloride (CaCl2) and optionally from 3 mM to 500 mM, preferably from 4 mM to 300 mM, more preferably from 5 mM to 200 mM in potassium chloride (KCl). Organic anions can also occur as further anions in addition to the abovementioned inorganic anions, for example halides, sulfates or carbonates. Among these there may be mentioned succinate, lactobionate, lactate, malate, maleate etc., which can also be present in combination.
- An injection buffer optionally contained in the pharmaceutical composition according to the invention preferably contains lactate. If it contains an organic anion, such an injection buffer particularly preferably contains exclusively lactate as the organic anion. Lactate in the context of the invention can be any desired lactate, for example L-lactate and D-lactate. Lactate salts which occur in connection with the present invention are typically sodium lactate and/or calcium lactate, especially if the injection buffer contains only Na+ as a monovalent cation and Ca2+ as a divalent cation. An injection buffer optionally used in the pharmaceutical composition according to the invention and as described above preferably contains, with respect to the total pharmaceutical composition, from 15 mM to 500 mM, more preferably from 15 mM to 200 mM, and even more preferably from 15 mM to 100 mM lactate. In this context, it has been found that the use of an injection buffer with the components described above, optionally with or without lactate (in the following: “RL injection buffer” if it does not contain the component lactate, or “RL injection buffer with lactate” if it does contain the component lactate) for RNA injection solutions (i.e. injection solutions which contain RNA and are suitable for injection of this RNA) significantly increases both the transfer and the translation of the RNA into/in the cells/tissue of a host organism (mammal) compared with other injection buffers conventionally used in the prior art.
- According to a particular embodiment, the pharmaceutical composition used here can also be provided as a passive vaccine (for passive immunization). In the present invention, without being restricted to a theory, passive immunization is based on the introduction of an antibody-coding (modified) RNA as described here into an organism, in particular into a cell, the coded antibody then being expressed, i.e. translated. As a result, binding of such molecules, e.g. nucleic acids or antigens, for which the coded antibody is specific can take place. Passive vaccines in connection with the present invention typically comprise a composition as described above for a pharmaceutical composition, the composition of such passive vaccines used being determined in particular by the mode in which they are administered. Preferably, the passive vaccines according to the invention are administered systemically or in some cases non-systemically. Administration routes of such passive vaccines according to the invention typically include transdermal, oral, parenteral, including subcutaneous, intravenous, or intraarterial injections, topical and/or intranasal routes. Passive vaccines according to the invention are therefore preferably formulated in a liquid or solid form.
- According to further preferred subject matter of the present invention, the antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention is used for treatment of indications mentioned by way of example in the following. Without being limited thereto, diseases or states, for example, such as e.g. cancer or tumour diseases chosen from melanomas, malignant melanomas, colon carcinomas, lymphomas, sarcomas, blastomas, kidney carcinomas, gastrointestinal tumours, gliomas, prostate tumours, bladder cancer, rectal tumours, stomach cancer, oesophageal cancer, pancreatic cancer, liver cancer, mammary carcinomas (=breast cancer), uterine cancer, cervical cancer, acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), hepatomas, diverse virus-induced tumours, such as e.g. papilloma virus-induced carcinomas (e.g. cervix carcinoma=cervical cancer), adenocarcinomas, herpes virus-induced tumours (e.g. Burkitt's lymphoma, EBV-induced B cell lymphoma), hepatitis B-induced tumours (hepatocell carcinomas), HTLV-1- and HTLV-2-induced lymphomas, acusticus neurinoma, lung carcinomas (=lung cancer=bronchial carcinoma), small cell lung carcinomas, throat cancer, anal carcinoma, glioblastoma, rectum carcinoma, astrocytoma, brain tumours, retinoblastoma, basalioma, brain metastases, medulloblastomas, vaginal cancer, testicular cancer, thyroid carcinoma, Hodgkin's syndrome, meningeomas, Schneeberger's disease, pituitary tumour, mycosis fungoides, carcinoids, neurinoma, spinalioma, Burkitt's lymphoma, laryngeal cancer, kidney cancer, thymoma, corpus carcinoma, bone cancer, non-Hodgkin's lymphomas, urethral cancer, CUP syndrome, head/neck tumours, oligodendroglioma, vulval cancer, intestinal cancer, colon carcinoma, oesophageal carcinoma (=oesophageal cancer), wart conditions, small intestine tumours, craniopharyngeomas, ovarian carcinoma, soft tissue tumours (sarcomas), ovarian cancer (=ovarian carcinoma), pancreatic carcinoma (=pancreatic cancer), endometrium carcinoma, liver metastases, penis cancer, tongue cancer, gallbladder cancer, leukaemia, plasmocytoma, lid tumour, prostate cancer (=prostate tumours) etc., or infectious diseases such as, for example, influenza, malaria, SARS, yellow fever, AIDS, Lyme borreliosis, leishmaniasis, anthrax, meningitis, can be treated with the pharmaceutical composition described.
- The antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can likewise be used for treatment of, for example, viral infectious diseases chosen from, without being limited thereto, AIDS, condyloma acuminata, molluscum contagiosum, dengue fever, three-day fever, Ebola virus, colds, early summer meningoencephalitis (ESME), influenza, shingles, hepatitis, herpes simplex type I, herpes simplex type II, herpes zoster, influenza, Japanese encephalitis, Lassa fever, Marburg virus, measles, foot and mouth disease, mononucleosis, mumps, Norwalk virus infection, Pfeiffer's glandular fever, smallpox, polio (poliomyelitis), pseuodcroup, infectious erythema, rabies, warts, West Nile fever, chicken-pox, cytomegalovirus (CMV), caused by viruses chosen from, without being limited thereto, e.g. HIV, orthopox variola virus, orthopox alastrim virus, parapox ovis virus, molluscum contagiosum virus, herpes simplex virus 1, herpes simplex virus 2, herpes B virus, varicella zoster virus, pseudorabies virus, human cytomegaly virus, human herpes virus 6, human herpes virus 7, Epstein-Barr virus, human herpes virus 8, hepatitis B virus, chikungunya virus, O'nyong'nyong virus, rubivirus, hepatitis C virus, GB virus C, West Nile virus, dengue virus, yellow fever virus, louping ill virus, St. Louis encephalitis virus, Japan B encephalitis virus, Powassan virus, FSME virus, SARS-associated corona virus, human corona virus 229E, human corona virus 0c43, Torovirus, human T cell lymphotropic virus type I, human T cell lymphotropic virus type II, human immunodeficiency virus type 1, human immunodeficiency virus type 2, Lassa virus, lymphocytic choriomeningitis virus, Tacaribe virus, Junin virus, Machupo virus, Borna disease virus, Bunyamwera virus, California encephalitis virus, Rift Valley fever virus, sand fly fever virus, Toscana virus, Crimean-Congo haemorrhagic fever virus, Hazara virus, Khasan virus, Hantaan virus, Seoul virus, Prospect Hill virus, Puumala virus, Dobrava Belgrade virus, Tula virus, sin nombre virus, Lake Victoria Marburg virus, Zaire Ebola virus, Sudan Ebola virus, Ivory Coast Ebola virus, influenza virus A, influenza virus B, influenza viruses C, parainfluenza virus, measles virus, mumps virus, respiratory syncytial virus, human metapneumovirus, vesicular stomatitis Indiana virus, rabies virus, Mokola virus, Duvenhage virus, European bat lyssavirus 1+2, Australian bat lyssavirus, adenoviruses A-F, human papilloma viruses, condyloma virus 6, condyloma virus 11, polyoma viruses, adeno-associated virus 2, rotaviruses, or orbiviruses etc., or bacterial infectious diseases, such as abortion (infectious, septic), prostatitis (prostate inflammation), anthrax, appendicitis (inflammation of the caecum), borreliosis, botulism, Campylobacter, Chlamydia trachomatis (inflammation of the urethra, conjunctiva), cholera, diphtheria, donavonosis, epiglottitis, louse-borne typhus, typhoid fever, gas gangrene, gonorrhoea, hare plague, Helicobacter pylori, whooping-cough, climatic bubo, osteomyelitis, legionnaires' disease, leprosy, listeriosis, pneumonia, meningitis, bacterial meningitis, anthrax, inflammation of the middle ear, Mycoplasma hominis, neonatal sepsis (chorioamnionitis), noma, paratyphoid fever, plague, Reiter's syndrome, Rocky Mountain spotted fever, Salmonella paratyphoid fever, Salmonella typhoid fever, scarlet fever, syphilis, tetanus, gonorrhoea, tsutsugamushi fever, tuberculosis, typhus, vaginitis (colpitis), soft chancre and infectious diseases caused by parasites, protozoa or fungi, such as amoebic dysentery, bilharziosis, Chagas' disease, Echinococcus, fish tapeworm, ichthyotoxism (ciguatera), fox tapeworm, mycosis pedis, dog tapeworm, candiosis, ptyriasis, the itch (scabies), cutaneous leishmaniasis, lamblian dysentery (giadiasis), lice, malaria, onchocercosis (river blindness), fungal diseases, beef tapeworm, schistosomiasis, sleeping sickness, pork tapeworm, toxoplasmosis, trichomoniasis, trypanosomiasis (sleeping sickness), visceral leishmaniasis, nappy dermatitis or dwarf tapeworm.
- The antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can also be used for treatment of cardiovascular diseases chosen from, without being limited thereto, coronary heart disease, arteriosclerosis, apoplexy and hypertension, and neuronal diseases chosen from Alzheimer's disease, amyotrophic lateral sclerosis, dystonia, epilepsy, multiple sclerosis and Parkinson's disease etc.
- The antibody-coding (modified) RNA according to the invention or a pharmaceutical composition according to the invention can furthermore be used for treatment of autoimmune diseases chosen from, without being limited thereto, autoimmune type I diseases or autoimmune type II diseases or autoimmune type III diseases or autoimmune type IV diseases, such as, for example, multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I (diabetes mellitus), systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergy type I diseases, allergy type II diseases, allergy type III diseases, allergy type IV diseases, fibromyalgia, hair loss, Bechterew's disease, Crohn's disease, myasthenia gravis, neurodermatitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter's syndrome, rheumatic arthritis, psoriasis, vasculitis etc., or diabetes type II.
- Diseases in the context of the present invention likewise include monogenetic diseases, i.e. (hereditary) diseases which are caused by an individual gene defect and are inherited according to Mendel's rules. Monogenetic diseases in the context of the present invention are preferably chosen from the group consisting of autosomally recessive hereditary diseases, such as, for example, adenosine deaminase deficiency, familial hypercholesterolaemia, Canavan's syndrome, Gaucher's disease, Fanconi's anaemia, neuronal ceroid lipofuscinoses, mucoviscidosis (cystic fibrosis), sickle cell anaemia, phenylketonuria, alcaptonuria, albinism, hypothyroidism, galactosaemia, alpha-1 antitrypsin deficiency, xeroderma pigmentosum, Ribbing's syndrome, mucopolysaccharidoses, cleft lip, jaw, palate, Laurence-Moon-Biedl-Bardet syndrome, short rib polydactyly syndrome, cretinism, Joubert's syndrome, progeria type II, brachydactyly, adrenogenital syndrome, and X chromosomal hereditary diseases, such as, for example, colour blindness, e.g. red-green blindness, fragile X syndrome, muscular dystrophy (Duchenne and Becker-Kiener type), haemophilia A and B, G6PD deficiency, Fabry's disease, mucopolysaccharidosis, Norrie's syndrome, retinitis pigmentosa, septic granulomatosis, X-SCID, ornithine transcarbamylase deficiency, Lesch-Nyhan syndrome, or from autosomally dominant hereditary diseases, such as, for example, hereditary angioedema, Marfan's syndrome, neurofibromatosis, progeria type I, osteogenesis imperfecta, Klippel-Trenaunay syndrome, Sturge-Weber syndrome, Hippel-Lindau syndrome and tuberous sclerosis. RNA according to the invention which encodes an antibody as described here can be used on monogenetic diseases in the context of the present invention, the coded antibody being able to intervene in a regulatory manner, and also as a therapy, for example by regulation of undesirable metabolism products, trapping of specific gene products, interference with undesired certain interactions of proteins, e.g. inhibiting certain undesired ligand/receptor interactions etc.
- A (modified) RNA according to the invention which encodes an antibody can be employed in various ways for treatment of the abovementioned indications. Thus, cancer diseases, for example, can be treated by immunotherapy in addition or as an alternative to known therapies. For this, for example, an RNA according to the invention which codes for a bispecific antibody can be employed, the antibody recognizing on the one hand a surface antigen, such as e.g. CD3, on T cells and on the other hand a tumour antigen, such as e.g. Her2/neu, C20, EGFR or CA-125. As a result, T cells which are positive in respect of certain surface antigens and tumour cells which express the tumour antigen are brought spatially close, which improves the recognition of the tumour cells by the immune system and therefore increases the destruction of the tumour cells.
- Furthermore, e.g. in cardiac infarction cases, for example, it is possible to employ an RNA according to the invention which codes for a bispecific antibody which recognizes on the one hand a stem cell antigen, such as e.g. CD45, and on the other hand an antigen of the target tissue, such as e.g. myosin light chain, in order to increase the concentration of stem cells in the heart muscle (see also Reusch et al. Anti-CD3× anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006).
- Furthermore, by using RNA according to the invention which codes bispecific antibodies, e.g. two different cell types can be brought into contact or spatially close by the coded antibodies. This is advantageous, for example, in order to concentrate a cell in a tissue or to bring two proteins, e.g. antigens, into contact with or spatially close to one another, e.g. ligand and receptor or proteins which must dimerize/oligomerize in order to become activated.
- RNAs according to the invention as described here which code for intrabodies can also be employed for use on the abovementioned diseases, in particular infectious diseases, autoimmune diseases and neuronal diseases and also on monogenetic diseases. Thus, intrabodies can be used in order to inhibit, as e.g. bispecific intracellularly expressed antibodies, cytoplasmic proteins (be it proteins originating from the pathogenic organism or be it proteins from the host organism), as described above. For example, RNAs according to the invention which code for intrabodies can be employed in order to inhibit IL-2R (receptor of IL-2) or ErbB2 (Her2/neu) by the coded antibodies. RNAs according to the invention which code for intrabodies are also suitable for use on virus diseases, such as e.g. HIV-1. It has furthermore been possible to demonstrate e.g. that infection of mice with scrapie, a prion disease, can be prevented by expression of an scFv fragment against the prion protein (Vertrugno et al., KDEL-tagged (“KDEL” disclosed as SEQ ID NO: 18) anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity, Biochem Biophys Res Commun. 2005; Marasco W A, Intrabodies: turning the humoral immune system outside in for intracellular immunization, Gene Therapy (1997) 4: 11-15). RNAs according to the invention which code for intrabodies can furthermore be employed in order to bind and preferably to neutralize, by the coded antibodies, intracellularly expressed factors as described here, such as e.g. antigens, nucleic acids etc. (see above).
- In this connection, the invention therefore also provides the use of an antibody-coding (modified) RNA according to the invention or of a pharmaceutical composition according to the invention, e.g. a passive vaccine according to the invention, for treatment of indications and diseases described here. This also includes, in particular, the use of the antibody-coding (modified) RNA according to the invention for passive immunization and, respectively, the use of the pharmaceutical composition described according to the invention as a passive vaccine. The use of the antibody-coding (modified) RNA according to the invention for the preparation of a pharmaceutical composition or a passive vaccine, as described here, for treatment of the indications described here is likewise included. The use of the antibody-coding (modified) RNA according to the invention for the preparation of a passive vaccine, as described here, for passive immunization against the abovementioned indications is also included.
- In this connection, the invention therefore likewise provides the use of an antibody-coding (modified) RNA according to the invention, of the antibody thereby coded, of the pharmaceutical composition described here or of the passive vaccine according to the invention for therapeutic use or for inhibition/neutralization of a protein function in one of the indications described here. In this context, a protein function is preferably suppressed (neutralizing antibodies). In principle, any of the antibodies coded by the RNA according to the invention and described here simultaneously also has a neutralizing action by binding of its specific substrate. Examples include e.g. anti-CD4 antibodies for prevention of rejection of transplants, Avastin (see above), Herceptin (see above) etc.
- In this connection, the invention therefore also furthermore provides the use of an antibody-coding (modified) RNA according to the invention, of the antibody thereby coded or of the pharmaceutical composition described here for therapeutic use for passive immunization by triggering an immunological effector function in the sense of a monoclonal antibody. In this context, e.g. therapy of tumour cells or pathogens, such as viruses or bacteria, in the indications as described here is rendered possible by expression and secretion of the antibody or antibody fragment. Hereby, the immune defense of the host is supported by the inventive RNA by triggering the innate, cellular or humoral immune system. Antibodies may be directed against immune suppressing factors or they may simulate the function of certain immunologically active cytokines by e.g. activating cytokine receptors.
- Furthermore, in this connection an antibody-coding (modified) RNA according to the invention or the pharmaceutical composition according to the invention described here or the passive vaccine according to the invention can also be used as an immunosuppressant in the indications described above. For example, it has been possible to demonstrate that it was possible for antibodies against the CD40 ligand (CD154) or against CD3 to prevent or reduce the rejection of transplants. Such (modified) RNAs according to the invention which encode an antibody, the coded antibodies of which can bind to surface antigens or generally to surface factors of cells, such as e.g. MHC class I molecules, MHC class II molecules, T cell receptors, LMP2 molecules, LMP7 molecules, CD1, CD2, CD3, CD4, CD8, CD11, CD28, CD30, CD31, CD40, CD50, CD54, CD56, CD58, CD80, CD86, CD95, CD153, CD154, CD178, CD3=TCR (T cell receptor) etc. are therefore preferably employed for use as immunosuppressants.
- In this connection, the invention also additionally provides the use of an antibody-coding (modified) RNA according to the invention or of the pharmaceutical composition described here for therapeutic use for expansion of (certain) cells in vitro or in vivo. For example, CD4- and CD25-positive cells and regulatory T cells can be stimulated to expansion by expression of the superantagonistic CD28 antibody. Regulatory T cells which can be multiplied by expression of the superantagonistic CD28 antibody play a role above all in autoimmune diseases (Beyersdorf N, Hanke T, Kerkau T, Hunig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. 2005 November; 64).
- An antibody-coding (modified) RNA according to the invention or the pharmaceutical composition described here can likewise be used on rheumatoid arthritis for prevention of inflammation reactions by antibodies against e.g. TNFα or other factors exacerbating the undesired immune response against e.g. the patients' proteins, as for the treatment of autoimmune diseases.
- A (modified) RNA according to the invention which encodes anti-CD18 antibodies or the pharmaceutical composition described here or the passive vaccine according to the invention can furthermore also be used for reduction of inflammations by inhibition of leukocytes, e.g. in the abovementioned indications.
- The present invention furthermore also provides a method for treatment and/or prevention of the abovementioned diseases and, respectively, for (preventive) passive immunization against the abovementioned diseases, which comprises administration of the pharmaceutical composition according to the invention described, the passive vaccine according to the invention or, respectively, the RNA according to the invention to a patient, in particular a human. Such methods also relate to treatment of indications which are connected with the intra- and extracellular processes described above, with neutralization functions of antibodies, the abovementioned inhibition of certain (cell) functions by antibodies etc.
- The present invention also provides an in vitro transcription method for the preparation of an antibody-coding (modified) RNA, comprising the following steps:
- a) provision of a nucleic acid, in particular a cDNA, which codes for an antibody as described above;
- b) addition of the nucleic acid, in particular a cDNA, which codes for an antibody to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, a nucleic acid mix comprising one or more optionally modified nucleotides as described above in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, and optionally an RNase inhibitor;
- c) incubation of the nucleic acid, in particular a cDNA, which codes for an antibody in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding optionally modified RNA according to the invention;
- d) optionally purification of the antibody-coding (modified) RNA according to the invention and removal of the non-incorporated nucleotides from the in vitro transcription medium.
- A nucleic acid as described in step a) of the in vitro transcription method according to the invention can be any nucleic acid as described here (for example single- or double-stranded DNA, cDNA etc.) which encodes an antibody as described here. DNA sequences, e.g. genomic DNA or fragments thereof, or plasmids which encode an antibody as described here, preferably in linearized form, are typically employed for this. The in vitro transcription can conventionally be carried out using a vector which has an RNA polymerase binding site. Any (expression) vectors known in the prior art, e.g. commercially obtainable (expression) vectors, can be used for this. Preferred (expression) vectors are, for example, those which have an SP6 or a T7 or T3 binding site upstream and/or downstream of the cloning site. The nucleic acid sequences used can thus be transcribed later as desired, depending on the RNA polymerase chosen. A nucleic acid sequence which is used for the in vitro transcription and codes for an antibody as described here is typically cloned into the (expression) vector, e.g. via a multiple cloning site of the vector used. Before the transcription, the (expression) vector is typically cleaved with restriction enzymes at the site at which the
future 3′ end of the RNA is to be found, using a suitable restriction enzyme, and the fragment is purified. This excludes the transcribed RNA from containing vector sequences, and an RNA transcript of defined length is obtained. In this context, preferably no restriction enzymes which generate overhanging ends (such as e.g. Aat II, Apa I, Ban II, Bgl I, Bsp 1286, BstX I, Cfo I, Hae II, HgiA I, Hha I, Kpn I, Pst I, Pvu I, Sac I, Sac II, Sfi I, Sph I etc.) are used. Should such restriction enzymes nevertheless be used, theoverhanging 3′ end is preferably filled up, e.g. with Klenow or T4 DNA polymerase. - As an alternative for step a) the nucleic acid can also be prepared as a transcription template by a polymerase chain reaction (PCR). For this, one of the primers used typically contains the sequence of an RNA polymerase binding site. Furthermore, the 5′ end of the primer used preferably contains an extension of about 10-50 further nucleotides, more preferably of from 15 to 30 further nucleotides and most preferably of about 20 nucleotides.
- Before the in vitro transcription, the nucleic acid, e.g. the DNA or cDNA, template is typically purified and freed from RNase in order to ensure a high yield. Purification can be carried out with the aid of any method known in the prior art, for example using a caesium chloride gradient, ion exchange methods or by purification via agarose gel electrophoresis.
- According to method step b), the nucleic acid (used as the transcription template) is added to an in vitro transcription medium. A suitable in vitro transcription medium initially comprises a nucleic acid as provided under step a), for example about 0.1-10 μg, preferably about 1-5 μg, more preferably 2.5 μg and most preferably about 1 μg of such a nucleic acid. A suitable in vitro transcription medium furthermore optionally comprises a reducing agent, e.g. DTT, more preferably about 1-20
μl 50 mM DTT, even more preferably about 5μl 50 mM DTT. The in vitro transcription medium furthermore comprises nucleotides, e.g. a nucleotide mix, in the case of the present invention comprising a mixture of (modified) nucleotides as defined here (typically about 0.1-10 mM per nucleotide, preferably 0.1 to 1 mM per nucleotide (preferably about 4 mM in total)) and optionally non-modified nucleotides. If modified nucleotides as defined here (about 1 mM per nucleotide, preferably about 4 mM in total), e.g. pseudouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate etc., are employed, they are typically added in an amount such that the modified or base-modified nucleotides is completely replaced by the natural nucleotide. However, it is also possible to employ mixtures of one or more modified or base-modified nucleotides and one or more naturally occurring nucleotides instead of a particular nucleotide, i.e. it is thus possible to employ one or more modified nucleotides as described above in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally additionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged. Conversely, it is also possible to use only natural nucleotides. By selective addition of the desired nucleotide to the in vitro transcription medium the content, i.e. the occurrence and the amount, of the desired modification of nucleotides in the transcribed antibody-coding (modified) RNA sequence can therefore be controlled. A suitable in vitro transcription medium likewise comprises an RNA polymerase, e.g. T7 RNA polymerase (for example T7-Opti mRNA Kit, CureVac, Tubingen, Germany), T3 RNA polymerase or SP6, typically about 10 to 500 U, preferably about 25 to 250 U, more preferably about 50 to 150 U, and most preferably about 100 U of RNA polymerase. The in vitro transcription medium is furthermore preferably kept free from RNase in order to avoid degradation of the transcribed RNA. A suitable in vitro transcription medium therefore optionally additionally comprises an RNase inhibitor. - The nucleic acid is incubated in the in vitro transcription medium in a step c) and is transcribed to an antibody-coding (modified) RNA. The incubation times are typically about 30 to 240 minutes, preferably about 40 to 120 minutes and most preferably about 90 minutes. The incubation temperatures are typically about 30-45° C., preferably 37-42° C. The incubation temperature depends on the RNA polymerase used, e.g. for T7 RNA polymerase it is about 37° C. The RNA obtained by the transcription is preferably an mRNA. The yields obtained in the in vitro transcription are, for the stated starting amounts employed in step b), typically in the region of about 30 μg of RNA per μg of template DNA used. In the context of the present invention, the yields obtained in the in vitro transcription can be increased by linear up scaling. For this, the stated starting amounts employed in step b) are preferably increased according to the yields required, e.g. by a multiplication factor of 5, 10, 50, 100, 500, 1,000, 5,000, 10,000, 50,000, 100,000 etc.
- After the incubation, a purification of the transcribed antibody-coding (modified) RNA can optionally take place in step d) of the in vitro transcription method according to the invention. Any suitable method known in the prior art, e.g. chromatographic purification methods, e.g. affinity chromatography, gel filtration etc., can be used for this. By the purification, non-incorporated, i.e. excess nucleotides and template DNA can be removed from the in vitro transcription medium and a clean (modified) RNA can be obtained. For example, after the transcription the reaction mixture containing the transcribed RNA can typically be digested with DNase in order to remove the DNA template still contained in the reaction mixture. The transcribed RNA can be subsequently or alternatively precipitated with LiCl. Purification of the transcribed RNA can then take place via IP RP-HPLC. This renders it possible in particular to separate longer and shorter fragments from one another effectively.
- Preferably, in this context the purification takes place via a method for purification of RNA on a preparative scale, which is distinguished in that the RNA is purified by means of HPLC using a porous reverse phase as the stationary phase (PURE Messenger). For example, for the purification in step d) of the in vitro method according to the invention, a reverse phase can be employed as the stationary phase for the HPLC purification. For the chromatography with reverse phases, a non-polar compound typically serves as stationary phase, and a polar solvent, such as mixtures of water, which is usually employed in the form of buffers, with acetonitrile and/or methanol, serves as the mobile phase for the elution. Preferably, the porous reverse phase has a particle size of 8.0±2 μm, preferably ±1 μm, more preferably +/−0.5 μm. The reverse phase material can be in the form of beads. The purification can be carried out in a particularly favourable manner with a porous reverse phase having this particle size, optionally in the form of beads, particularly good separation results being obtained. The reverse phase employed is preferably porous since with stationary reverse phases which are not porous, such as are described e.g. by Azarani A. and Hecker K. H., pressures which are too high are built up, so that preparative purification of the RNA is possible, if at all, only with great difficulty. The reverse phase preferably has a pore size of from 200 Å to 5,000 Å, in particular a pore size of from 300 Å to 4,000 Å. Particularly preferred pore sizes for the reverse phases are 200-400 Å, 800-1,200 Å and 3,500-4,500 Å. With a reverse phase having these pore sizes, particularly good results are achieved in respect of the purification of the RNA in process step d). The material for the reverse phase is preferably a polystyrene-divinylbenzene, and non-alkylated polystyrene-divinylbenzenes can be employed in particular. Stationary phases with polystyrene-divinylbenzene are known per se. For the purification in method step d), the polystyrene-divinylbenzenes which are known per se and already employed for HPLC methods and are commercially obtainable can be used. A non-alkylated porous polystyrene-divinylbenzene which in particular has a particle size of 8.0±0.5 μm and a pore size of 250-300 Å, 900-1,100 Å or 3,500-4,500 Å is very particularly preferably used for the purification in method step d). The advantages described above can be achieved in a particularly favourable manner with this material for the reverse phases. The HPLC purification can be carried out by the ion pair method, an ion having a positive charge being added to the mobile phase as a counter-ion to the negatively charged RNA. An ion pair having a lipophilic character, which is slowed down by the non-polar stationary phase of the reverse phase system, is formed in this manner. In practices, the precise conditions for the ion pair method must be worked out empirically for each concrete separation problem. The size of the counter-ion, its concentration and the pH of the solution contribute greatly towards the result of the separation. In a favourable manner, alkylammonium salts, such as triethylammonium acetate and/or tetraalkylammonium compounds, such as tetrabutylammonium, are added to the mobile phase. Preferably, 0.1 M triethylammonium acetate is added and the pH is adjusted to about 7. The choice of mobile phase depends on the nature of the desired separation. This means that the mobile phase found for a specific separation, such as can be known, for example, from the prior art, cannot be transferred readily to another separation problem with adequate prospect of success. The ideal elution conditions, in particular the mobile phase used, must be determined for each separation problem by empirical experiments. A mixture of an aqueous solvent and an organic solvent can be employed as the mobile phase for elution of the RNA by the HPLC method. In this context, it is favourable if a buffer which has, in particular, a pH of about 7, for example 6.5-7.5, e.g. 7.0, is used as the aqueous solvent; preferably, the buffer triethylammonium acetate is used, particularly preferably a 0.1 M triethylammonium acetate buffer which, as described above, also acts as a counter-ion to the RNA in the ion pair method. The organic solvent employed in the mobile phase can be acetonitrile, methanol or a mixture of these two, very particularly preferably acetonitrile. The purification of the RNA in method step d) using an HPLC method as described is carried out in a particularly favourable manner with these organic solvents. The mobile phase is particularly preferably a mixture of 0.1 M triethylammonium acetate, pH 7, and acetonitrile. It has emerged to be likewise particularly favourable if the mobile phase contains 5.0 vol. % to 20.0 vol. % of organic solvent, based on the mobile phase, and the remainder to make up 100 vol. % is the aqueous solvent. It is very particularly favourable for the method according to the invention if the mobile phase contains 9.5 vol. % to 14.5 vol. % of organic solvent, based on the mobile phase, and the remainder to make up 100 vol. % is the aqueous solvent. Elution of the RNA can subsequently be carried out isocratically or by means of a gradient separation. In the case of an isocratic separation, elution of the RNA is carried out with a single eluting agent or a mixture of several eluting agents which remains constant, it being possible for the solvents described above in detail to be employed as the eluting agent.
- The present invention also provides an in vitro transcription and translation method for expression of an antibody, comprising the following steps:
- a) provision of a nucleic acid, in particular a cDNA, which encodes an antibody as described above;
- b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, a nucleic acid mix comprising one or more (modified) nucleotides as described above in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, and optionally an RNase inhibitor;
- c) incubation of the nucleic acid, in particular a cDNA, in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding (modified) RNA according to the invention;
- d) optionally purification of the antibody-coding (modified) RNA according to the invention and removal of the non-incorporated nucleotides from the in vitro transcription medium;
- e) addition of the (modified) RNA obtained in step c) (and optionally in step d) to an in vitro translation medium;
- f) incubation of the (modified) RNA in the in vitro translation medium and in vitro translation of the antibody coded by the (modified) RNA;
- g) optionally purification of the antibody translated in step f).
- Steps a), b), c) and d) of the in vitro transcription and translation method according to the invention for expression of an antibody are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here.
- In step e) of the in vitro transcription and translation method according to the invention for expression of an antibody, the (modified) RNA transcribed in step c) (and optionally purified in step d) is added to a suitable in vitro translation medium. A suitable in vitro translation medium comprises, for example, reticulocyte lysate, wheat germ extract etc. Such a medium conventionally furthermore comprises an amino acid mix. The amino acid mix typically comprises (all) naturally occurring amino acids and optionally modified amino acids, e.g. 35S-methionine (for example for monitoring the translation efficiency via autoradiography). A suitable in vitro translation medium furthermore comprises a reaction buffer. In vitro translation media are described, for example, in Krieg and Melton (1987) (P. A. Krieg and D. A. Melton (1987) In vitro RNA synthesis with SP6 RNA polymerase; Methods Enzymol 155:397-415), the disclosure content of which in this respect is included in its full scope in the present invention.
- In a step f) of the in vitro transcription and translation method according to the invention for expression of an antibody, the (modified) nucleic acid is incubated in the in vitro translation medium and the antibody coded by the (modified) nucleic acid is translated in vitro. The incubation typically lasts about 30 to 240 minutes, preferably about 40 to 120 minutes and most preferably about 90 minutes. The incubation temperature is typically in a range of about 20-40° C., preferably about 25 to 35° C. and most preferably about 30° C.
- Steps b) to f) of the in vitro transcription and translation method according to the invention for expression of an antibody or individual steps of steps b) to f) can be combined with one another, i.e. can be carried out together. In this context, all the necessary components are preferably added to the reaction medium together at the start or successively during the reaction in accordance with the sequence of the steps b) to f) described.
- The translated antibody obtained in step f) can be purified in an optional step g). A purification can be carried out with methods which are known to a person skilled in the art from the prior art, e.g. chromatography, such as, for example, affinity chromatography (HPLC, FPLC, etc.), ion exchange chromatography, gel chromatography, size exclusion chromatography, gas chromatography, or antibody detection, or biophysical methods, such as e.g. NMR analyses, etc. (see e.g. Maniatis et al. (2001) supra). Chromatography methods, including affinity chromatography methods, can employ tags in a suitable manner for the purification, as described above, e.g. a hexahistidine tag (SEQ ID NO: 59) (His tag, polyhistidine tag), a streptavidin tag (Strep tag), an SBP tag (streptavidin-binding tag), a GST (glutathione S transferase) tag etc. The purification can furthermore be carried out via an antibody epitope (antibody-binding tag), e.g. a Myc tag, an
Swal 1 epitope, a FLAG tag, an HA tag etc., i.e. via recognition of the epitope via a corresponding (immobilized) antibody. The purification can likewise be carried out via the immobilized substrate of the specific antibody, i.e. by binding of the antibody to an immobilized antigen which is recognized and, respectively, bound specifically by the translated antibody. - The present invention also provides an in vitro transcription and translation method for expression of an antibody in a host cell, comprising the following steps:
-
- a) provision of a nucleic acid, in particular a cDNA, which encodes an antibody as described above;
- b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, one or more (modified) nucleotides as described above in exchange for one or more of the naturally occurring nucleotides A, G, C or U and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged;
- c) incubation of the nucleic acid, in particular a cDNA, in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding (modified) RNA according to the invention;
- d) optionally purification of the antibody-coding (modified) RNA according to the invention and removal of the non-incorporated nucleotides from the in vitro transcription medium;
- e′) transfection of the (modified) RNA obtained in step c) (and optionally d)) into a host cell;
- f′) incubation of the (modified) nucleic acid in the host cell and translation of the antibody coded by the (modified) RNA in the host cell;
- g′) optionally isolation and/or purification of the antibody translated in step f).
- Steps a), b), c) and d) of the in vitro transcription and translation method according to the invention for expression of an antibody in a host cell are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here and of the in vitro transcription and translation method according to the invention described here for expression of an antibody.
- According to step e′) of the in vitro transcription and translation method according to the invention, transfection of the (modified) RNA obtained in step c) (and optionally in step d)) into a host cell is carried out. The transfection is in general carried out via transfection methods known in the prior art (see, for example, Maniatis et al. (2001) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Suitable transfection methods in the context of the present invention include, without being limited thereto, e.g. electroporation methods, including modified electroporation methods (e.g. nucleofection), calcium phosphate methods, e.g. the calcium coprecipitation method, the DEAE-dextran method, the lipofection method, e.g. the transferrin-mediated lipofection method, polyprene transfection, particle bombardment, nanoplexes, e.g. PLGA, polyplexes, e.g. PEI, protoplast fusion and the microinjection method, the lipofection method having emerged in particular as a suitable method. In this context, the (modified) RNA according to the invention can be in the naked or complexed form, as described above for the (modified) RNA according to the invention.
- In connection with the present invention and with step e′) of the in vitro transcription and translation method according to the invention for expression of an antibody in a host cell, a (suitable) host cell includes any cell which allows expression of the antibody coded by the (modified) RNA according to the invention, preferably any cultured eukaryotic cell (e.g. yeast cells, plant cells, animal cells and human cells) or prokaryotic cell (e.g. bacteria cells etc.). Cells of multicellular organisms are preferably chosen for expression of the antibody coded by the (modified) RNA according to the invention if posttranslational modifications, e.g. glycosylation of the coded protein, are necessary (N- and/or O-coupled). In contrast to prokaryotic cells, such (higher) eukaryotic cells render possible posttranslational modification of the protein synthesized. The person skilled in the art knows a large number of such higher eukaryotic cells or cell lines, e.g. 293T (embryonal kidney cell line), HeLa (human cervix carcinoma cells), CHO (cells from the ovaries of the Chinese hamster) and further cell lines, including such cells and cell lines developed for laboratory purposes, such as, for example, hTERT-MSC, HEK293, Sf9 or COS cells. Suitable eukaryotic cells furthermore include cells or cell lines which are impaired by diseases or infections, e.g. cancer cells, in particular cancer cells of any of the types of cancer mentioned here in the description, cells impaired by HIV, and/or cells of the immune system or of the central nervous system (CNS). Human cells or animal cells, e.g. of animals as mentioned here, are particularly preferred as eukaryotic cells. Suitable host cells can likewise be derived from eukaryotic microorganisms, such as yeast, e.g. Saccharomyces cerevisiae (Stinchcomb et al., Nature, 282:39, (1997)), Schizosaccharomyces pombe, Candida, Pichia, and filamentous fungi of the genera Aspergillus, Penicillium, etc. Suitable host cells likewise include prokaryotic cells, such as e.g. bacteria cells, e.g. from Escherichia coli or from bacteria of the genera Bacillus, Lactococcus, Lactobacillus, Pseudomonas, Streptomyces, Streptococcus, Staphylococcus, preferably E. coli, etc.
- In step f) of the in vitro transcription and translation method according to the invention for expression of an antibody in a host cell, incubation of the (modified) RNA in the host cell and translation of the antibody coded by the (modified) RNA in the host cell are carried out. Expression mechanisms intrinsic to the host cell are preferably used for this, e.g. by translation of the RNA in the host cell via ribosomes and tRNAs. The incubation temperatures used in this context depend on the particular host cell systems used.
- In an optional step g′), the translated antibody obtained in step f) can be isolated and/or purified. In this context, an isolation of the translated (expressed) antibody typically comprises separating off the antibody from reaction constituents, and can be carried out by methods which are known to a person skilled in the art, for example by cell lysis, breakdown by ultrasound, or similar methods, including the abovementioned methods. A purification can therefore also be carried out by methods as described for step e) of the in vitro transcription and translation method according to the invention for expression of an antibody.
- For purification of (recombinant) antibodies from a host cell in step g′) of the method described above, a different choice of the host cells described above is necessary, depending on the use. Thus, the production of recombinant antibodies in E. coli typically is possible to only a limited extent, since the antibodies coded by a (modified) RNA according to the invention are very complex, require complicated folding mechanisms and are conventionally modified posttranslationally for use in multicellular organisms or beings. These mechanisms conventionally cannot be implemented in the cytoplasm of E. coli. Periplasmic production in E. coli, in which correct folding and modification of the antibody fragments is possible, can therefore be used. In this context, the purification usually requires an involved breakdown of the bacteria and a difficult separating off of all the bacterial constituents which can act as endotoxins during a therapeutic use. To by-pass these purification problems, expression systems for yeasts, insect cells, mammalian cells and plants can be employed according to the invention in such cases, the production preferably being carried out in suitable mammalian cells, such as e.g. hamster cells (CHO), as described here.
- Regardless of steps (a) to (d), the antibody coded by the (modified) RNA according to the invention can also be expressed by an in vitro translation method of steps (e′) to (g′), which is also subject matter of the present invention as such.
- The present invention also provides an in vitro transcription and in vivo translation method for expression of an antibody in an organism, comprising the following steps:
-
- a) provision of a nucleic acid, in particular a cDNA, which encodes an antibody as described above;
- b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, a nucleic acid mix comprising one or more (modified) nucleotides as described above in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, and optionally an RNase inhibitor;
- c) incubation of the nucleic acid, in particular a cDNA, in the in vitro transcription medium and in vitro transcription of the nucleic acid to give a (modified) RNA according to the invention as described here;
- d) optionally purification and removal of the non-incorporated nucleotides from the in vitro transcription medium;
- e″) transfection of the (modified) RNA obtained in step c) (and optionally in step d)) into a host cell and transplanting of the transfected host cell into an organism;
- f″) translation of the antibody coded by the (modified) RNA in the organism.
- Steps a), b), c) and d) of the in vitro transcription and in vivo translation method according to the invention for expression of an antibody in an organism are identical to steps a), b), c) and d) of the in vitro transcription method according to the invention described here, of the in vitro transcription and translation method according to the invention described here for expression of an antibody and of the in vitro transcription and translation method according to the invention described here for expression of an antibody in a host cell.
- Host cells in the context of the present invention, and in particular in step e″), can also include autologous cells, i.e. cells which are taken from a patient and returned again (endogenous cells). Such autologous cells reduce the risk of rejection by the immune system in the case of in vivo uses. In the case of autologous cells, (healthy or diseased) cells from the affected body regions/organs of the patient are preferably employed. Transfection methods are preferably those as described above for step e). In step e″), transplanting of the host cell into an organism is carried out, additionally to step e). An organism or a being in connection with the present invention typically means mammals, i.e. animals, including cattle, pig, dog, cat, donkey, monkey, including rodents, e.g. mouse, hamster, rabbit etc., and humans. As an alternative to step e″) and f′), the isolation and/or purification can be carried out according to steps f)/f) and/or g)/g′) and the translated (therapeutically active) protein can be administered subsequently to the being. The administration can be carried out as described for pharmaceutical compositions.
- In step f′), translation of the antibody coded by the (modified) RNA is carried out in the organism. In this context, the translation is preferably carried out by means of systems specific to the host cell, depending on the host cell used.
- Regardless of steps (a) to (d), the transcribed (modified) RNA according to the invention can also be expressed by an in vitro translation method of steps (e″) to (g″), which is also subject matter of the present invention as such.
- As an alternative to the methods described above, according to a particularly preferred embodiment in a further step e′″) a (modified) RNA according to the invention transcribed according to steps a) to d) can be administered directly into the organism, e.g. human, e.g. by administration of the naked or complexed RNA according to the invention, for example using the transfection methods described above, optionally using certain stabilizing factors described here. In this context, after uptake the RNA is preferably transported into the cells, e.g. with localization or signal sequences as described here, and preferably translated into the coded antibody in the cells.
- The present invention describes in particular an antibody-coding RNA according to the invention. This can be modified or non-modified, where the definition of “modification” is to be understood in the broadest sense. A native RNA covalently bonded to another group, for example a lipid or a sugar residue, is modified in the context of this invention. An RNA which contains non-natively occurring constituents, for example non-native nucleotides, or an RNA which is modified with respect to its precursor by exchange of nucleotides, regardless of whether these are native or non-native, is also modified in the context of the invention. The great advantage of such RNAs is that these do not have the negative actions of DNA transfections (with stable incorporation into the genome). In the case of modified antibody-coding RNAs, the limited stability of the RNA coding for the antibodies or antibody fragments is moreover improved. According to the invention, after administration to patients, in particular mammals, above all humans, the antibodies are therefore thus expressed in vivo for only an estimatable time beyond the treatment and therefore do not lead to harmful effects. In contrast, the conventional intrabody DNAs can be integrated into the genome in a stable manner or at least expressed persistently, which can lead to uncontrollable events. The great advantage compared with administration of monoclonal antibodies in vivo is furthermore that with the use of an antibody-coding (modified) RNA as described here, no antibodies have to be prepared and purified in an involved manner and they are therefore considerably less expensive to prepare. The most essential advantage of the present invention is, however, that intracellularly expressed proteins can also be achieved with the antibodies coded by (modified) RNAs according to the invention, which is not possible with monoclonal antibodies known hitherto from the prior art.
- The following figures and examples are intended to explain in more detail and illustrate the above description, without being limited thereto.
-
FIG. 1 illustrates the structure of an IgG antibody. IgG antibodies are built up from in each case two identical light and two heavy protein chains which are bonded to one another via disulfide bridges. The light chain comprises the N-terminal variable domain VL and the C-terminal constant domain CL. The heavy chain of an IgG antibody can be divided into an N-terminal variable domain VH and threeconstant domains C H1,C H2 andC H3. -
FIGS. 2A-D show the gene cluster for the light and the heavy chains of an antibody: -
- (A): Gene cluster for the light chain κ.
- (B): Gene cluster for the light chain λ.
- (C): and (D): Gene cluster for the heavy chain.
- In this context, the variable region of a heavy chain is composed of three different gene segments. In addition to the V and J segments, additional D segments are also found here. The VH, DH and JH segments can likewise be combined with one another virtually as desired to form the variable region of the heavy chain.
-
FIG. 3 illustrates in the form of a diagram the differences in the light and heavy chains of murine (i.e. obtained in the mouse host organism), chimeric, humanized and human antibodies. -
FIG. 4 shows an overview of the structure of various antibody fragments. The constituents of the antibody fragments are shown on a dark grey background. -
FIGS. 5A-C show various variants of antibodies and antibody fragments inFIGS. 5A, 5B and 5C : -
- (A) shows a diagram of an IgG antibody of two light and two heavy chains.
- (B) shows an Fab fragments from the variable and a constant domain in each case of a light and a heavy chain. The two chains are bonded to one another via a disulfide bridge.
- (C) shows an scFv fragment from the variable domain of the light and the heavy chain, which are bonded to one another via an artificial polypeptide linker.
-
FIG. 6 shows a presentation of an antibody-coding (modified) RNA according to the invention as an expression construct. In this: -
- VH=variable domain of the heavy chain;
- CH=constant domain of the heavy chain;
- VL=variable domain of the light chain;
- CL=constant domain of the light chain;
- SIRES=internal ribosomal entry site (IRES, superIRES)
- muag=mutated form of the 3′ UTR of the alpha-globin gene; and
- A70C30=polyA-polyC tail.
-
FIG. 7 shows a diagram of the detection of an antibody coded by an RNA according to the invention by means of ELISA on the example of the antigen Her2. -
FIG. 8 shows the wild-type DNA sequence of the heavy chain of the antibody rituximab (=Rituxan, MabThera) (wild-type: GC content: 56.5%, length: 1,344) (SEQ ID NO: 1). -
FIG. 9 shows the GC-optimized DNA sequence of the heavy chain of the antibody rituximab (=Rituxan, MabThera) (GC content: 65.9%, length: 1,344) (SEQ ID NO: 2). -
FIG. 10 shows the wild-type DNA sequence of the light chain of the antibody rituximab (=Rituxan, MabThera) (wild-type: GC content: 58.5%, length: 633) (SEQ ID NO: 3). -
FIG. 11 shows the GC-optimized DNA sequence of the light chain of the antibody rituximab (=Rituxan, MabThera) (GC content: 67.2%, length: 633) (SEQ ID NO: 4). -
FIG. 12 shows the total construct of the GC-optimized DNA sequence of the antibody rituximab (=Rituxan, MabThera) with the light and heavy chains (SEQ ID NO: 5). The total construct contains the following sequences and cleavage sites (see also alternative cleavage sites ofFIG. 25 , SEQ ID No. 51): -
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with CAG represents the actual antibody coding sequence (see
FIG. 9 ) for the heavy chain, which ends with AAG and is followed by the above described His tag sequence. Finally, the open reading frame for the heavy chain ends with the stop codon TGA (). The coding region for the light chain sequence starts 3′ upstream with the signal peptide's ATG as given above followed by the light chain's coding region for the light chain starting with CAG running to the stop codon TGA ()(seeFIG. 11 ). Both coding regions for the light and the heavy chain are separated by an IRES element (). The inventive RNA coded by the construct given inFIG. 12 may or may not contain a (His) tag sequence and may contain a signal peptide sequence different from the above peptide sequence or may even have no signal peptide sequence. Accordingly, the inventive RNA molecule contains preferably the coding region (with or without a signal peptide sequence at its beginning) of the heavy and/or the light chain (e.g. as shown inFIG. 12 ), preferably in combination with at least one ribosomal entry site.
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with CAG represents the actual antibody coding sequence (see
-
FIG. 13 shows the wild-type DNA sequence of the heavy chain of the antibody cetuximab (=Erbitux) (wild-type: GC content: 56.8%, length: 1,359) (SEQ ID NO: 6). -
FIG. 14 shows the GC-optimized DNA sequence of the heavy chain of the antibody cetuximab (=Erbitux) (GC content: 65.9%, length: 1,359) (SEQ ID NO: 7). -
FIG. 15 shows the wild-type DNA sequence of the light chain of the antibody cetuximab (=Erbitux) (wild-type: GC content: 58.2%, length: 642) (SEQ ID NO: 8). -
FIG. 16 shows the GC-optimized DNA sequence of the light chain of the antibody cetuximab (=Erbitux) (GC content: 65.7%, length: 642) (SEQ ID NO: 9). -
FIG. 17 shows the total construct of the GC-optimized DNA sequence of the antibody cetuximab (=Erbitux) with the light and heavy chains (SEQ ID NO: 10). The total construct contains the following sequences and cleavage sites (see also alternative cleavage sites ofFIG. 26 , SEQ ID No 52): -
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with CAG represents the actual antibody coding sequence (see
FIG. 14 ) for the heavy chain, which ends with AAG and is followed by the above described His tag sequence. Finally, the open reading frame for the heavy chain ends with the stop codon TGA (). The coding region for the light chain sequence starts 3′ upstream with the signal peptide's ATG as given above followed by the light chain's coding region for the light chain starting with GAC running to the stop codon TGA ()(seeFIG. 16 ). Both coding regions for the light and the heavy chain are separated by an IRES element (). The inventive RNA coded by the construct given inFIG. 17 may or may not contain a (His) tag sequence and may contain a signal peptide sequence different from the above peptide sequence or may even have no signal peptide sequence. Accordingly, the inventive RNA molecule contains preferably the coding region (with or without a signal peptide sequence at its beginning) of the heavy and/or the light chain (e.g. as shown inFIG. 17 ), preferably in combination with at least one ribosomal entry site.
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with CAG represents the actual antibody coding sequence (see
-
FIG. 18 shows the wild-type DNA sequence of the heavy chain of the antibody trastuzumab (=Herceptin) (wild-type: GC content: 57.8%, length: 1,356) (SEQ ID NO: 11). -
FIG. 19 shows the GC-optimized DNA sequence of the heavy chain of the antibody trastuzumab (=Herceptin) (GC content: 67.0%, length: 1,356) (SEQ ID NO: 12). -
FIG. 20 shows the wild-type DNA sequence of the light chain of the antibody trastuzumab (=Herceptin) (wild-type: GC content: 56.9%, length: 645) (SEQ ID NO: 13). -
FIG. 21 shows the GC-optimized DNA sequence of the light chain of the antibody trastuzumab (=Herceptin) (GC content: 66.4%, length: 645) (SEQ ID NO: 14). -
FIG. 22 shows the total construct of the GC-optimized DNA sequence of the antibody trastuzumab (=Herceptin) with the light and heavy chains (SEQ ID NO: 15). The total construct contains the following sequences and cleavage sites (see also alternative cleavage sites ofFIG. 27 , SEQ ID No. 53): -
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with GAG represents the actual antibody coding sequence (see
FIG. 19 ) for the heavy chain, which ends with AAG and is followed by the above described His tag sequence. Finally, the open reading frame for the heavy chain ends with the stop codon TGA (). The coding region for the light chain sequence starts 3′ upstream with the signal peptide's ATG as given above followed by the light chain's coding region for the light chain starting with GAC running to the stop codon TGA ()(seeFIG. 21 ). Both coding regions for the light and the heavy chain are separated by an IRES element (). The inventive RNA coded by the construct given inFIG. 22 may or may not contain a (His) tag sequence and may contain a signal peptide sequence different from the above peptide sequence or may even have no signal peptide sequence. Accordingly, the inventive RNA molecule contains preferably the coding region (with or without a signal peptide sequence at its beginning) of the heavy and/or the light chain (e.g. as shown inFIG. 22 ), preferably in combination with at least one ribosomal entry site.
- The coding region of the heavy chain sequence starts with the signal peptide as given above (italic). This region is G/C enriched as well. The subsequent sequence starting with GAG represents the actual antibody coding sequence (see
-
FIG. 23 shows RNA-mediated antibody expression in cell culture. CHO or BHK cells were transfected with 20 μg of antibody-encoding mRNA according to the invention which was produced (RNA, G/C enriched, see above) or mock-transfected. 24 hours after transfection protein synthesis was analysed by Western blotting of cell lysates. Cells harboured about 0.5 μg of protein as assessed by Western Blot analysis. Each lane represents 10% of total lysate. Humanised antibodies served as control and for a rough estimate of protein levels. The detection antibody recognises both heavy and light chains; moreover, it shows some unspecific staining with cell lysates (three distinct bands migrating much slower than those of the antibodies). A comparison with control antibodies clearly demonstrates that heavy and light chains were produced in equal amounts. -
FIGS. 24A-E show that RNA-mediated antibody expression gives rise to a functional protein (antibody). Functional antibody formation was addressed by FACS staining of antigen-expressing target cells. In order to examine the production of functional antibodies, cell culture supernatants of RNA-transfected (20 μg of Ab-RNA as defined above in Example 1) cells were collected after 48 to 96 hours. About 8% of total supernatant was used to stain target cells expressing the respective antigen. Humanised antibodies served as control and for a rough estimate of protein levels. Primary antibody used for cell staining: a) humanised antibody; b) none; c,d) supernatant from RNA-transfected cells expressing the respective antibody; e) supernatant from mock-transfected CHO cells. Calculations on the basis of the analysis shown inFIG. 24 reveal that cells secreted more than 12-15 μg of functional antibody within 48-96 hours. Accordingly, the present invention proves that RNA encoding antibodies may enter into cell, may be expressed within the cell and considerable amounts of RNA encoded antibodies are then secreted by the cell into the surrounding medium/extracellular space. Cell transfection in vivo or in vitro by the inventive RNA may therefore be used to provide antibodies acting e.g. therapeutically in the extracellular space. -
FIG. 25 shows an alternative sequence of the construct ofFIG. 12 (antibody rituximab), wherein the restriction sites have been modified as compared to SEQ ID No. 5 ofFIG. 12 (SEQ ID No.: 51). For closer information with regard to the description of various sequence elements it is referred toFIG. 12 . -
FIG. 26 shows an alternative sequence of the construct ofFIG. 17 (antibody cetuximab), wherein the restriction sites have been modified as compared to SEQ ID No. 10 ofFIG. 17 (SEQ ID No.: 52). For closer information with regard to the description of various sequence elements it is referred toFIG. 17 . -
FIG. 27 shows an alternative sequence of the construct ofFIG. 22 (antibody trastuzumab), wherein the restriction sites have been modified as compared to SEQ ID No. 15 ofFIG. 22 (SEQ ID No.: 53). For closer information with regard to the description of various sequence elements it is referred toFIG. 22 . - The following examples explain the present invention in more detail, without limiting it.
- The cell lines HeLa (human cervix carcinoma cell line; Her2-positive), HEK293 (human embryonal kidney; Her2-negative) and BHK21 (Syrian hamster kidney; Her2-negative) were obtained from the DMSZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH) in Braunschweig and cultured in RPMI medium enriched with 2 mM L-glutamine (Bio Whittaker) and 10 μg/ml streptomycin and 10 U/ml of penicillin at 37° C. under 5% CO2.
- For the production of modified RNA sequences according to the invention, the GC-enriched and translation-optimized DNA sequences which code for a heavy chain and a light chain of an antibody (e.g. cetuximab (ERBITUX®), trastuzumab (HERCEPTIN®) and rituximab (RITUXAN®), cf. SEQ ID NO: 1-15, where SEQ ID NO: 1, 3, 6, 8, 11 and 13 represent the particular coding sequences which are not GC-optimized of the heavy and the light chains of these antibodies and SEQ ID NO: 2, 4, 5, 7, 9, 10, 12, 14 and 15 represent the coding GC-enriched sequences (see above)) were cloned into the pCV19 vector (CureVac GmbH) by standard molecular biology methods. To ensure equimolar expression of the two chains, an IRES (internal ribosomal entry site) was introduced. The mutated 3′ UTR (untranslated region) of the alpha-globin gene and a polyA-polyC tail at the 3′ end serve for additional stabilizing of the mRNA. The signal peptide of the HLA-A*0201 gene is coded for secretion of the antibody expressed. A His tag was additionally introduced for detection of the antibody.
FIG. 6 shows the expression constructs used. - 1.3 Preparation of the G/C-Enriched and Translation-Optimized Antibody-Coding mRNA
- An in vitro transcription was carried out by means of T7 polymerase (T7-Opti mRNA Kit, CureVac, Tubingen, Germany), followed by purification with Pure Messenger™ (CureVac, Tubingen, Germany). For this, a DNase digestion was first carried out, followed by an LiCl precipitation and thereafter an HPLC using a porous reverse phase as the stationary phase (PURE Messenger).
- 1 million cells were transfected with the mRNA according to one of SEQ ID NO: 5, 10 or 15 (see above), which codes for an antibody as described above, by means of electroporation and were then cultured in the medium for 16 h. The antibody expressed was detected by means of an FITC-coupled His tag antibody. Alternatively, the secreted antibody from the supernatant of transfected cells was added to non-transfected, antigen-expressing cells and, after incubation, detected by the same method.
- 1.5 In Vitro Detection of an Antibody Coded by an RNA According to the Invention by Means of ELISA:
- A microtitre plate was loaded with a murine antibody (1) against a first antigen (HER-2). Cell lysate of antigen-expressing cells was then added to the plate. The antigen was bound here by the murine antigen-specific antibody (1). The supernatant of cells which were transfected with a modified mRNA according to the invention which codes for an HER-2-specific antibody was then added to the microtitre plate. The HER-2-specific antibody (2) contained in the supernatant likewise binds to the antibody-bound antigen, the two antibodies recognizing different domains of the antigen. For detection of the bound antibody (2), anti-human IgG coupled to horseradish peroxidase (3-HRP) was added, the substrate TMB being converted and the result determined photometrically.
- An antibody-coding (m)RNA according to the invention as described above was injected intradermally or intramuscularly into BALB/c mice. 24 h thereafter, the corresponding tissues were removed and protein extracts were prepared. The expression of the antibody was detected by means of ELISA as described here.
- The expressed antibodies from the supernatant of cells which were transfected with a modified mRNA which codes for an antibody as described above were separated by means of a polyacrylamide gel electrophoresis and then transferred to a membrane. After incubation with anti-His tag antibody and a second antibody coupled to horseradish peroxidase, the antibody expressed was detected by means of chemoluminescence.
- SKOV-3 cells were injected subcutaneously into BALB/c mice. Within the following 28 days, eight portions of 10 μg of a modified mRNA which codes for an antibody as described above were injected into the tail vein of the mice. The tumour growth was monitored over a period of 5 weeks.
- RNA-based expression of humanised antibodies was done in either CHO-K1 or BHK-21 cells. The tumour cell lines BT-474, A-431 and Raji strongly expressing HER2, EGFR and CD20, respectively, were used to record antibody levels. All cell lines except CHO were maintained in RPMI supplemented with FCS and glutamine according to the supplier's information. CHO cells were grown in Ham's F12 supplemented with 10% FCS. All cell lines were obtained from the German collection of cell cultures (DSMZ).
- Various amounts of antibody-RNA (G/C enriched as defined by
FIGS. 12, 17, 22, 25, 26, 27 ) encoding the humanised antibodies Herceptin, Erbitux, and Rituxan, respectively, (see the description given above for Example 1) were transfected into either CHO or BHK cells by electroporation. Conditions were as follows: 300 V, 450 μF for CHO and 300 V, 150 μF for BHK. After transfection, cells were seeded onto 24-well cell culture plates at a density of 2-400.000 cells per well. For collection of secreted protein, medium was replaced by 250 μl of fresh medium after cell attachment to the plastic surface. Secreted protein was collected for 24-96 hours and stored at 4° C. In addition, cells were harvested into 50 μl of phosphate buffered saline containing 0.5% BSA and broken up by three freeze-thaw cycles. Cell lysates were cleared by centrifugation and stored at −80° C. - In order to detect translation of transfected RNA, proteins from either cell culture supernatants or cell lysates were separated by a 12% SDS-PAGE and blotted onto a nitrocellulose membrane. Humanised antibodies Herceptin (Roche), Erbitux (Merck KGAA), and Mabthera=Rituxan (Roche) were used as controls. After blotting was completed, membranes were consecutively incubated with biotinylated goat anti-human IgG (Dianova), streptavidin coupled to horseradish peroxidase (BD), and a chemiluminescent substrate (SuperSignal West Pico, Pierce). Staining was detected with a Fuji LAS-1000 chemiluminescence camera.
- 200.000 target cells expressing the respective antigen were incubated with either control antibodies (Herceptin, Erbitux, Mabthera) or cell culture supernatants. For detection of bound antibodies, cells were stained with biotinylated goat anti-human IgG (Dianova) and PE-labelled streptavidin (Invitrogen). Cells were analysed on a FACSCalibur (BD).
Claims (37)
1. An RNA for intracellular expression of an antibody, wherein the RNA contains at least one coding region, wherein at least one coding region codes for at least one antibody.
2. An RNA according to claim 1 , wherein the RNA is single-stranded or double-stranded, linear or circular, in the form of rRNA, tRNA or mRNA.
3. An RNA according to claim 1 or 2 , wherein the RNA is an mRNA.
4. An RNA according to claims 1 to 3 , wherein the antibody coded is chosen from monoclonal and polyclonal antibodies, chimeric antibodies, human antibodies, humanized antibodies, bispecific antibodies, intrabodies and fragments of these antibodies.
5. An RNA according to claims 1 to 4 , wherein the coded antibody fragments are chosen from Fab, Fab′, F(ab′)2, Fc, Facb, pFc′, Fd, and Fv or scFv fragments of these antibodies.
6. An RNA according to claims 1 to 5 , wherein the coded antibodies or antibody fragments specifically recognize and bind tumour-specific surface antigens chosen from (TSSA), 5T4, α5β1-integrin, 707-AP, AFP, ART-4, B7H4, BAGE, β-catenin/m, Bcr-abl, MN/C IX-antigen, CA125, CAMEL, CAP-I, CASP-8, β-catenin/m, CD4, CD19, CD20, CD22, CD25, CDC27/m, CD 30, CD33, CD52, CD56, CD80, CDK4/m, CEA, CT, Cyp-B, DAM, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ETV6-AML1, G250, GAGE, GnT-V, GpIOO, HAGE, HER-2/neu, HLA-A*0201-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT), iCE, IGF-IR, IL-2R, IL-5, KIAA0205, LAGE, LDLR/FUT, MAGE, MART-1/Melan-A, MART-2/Ski, MC1R, myosin/m, MUC1, MUM-I, -2, -3, NA88-A, PAP, proteinase-3, p190 minor bcr-abl, Pml/RARα, PRAME, PSA, PSM, PSMA, RAGE, RU1 or RU2, SAGE, SART-I or SART-3, survivin, TEL/AML1, TGFβ, TPI/m, TRP-I, TRP-2, TRP-2/INT2, VEGF and WT1, NY-Eso-1 and NY-Eso-B.
7. An RNA according to one of claims 1 to 6 , wherein the RNA is modified.
8. An RNA according to one of the preceding claims, wherein the modification is chosen from modifications of the nucleotide sequence compared with a precursor RNA sequence by introduction of non-native nucleotides and/or by covalent coupling of the RNA with another group.
9. An RNA according to claim 8 , wherein the RNA has a G/C content in the coding region of the base-modified RNA which is greater than the G/C content of the coding region of the native RNA sequence, the coded amino acid sequence being unchanged with respect to the wild-type or, respectively, the precursor RNA.
10. An RNA according to claim 8 or 9 , wherein the coding region of the modified RNA is modified compared with the coding region of the native RNA such that at least one codon of the native RNA which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is relatively frequent in the cell and which carries the same amino acid as the relatively rare tRNA.
11. An RNA according to one of claims 8 to 10 , wherein the RNA has a lipid modification.
12. An RNA according to one of claims 8 to 11 , wherein the RNA contains on at least one nucleotide of the RNA a modification of a nucleotide, wherein the nucleotides are chosen from 1-methyl-adenine, 2-methyl-adenine, 2-methylthio-N6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine, inosine, 1-methyl-inosine, dihydro-uracil, 2-thio-uracil, 4-thio-uracil, 5-carboxymethylaminomethyl-2-thio-uracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5-bromo-uracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil, 5-methyl-uracil, N-uracil-5-oxyacetic acid methyl ester, 5-methylaminomethyl-uracil, 5-methoxyaminomethyl-2-thio-uracil, 5′-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-Oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), pseudouracil, 1-methyl-pseudouracil, queosine, β-D-mannosyl-queosine, wybutoxosine, and phosphoramidates, phosphorothioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine.
13. An RNA according to one of claims 8 to 12 , wherein the RNA contains on at least one nucleotide of the RNA a modification of a nucleotide, wherein the nucleotides are base-modified nucleotides chosen from the group consisting of 2-amino-6-chloropurine riboside 5′-triphosphate, 2-aminoadenosine 5′-triphosphate, 2-thiocytidine 5′-triphosphate, 2-thiouridine 5′-triphosphate, 4-thiouridine 5′-triphosphate, 5-aminoallylcytidine 5′-triphosphate, 5-aminoallyluridine 5′-triphosphate, 5-bromocytidine 5′-triphosphate, 5-bromouridine 5′-triphosphate, 5-iodocytidine 5′-triphosphate, 5-iodouridine 5′-triphosphate, 5-methylcytidine 5′-triphosphate, 5-methyluridine 5′-triphosphate, 6-azacytidine 5′-triphosphate, 6-azauridine 5′-triphosphate, 6-chloropurine riboside 5′-triphosphate, 7-deazaadenosine 5′-triphosphate, 7-deazaguanosine 5′-triphosphate, 8-azaadenosine 5′-triphosphate, 8-azidoadenosine 5′-triphosphate, benzimidazole riboside 5′-triphosphate, N1-methyladenosine 5′-triphosphate, N1-methylguanosine 5′-triphosphate, N6-methyladenosine 5′-triphosphate, O6-methylguanosine 5′-triphosphate, pseudouridine 5′-triphosphate, puromycin 5′-triphosphate or xanthosine 5′-triphosphate.
14. An RNA according to claim 13 , wherein the base-modified nucleotides are chosen from the group consisting of 5-methylcytidine 5′-triphosphate and pseudouridine 5′-triphosphate.
15. An RNA according to one of the preceding claims, wherein the RNA additionally has a 5′ cap structure chosen from the group consisting of m7G(5′)ppp (5′(A,G(5′)ppp(5′)A and G(5′)ppp(5′)G.
16. An RNA according to one of the preceding claims, wherein the RNA additionally has a poly-A tail of from about 10 to 200 adenosine nucleotides.
17. An RNA according to one of the preceding claims, wherein the RNA additionally has a poly-C tail of from about 10 to 200 cytosine nucleotides.
18. An RNA according to one of the preceding claims, wherein the RNA additionally codes a tag for purification chosen from the group consisting of a hexahistidine tag (HIS tag, polyhistidine tag), a streptavidin tag (Strep tag), an SBP tag (streptavidin-binding tag) or a GST (glutathione S-transferase) tag, or codes for a tag for purification via an antibody epitope chosen from the group consisting of antibody-binding tags, a Myc tag, a Swal 1 epitope, a FLAG tag or an HA tag.
19. An RNA according to one of the preceding claims, wherein the RNA additionally codes a signal peptide and/or a localization sequence, in particular a secretion sequence.
20. An RNA according to claim 19 , wherein the localization sequence is chosen from one of the sequences according to SEQ ID NO: 18 to 50.
21. An RNA according to one of the preceding claims, wherein the RNA contains an antibody-coding sequence which codes for the heavy chains according to SEQ ID NO: 2 and the light chains according to SEQ ID NO: 4.
22. An RNA according to one of the preceding claims 1 to 20 , wherein the RNA contains an antibody-coding sequence according to SEQ ID NO: 5.
23. An RNA according to one of the preceding claims 1 to 20 , wherein the RNA contains an antibody-coding sequence which codes for the heavy chains according to SEQ ID NO: 7 and the light chains according to SEQ ID NO: 9.
24. An RNA according to one of the preceding claims 1 to 20 , wherein the RNA contains an antibody-coding sequence according to SEQ ID NO: 10.
25. An RNA according to one of the preceding claims 1 to 20 , wherein the modified RNA contains an antibody-coding sequence which codes for the heavy chains according to SEQ ID NO: 12 and the light chains according to SEQ ID NO: 14.
26. An RNA according to one of the preceding claims 1 to 20 , wherein the RNA contains an antibody-coding sequence according to SEQ ID NO: 15.
27. An RNA according to one of the preceding claims 1 to 20 , wherein the modified RNA contains an antibody-coding sequence which has a sequence identity of at least 70% to the sequence SEQ ID NO: 5, 10 or 15 over the total length of the nucleic acid sequence of SEQ ID NO: 5, 10 or 15.
28. A pharmaceutical composition comprising an RNA according to one of claims 1 to 27 .
29. Use of an RNA sequence as defined in claims 1 to 27 for the preparation of a pharmaceutical composition for treatment of cancer diseases, cardiovascular diseases, infectious diseases or autoimmune diseases.
30. Use according to claim 29 , wherein the pharmaceutical composition is in the form of a passive vaccine for treatment of tumour or infectious diseases.
31. Use according to one of claim 29 or 30 , wherein the cancer diseases or tumour diseases are chosen from the group consisting of melanomas, malignant melanomas, colon carcinomas, lymphomas, sarcomas, blastomas, kidney carcinomas, gastrointestinal tumours, gliomas, prostate tumours, bladder cancer, rectal tumours, stomach cancer, oesophageal cancer, pancreatic cancer, liver cancer, mammary carcinomas (=breast cancer), uterine cancer, cervical cancer, acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), hepatomas, diverse virus-induced tumours, such as e.g. papilloma virus-induced carcinomas (e.g. cervix carcinoma=cervical cancer), adenocarcinomas, herpes virus-induced tumours (e.g. Burkitt's lymphoma, EBV-induced B cell lymphoma), hepatitis B-induced tumours (hepatocell carcinomas), HTLV-I- and HTLV-2-induced lymphomas, acusticus neurinoma, lung carcinomas (=lung cancer=bronchial carcinoma), small cell lung carcinomas, throat cancer, anal carcinoma, glioblastoma, rectum carcinoma, astrocytoma, brain tumours, retinoblastoma, basalioma, brain metastases, medulloblastomas, vaginal cancer, testicular cancer, thyroid carcinoma, Hodgkin's syndrome, meningeomas, Schneeberger's disease, pituitary tumour, mycosis fungoides, carcinoids, neurinoma, spinalioma, Burkitt's lymphoma, laryngeal cancer, kidney cancer, thymoma, corpus carcinoma, bone cancer, non-Hodgkin's lymphomas, urethral cancer, CUP syndrome, head/neck tumours, oligodendroglioma, vulval cancer, intestinal cancer, colon carcinoma, oesophageal carcinoma (=oesophageal cancer), wart conditions, small intestine tumours, cra-niopharyngeomas, ovarian carcinoma, soft tissue tumours (sarcomas), ovarian cancer (=ovarian carcinoma), pancreatic carcinoma (=pancreatic cancer), endometrium carcinoma, liver metastases, penis cancer, tongue cancer, gallbladder cancer, leukaemia, plasmocytoma, lid tumour and prostate cancer (=prostate tumours).
32. Use according to one of claims 29 to 30 , wherein the infectious diseases are chosen from the group consisting of influenza, malaria, SARS, yellow fever, AIDS, Lyme borreliosis, leishmaniasis, anthrax, meningitis, viral infectious diseases, such as AIDS, condyloma acuminata, molluscum contagiosum, dengue fever, three-day fever, Ebola virus, colds, early summer meningoencephalitis (ESME), influenza, shingles, hepatitis, herpes simplex type I, herpes simplex type II, herpes zoster, influenza, Japanese encephalitis, Lassa fever, Marburg virus, measles, foot and mouth disease, mononucleosis, mumps, Norwalk virus infection, Pfeiffer's glandular fever, smallpox, polio (poliomyelitis), pseuodcroup, infectious erythema, rabies, warts, West Nile fever, chicken-pox, cytomegalovirus (CMV), bacterial infectious diseases, such as abortion (infectious, septic), prostatitis (prostate inflammation), anthrax, appendicitis (inflammation of the caecum), borreliosis, botulism, Campylobacter, Chlamydia trachomatis (inflammation of the urethra, conjunctiva), cholera, diphtheria, donavonosis, epiglottitis, louse-borne typhus, typhoid fever, gas gangrene, gonorrhoea, hare plague, Helicobacter pylori, whooping-cough, climatic bubo, osteomyelitis, legionnaires' disease, leprosy, listeriosis, pneumonia, meningitis, bacterial meningitis, anthrax, inflammation of the middle ear, Mycoplasma hominis, neonatal sepsis (chorioamnionitis), noma, paratyphoid fever, plague, Reiter's syndrome, Rocky Mountain spotted fever, Salmonella paratyphoid fever, Salmonella typhoid fever, scarlet fever, syphilis, tetanus, gonorrhoea, tsutsugamushi fever, tuberculosis, typhus, vaginitis (colpitis), soft chancre, and infectious diseases caused by parasites, protozoa or fungi, such as amoebic dysentery, bilharziosis, Chagas' disease, Echinococcus, fish tapeworm, ichthyotoxism (ciguatera), fox tapeworm, mycosis pedis, dog tapeworm, candiosis, ptyriasis, the itch (scabies), cutaneous leishmaniasis, lamblian dysentery (giadiasis), lice, malaria, onchocercosis (river blindness), fungal diseases, beef tapeworm, schistosomiasis, sleeping sickness, pork tapeworm, toxoplasmosis, trichomoniasis, trypanosomiasis (sleeping sickness), visceral leishmaniasis, nappy dermatitis, or infections caused by the dwarf tapeworm.
33. Use according to one of claim 29 or 30 , wherein the cardiovascular diseases are chosen from the group consisting of coronary heart disease, arteriosclerosis, apoplexy and hypertension, and neuronal diseases chosen from Alzheimer's disease, amyotrophic lateral sclerosis, dystonia, epilepsy, multiple sclerosis and Parkinson's disease.
34. Use according to one of claim 29 or 30 , wherein the autoimmune diseases are chosen from the group consisting of autoimmune type I diseases or autoimmune type II diseases or auto-immune type III diseases or autoimmune type IV diseases, such as, for example, multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I (diabetes mellitus), systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergy type I diseases, allergy type II diseases, allergy type III diseases, allergy type IV diseases, fibromyalgia, hair loss, Bechterew's disease, Crohn's disease, myasthenia gravis, neurodermatitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter's syndrome, rheumatic arthritis, psoriasis or vasculitis.
35. An in vitro transcription method for the preparation of an antibody-coding, optionally modified RNA, comprising the following steps: a) provision of a nucleic acid which codes for an antibody, as defined in claims 4 to 6 ; b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, a nucleic acid mix comprising one or more modified nucleotides in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, or optionally only naturally occurring nucleotides and optionally an RNase inhibitor; c) incubation of the nucleic acid in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding, optionally modified RNA according to claims 1 to 27 ; d) optionally purification of the antibody-coding, optionally modified RNA and removal of the non-incorporated nucleotides from the in vitro transcription medium.
36. An in vitro transcription and translation method for expression of an antibody, comprising the following steps: a) provision of a nucleic acid which codes for an antibody, as defined in claims 4 to 6 ; b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, a nucleic acid mix comprising one or more modified nucleotides in exchange for one or more of the naturally occurring nucleotides A, G, C or U, and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, or optionally only naturally occurring nucleotides and optionally an RNase inhibitor; c) incubation of the nucleic acid in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding, optionally modified RNA according to claims 1 to 27 ; d) optionally purification of the antibody-coding, optionally modified RNA and removal of the non-incorporated nucleotides from the in vitro transcription medium, e) addition of the optionally modified RNA obtained in step c) (and optionally in step d) to an in vitro translation medium; f) incubation of the optionally modified RNA in the in vitro translation medium and in vitro translation of the antibody coded by the optionally modified RNA; g) optionally purification of the antibody translated in step f).
37. An in vitro transcription and translation method for expression of an antibody in a host cell, comprising the following steps: a) provision of a nucleic acid which codes for an antibody, as defined in claims 4 to 6 ; b) addition of the nucleic acid to an in vitro transcription medium comprising an RNA polymerase, a suitable buffer, one or more modified nucleotides in exchange for one or more of the naturally occurring nucleotides A, G, C or U and optionally one or more naturally occurring nucleotides A, G, C or U, if not all the naturally occurring nucleotides A, G, C or U are to be exchanged, or only naturally occurring nucleotides and optionally an RNase inhibitor; c) incubation of the nucleic acid in the in vitro transcription medium and in vitro transcription of the nucleic acid to give an antibody-coding, optionally modified RNA according to claims 1 to 27 ; d) optionally purification of the antibody-coding, optionally modified RNA according to the invention and removal of the non-incorporated nucleotides from the in vitro transcription medium, e′) transfection of the optionally modified RNA obtained in step c) (and optionally d)) into a host cell; f) incubation of the optionally modified nucleic acid in the host cell and translation of the antibody coded by the optionally modified RNA in the host cell; g′) optionally isolation and/or purification of the antibody translated in step f).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/813,530 US20220372158A1 (en) | 2007-01-09 | 2022-07-19 | Rna-coded antibody |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007001370.3 | 2007-01-09 | ||
DE102007001370A DE102007001370A1 (en) | 2007-01-09 | 2007-01-09 | RNA-encoded antibodies |
PCT/EP2008/000081 WO2008083949A2 (en) | 2007-01-09 | 2008-01-08 | Rna-coded antibody |
US52221410A | 2010-01-04 | 2010-01-04 | |
US17/813,530 US20220372158A1 (en) | 2007-01-09 | 2022-07-19 | Rna-coded antibody |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/000081 Continuation WO2008083949A2 (en) | 2007-01-09 | 2008-01-08 | Rna-coded antibody |
US12/522,214 Continuation US11421038B2 (en) | 2007-01-09 | 2008-01-08 | RNA-coded antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220372158A1 true US20220372158A1 (en) | 2022-11-24 |
Family
ID=39427526
Family Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,214 Active US11421038B2 (en) | 2007-01-09 | 2008-01-08 | RNA-coded antibody |
US13/709,897 Abandoned US20130195867A1 (en) | 2007-01-09 | 2012-12-10 | Rna-coded antibody |
US15/007,072 Abandoned US20160145346A1 (en) | 2007-01-09 | 2016-01-26 | Rna-coded antibody |
US15/015,657 Abandoned US20160168254A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/015,798 Abandoned US20160152706A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/015,879 Abandoned US20160152691A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/053,755 Abandoned US20160166691A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/053,890 Abandoned US20160166690A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/053,826 Abandoned US20160166692A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/067,160 Abandoned US20160185840A1 (en) | 2007-01-09 | 2016-03-10 | Rna-coded antibody |
US16/392,004 Abandoned US20190284260A1 (en) | 2007-01-09 | 2019-04-23 | Rna-coded antibody |
US17/813,530 Pending US20220372158A1 (en) | 2007-01-09 | 2022-07-19 | Rna-coded antibody |
Family Applications Before (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,214 Active US11421038B2 (en) | 2007-01-09 | 2008-01-08 | RNA-coded antibody |
US13/709,897 Abandoned US20130195867A1 (en) | 2007-01-09 | 2012-12-10 | Rna-coded antibody |
US15/007,072 Abandoned US20160145346A1 (en) | 2007-01-09 | 2016-01-26 | Rna-coded antibody |
US15/015,657 Abandoned US20160168254A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/015,798 Abandoned US20160152706A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/015,879 Abandoned US20160152691A1 (en) | 2007-01-09 | 2016-02-04 | Rna-coded antibody |
US15/053,755 Abandoned US20160166691A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/053,890 Abandoned US20160166690A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/053,826 Abandoned US20160166692A1 (en) | 2007-01-09 | 2016-02-25 | Rna-coded antibody |
US15/067,160 Abandoned US20160185840A1 (en) | 2007-01-09 | 2016-03-10 | Rna-coded antibody |
US16/392,004 Abandoned US20190284260A1 (en) | 2007-01-09 | 2019-04-23 | Rna-coded antibody |
Country Status (6)
Country | Link |
---|---|
US (12) | US11421038B2 (en) |
EP (5) | EP2101823B1 (en) |
DE (1) | DE102007001370A1 (en) |
DK (1) | DK2101823T3 (en) |
ES (2) | ES2904550T3 (en) |
WO (1) | WO2008083949A2 (en) |
Families Citing this family (341)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
US8097256B2 (en) | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
DE102006061015A1 (en) * | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
US9068020B2 (en) | 2008-09-02 | 2015-06-30 | Cedars-Sinai Medical Center | CD133 epitopes |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
US10837020B2 (en) | 2009-04-22 | 2020-11-17 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long RNA molecules |
WO2010123501A1 (en) * | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
ES2734973T3 (en) | 2009-12-01 | 2019-12-13 | Translate Bio Inc | Administration of mRNA for the increase of proteins and enzymes in human genetic diseases |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
LT3243526T (en) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
JP5940064B2 (en) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | Immunization of large mammals with low doses of RNA |
WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
MX336839B (en) | 2010-07-30 | 2016-02-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation. |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
RS63983B1 (en) | 2010-08-31 | 2023-03-31 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding rna |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
CN105061534A (en) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | Substituted nucleotide analogs |
CA2821992A1 (en) * | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP2013544504A (en) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | Antigen delivery platform |
US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (en) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleosides, nucleotides and modified nucleic acids, and their uses |
CN109022465B (en) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
DE12858350T1 (en) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | MODIFIED MRNA COMPOSITIONS |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
EP2802351B1 (en) | 2012-01-09 | 2019-03-27 | ADC Therapeutics SA | Agents for treating triple negative breast cancer |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
ES2660459T3 (en) | 2012-03-27 | 2018-03-22 | Curevac Ag | Artificial Nucleic Acid Molecules |
KR20140139101A (en) | 2012-03-27 | 2014-12-04 | 큐어백 게엠바하 | Artificial nucleic acid molecules comprising a 5'top utr |
ES2654205T3 (en) | 2012-03-27 | 2018-02-12 | Curevac Ag | Artificial nucleic acid molecules for enhanced protein or peptide expression |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CN104411338A (en) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | Modified polynucleotides for the production of biologics and proteins associated with human disease |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US20140234350A1 (en) * | 2013-02-14 | 2014-08-21 | Cedars-Sinai Medical Center | Ovarian cancer vaccines and vaccination methods |
WO2014127296A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
SG10201710472PA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
EP3292873B1 (en) | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
IL290953B2 (en) | 2013-03-14 | 2024-01-01 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
EA201591293A1 (en) * | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | METHODS AND COMPOSITIONS FOR DELIVERY OF ANTIBODIES CODED BY mRNAs |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2971033B8 (en) * | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
KR102094022B1 (en) | 2013-04-29 | 2020-03-30 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
JP6648019B2 (en) | 2013-08-21 | 2020-02-14 | キュアバック アーゲー | Pharmaceutical compositions for promoting expression of RNA-encoded proteins, use of modified RNA for the manufacture of pharmaceutical compositions, and kits of parts comprising the pharmaceutical compositions |
WO2015024665A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Rabies vaccine |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160213754A1 (en) * | 2013-09-20 | 2016-07-28 | Nils LANDEGREN | Transglutaminase 4 as a prostate specific autoantigen and the methods of use thereof |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
MX2016005237A (en) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Mrna therapy for argininosuccinate synthetase deficiency. |
EP3060258A1 (en) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
ES2806575T3 (en) | 2013-11-01 | 2021-02-18 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
KR102399799B1 (en) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | Artificial nucleic acid molecules |
WO2015105926A1 (en) * | 2014-01-08 | 2015-07-16 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
PL3122878T3 (en) * | 2014-03-24 | 2019-06-28 | Translate Bio, Inc. | Mrna therapy for the treatment of ocular diseases |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
JP6881813B2 (en) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | Nucleic acid vaccine |
CN117402871A (en) | 2014-04-25 | 2024-01-16 | 川斯勒佰尔公司 | Method for purifying messenger RNA |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
WO2015188933A1 (en) | 2014-06-10 | 2015-12-17 | Curevac Ag | Methods and means for enhancing rna production |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
SI3766916T1 (en) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
JP2017522028A (en) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Circular polynucleotide |
AU2015289583A1 (en) | 2014-07-16 | 2017-02-02 | Modernatx, Inc. | Chimeric polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
MA40871A (en) * | 2014-10-29 | 2017-09-05 | Novartis Ag | DIRECT EXPRESSION OF ANTIBODIES |
BR112017008880A2 (en) | 2014-10-29 | 2018-07-10 | Teva Pharmaceuticals Australia Pty Ltd | interferon a2b variants |
EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
PT3708668T (en) | 2014-12-12 | 2022-09-14 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
SG10202007176TA (en) * | 2014-12-30 | 2020-08-28 | Celgene Corp | Anti-cd47 antibodies and uses thereof |
US10293059B2 (en) | 2015-04-09 | 2019-05-21 | Cornell University | Gene therapy to prevent reactions to allergens |
US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
SG11201707663SA (en) | 2015-04-17 | 2017-11-29 | Curevac Ag | Lyophilization of rna |
BR112017018368B1 (en) | 2015-04-22 | 2022-08-02 | Curevac Ag | COMPOSITION CONTAINING RNA FOR USE IN THE TREATMENT OR PROPHYLAXIS OF TUMOR AND/OR CANCER DISEASES, AND USE OF AN RNA FOR THE PREPARATION OF THE COMPOSITION |
ES2897823T3 (en) | 2015-04-30 | 2022-03-02 | Curevac Ag | Immobilized poly(N)polymerase |
DK3294885T3 (en) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | METHOD OF PREPARING RNA |
CN107810009A (en) | 2015-05-15 | 2018-03-16 | 库瑞瓦格股份公司 | It is related to and exempts from strengthened scheme using at least one the first of mRNA constructs |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
US10517827B2 (en) | 2015-05-20 | 2019-12-31 | Curevac Ag | Dry powder composition comprising long-chain RNA |
EP4108769B1 (en) | 2015-05-29 | 2023-08-30 | CureVac Manufacturing GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2016193226A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | Method for adding cap structures to rna using immobilized enzymes |
NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
MA42502A (en) | 2015-07-21 | 2018-05-30 | Modernatx Inc | VACCINES AGAINST INFECTIOUS DISEASE |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
PL3350157T3 (en) | 2015-09-17 | 2022-05-16 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
US20190225644A1 (en) | 2015-10-16 | 2019-07-25 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
EP4349404A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
EA201891001A1 (en) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV) |
FI3368507T3 (en) | 2015-10-28 | 2023-03-21 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
JP7114465B2 (en) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of drugs |
SG11201804398XA (en) | 2015-12-22 | 2018-07-30 | Curevac Ag | Method for producing rna molecule compositions |
EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP3416683A1 (en) | 2016-02-17 | 2018-12-26 | CureVac AG | Zika virus vaccine |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
US11141474B2 (en) | 2016-05-04 | 2021-10-12 | Curevac Ag | Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
BR112018073683A2 (en) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | relaxin encoding polynucleotides |
CN109475640B (en) | 2016-06-09 | 2023-03-10 | 库瑞瓦格欧洲公司 | Mixed carrier for nucleic acid carried article |
JP2019525901A (en) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Stabilized preparation of lipid nanoparticles |
EP3500295A2 (en) | 2016-08-19 | 2019-06-26 | CureVac AG | Rna for cancer therapy |
AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN110352071A (en) | 2016-10-26 | 2019-10-18 | 库瑞瓦格股份公司 | Lipidic nanoparticles mRNA vaccine |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3538549A1 (en) | 2016-11-10 | 2019-09-18 | iOmx Therapeutics AG | Or10h1 antigen binding proteins and uses thereof |
EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | Influenza vaccine |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
CN110582304A (en) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | RNA for treating or preventing liver disease |
MA50335A (en) | 2016-12-08 | 2020-08-19 | Modernatx Inc | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
WO2018141371A1 (en) | 2017-01-31 | 2018-08-09 | Curevac Ag | Purification and/or formulation of rna |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | High potency immunogenic compositions |
EA201991747A1 (en) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | NEW CODON-OPTIMIZED CFTR mRNA |
FI3596041T3 (en) | 2017-03-15 | 2023-01-31 | Compound and compositions for intracellular delivery of therapeutic agents | |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
JP7332478B2 (en) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | Lipid nanoparticle formulation |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA47787A (en) | 2017-03-15 | 2020-01-22 | Modernatx Inc | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Zoonotic disease rna vaccines |
BR112019015244A2 (en) | 2017-03-24 | 2020-04-14 | Curevac Ag | nucleic acids encoding proteins associated with crispr and uses thereof |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
EP3615054A4 (en) | 2017-04-27 | 2021-03-24 | The Trustees Of The University Of Pennsylvania | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS |
WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
CN110914414A (en) | 2017-06-14 | 2020-03-24 | 德累斯顿工业大学 | Methods and means for genetically altering genomes using designed DNA recombinases |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
KR20200024905A (en) | 2017-07-04 | 2020-03-09 | 큐어백 아게 | New nucleic acid molecule |
JP7355731B2 (en) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | Lipids for use in lipid nanoparticle formulations |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Methods of preparing modified rna |
CA3072998A1 (en) * | 2017-08-18 | 2019-02-21 | Ultrahuman Four Limited | Binding agents |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Zika virus rna vaccines |
US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
RU2020117848A (en) | 2017-11-08 | 2021-12-08 | Куревак Аг | PHK SEQUENCE ADAPTATION |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3728309A2 (en) | 2017-12-22 | 2020-10-28 | Genentech, Inc. | Targeted integration of nucleic acids |
WO2019129677A1 (en) | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Anti-vegf antibodies and methods of use |
MA51523A (en) * | 2018-01-05 | 2020-11-11 | Modernatx Inc | POLYNUCLEOTIDES CODING ANTI-BODY ANTI-CHIKUNGUNYA VIRUS |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
EP3746470A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Stabilized immunoglobulin domains |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
EP3775184A1 (en) | 2018-03-29 | 2021-02-17 | F. Hoffmann-La Roche AG | Modulating lactogenic activity in mammalian cells |
AR114284A1 (en) | 2018-04-13 | 2020-08-12 | Hoffmann La Roche | HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL |
EP3787635A4 (en) | 2018-04-30 | 2022-03-02 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3818082A1 (en) | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
SG11202012993SA (en) | 2018-07-13 | 2021-02-25 | Genmab As | Variants of cd38 antibody and uses thereof |
JP2021526845A (en) | 2018-07-13 | 2021-10-11 | ゲンマブ エー/エス | Treatment via trogocytosis with CD38 antibody |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
JP7410135B2 (en) | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3852728A1 (en) | 2018-09-20 | 2021-07-28 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
MX2021003548A (en) | 2018-10-01 | 2021-05-27 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212. |
WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
AU2019403279A1 (en) | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
CN113286821A (en) | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | Tumor-targeting agonistic CD28 antigen binding molecules |
SG11202106198YA (en) | 2018-12-21 | 2021-07-29 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
TWI829831B (en) | 2018-12-21 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to cd3 |
WO2020146421A1 (en) * | 2019-01-08 | 2020-07-16 | Garrison Aura Rae | Gp38-targeting monoclonal antibodies protect adult mice against lethal crimean-congo hemorrhagic fever virus infection |
CN113329763A (en) | 2019-01-22 | 2021-08-31 | 豪夫迈·罗氏有限公司 | Immunoglobulin a antibodies and methods of making and using |
KR20210135494A (en) | 2019-01-31 | 2021-11-15 | 모더나티엑스, 인크. | Method for preparing lipid nanoparticles |
US20220126244A1 (en) | 2019-01-31 | 2022-04-28 | Modernatx, Inc. | Vortex mixers and associated methods, systems, and apparatuses thereof |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
JP2022522898A (en) | 2019-03-05 | 2022-04-20 | エフ.ホフマン-ラ ロシュ アーゲー | Intracellular targeting of molecules |
EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
TW202115124A (en) | 2019-06-26 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Novel antigen binding molecules binding to cea |
CN114401992A (en) | 2019-07-05 | 2022-04-26 | 艾欧麦克斯治疗股份公司 | Antibodies to IGSF11(VSIG3) that bind IGC2 and uses thereof |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
CA3149497A1 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
AU2020328855A1 (en) | 2019-08-14 | 2022-03-03 | CureVac SE | RNA combinations and compositions with decreased immunostimulatory properties |
JP2022547297A (en) | 2019-09-09 | 2022-11-11 | エフ.ホフマン-ラ ロシュ アーゲー | glucocerebrosidase mutant |
EP4031579A2 (en) | 2019-09-18 | 2022-07-27 | F. Hoffmann-La Roche AG | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
MX2022004737A (en) | 2019-10-24 | 2023-02-16 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies. |
MX2022005256A (en) | 2019-10-30 | 2022-08-25 | Oric Pharmaceuticals Inc | Cd73 inhibitors. |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
MX2022007635A (en) | 2019-12-18 | 2022-07-19 | Hoffmann La Roche | Antibodies binding to hla-a2/mage-a4. |
US20230192793A1 (en) | 2019-12-20 | 2023-06-22 | Hoffmann-La Roche Inc. | Il-37 fusion proteins and uses thereof |
IL294131A (en) | 2019-12-23 | 2022-08-01 | Genentech Inc | Apolipoprotein l1-specific antibodies and methods of use |
KR20220107251A (en) | 2020-01-09 | 2022-08-02 | 에프. 호프만-라 로슈 아게 | Novel 4-1BBL Trimer-Containing Antigen Binding Molecules |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
EP4127153A2 (en) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modified mammalian cells having reduced host cell proteins |
IL296781A (en) * | 2020-03-30 | 2022-11-01 | BioNTech SE | Rna compositions targeting claudin-18.2 |
EP4126940A1 (en) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
JP2023529522A (en) | 2020-04-09 | 2023-07-11 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | Lipid nanoparticle composition |
JP2023106635A (en) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions |
US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
US20230340081A1 (en) | 2020-06-08 | 2023-10-26 | Hoffmann-La Roche Inc. | Anti-hbv antibodies and methods of use |
AR122658A1 (en) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | ANTIBODIES THAT BIND TO CD3 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
US11780920B2 (en) | 2020-06-19 | 2023-10-10 | Hoffmann-La Roche Inc. | Antibodies binding to CD3 and CD19 |
PE20230470A1 (en) | 2020-06-19 | 2023-03-14 | Hoffmann La Roche | BINDING MOLECULES TO THE FC DOMAIN OF IMMUNE ACTIVATION |
CN115916826A (en) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | Antibodies that bind to CD3 and FolR1 |
JP2023530760A (en) | 2020-06-23 | 2023-07-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Agonist CD28 antigen-binding molecules targeting Her2 |
WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
MX2022015205A (en) | 2020-06-24 | 2023-01-05 | Genentech Inc | Targeted integration of nucleic acids. |
WO2021260064A1 (en) | 2020-06-25 | 2021-12-30 | F. Hoffmann-La Roche Ag | Anti-cd3/anti-cd28 bispecific antigen binding molecules |
CA3182994A1 (en) | 2020-06-30 | 2022-01-06 | Bo YING | Lipid compounds and lipid nanoparticle compositions |
EP4175668A1 (en) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
JP2023533533A (en) | 2020-07-10 | 2023-08-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibodies that bind to cancer cells and target radionucleotides to those cells |
EP4179332A1 (en) | 2020-07-13 | 2023-05-17 | Genentech, Inc. | Cell-based methods for predicting polypeptide immunogenicity |
KR20230051172A (en) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | Cationic Lipids for Use in Lipid Nanoparticles |
JP2023534458A (en) | 2020-07-17 | 2023-08-09 | ジェネンテック, インコーポレイテッド | Anti-Notch2 antibody and method of use |
MX2023001120A (en) | 2020-07-31 | 2023-02-22 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition including cell expressing chimeric receptor. |
EP4192942A1 (en) | 2020-08-07 | 2023-06-14 | Genentech, Inc. | T cell-based methods for predicting polypeptide immunogenicity |
EP4168391A1 (en) | 2020-08-20 | 2023-04-26 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CA3192344A1 (en) | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
KR20230061458A (en) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Antibodies that bind to VEGF-A and ANG2 and methods of use |
CA3190782A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors |
TW202233671A (en) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg-conjugated anti-mertk antibodies and methods of use |
WO2022096536A1 (en) | 2020-11-03 | 2022-05-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
CN117916261A (en) | 2020-11-16 | 2024-04-19 | 豪夫迈·罗氏有限公司 | Combination therapy with FAP-targeted CD40 agonists |
US20230406922A1 (en) | 2020-11-20 | 2023-12-21 | Simcere Zaiming Pharmaceutical Co., Ltd. | Humanized cd19 antibody and use thereof |
US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
JP2024503826A (en) | 2021-01-06 | 2024-01-29 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2024504931A (en) | 2021-01-12 | 2024-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Split antibodies that bind to cancer cells and target radionuclides to said cells |
US20240173442A1 (en) | 2021-01-13 | 2024-05-30 | Hoffmann-La Roche Inc. | Combination therapy |
CN116615472A (en) | 2021-01-14 | 2023-08-18 | 苏州艾博生物科技有限公司 | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
EP4277929A1 (en) * | 2021-01-14 | 2023-11-22 | Translate Bio, Inc. | Methods and compositions for delivering mrna coded antibodies |
EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
CA3210650A1 (en) | 2021-03-03 | 2022-09-09 | Winfried Wels | Bispecific antibodies enhancing cell mediated immune responses |
JP2024512377A (en) | 2021-03-12 | 2024-03-19 | ジェネンテック, インコーポレイテッド | Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use |
IL307501A (en) | 2021-04-19 | 2023-12-01 | Hoffmann La Roche | Modified mammalian cells |
KR20240007928A (en) | 2021-05-14 | 2024-01-17 | 제넨테크, 인크. | Agonist of TREM2 |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
CN117396599A (en) | 2021-05-21 | 2024-01-12 | 基因泰克公司 | Modified cells for production of recombinant products of interest |
WO2022247755A1 (en) | 2021-05-24 | 2022-12-01 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
AR126009A1 (en) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM |
BR112023025738A2 (en) | 2021-06-09 | 2024-02-27 | Hoffmann La Roche | COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, USE OF A COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER, PHARMACEUTICAL COMPOSITION AND INVENTION |
BR112023023480A2 (en) | 2021-06-25 | 2024-01-30 | Chugai Pharmaceutical Co Ltd | USE OF ANTI-CTLA-4 ANTIBODY |
BR112023022992A2 (en) | 2021-06-25 | 2024-01-23 | Chugai Pharmaceutical Co Ltd | ANTI-CTLA-4 ANTIBODY |
CN117580865A (en) | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | CD16 antibodies and uses thereof |
WO2023280297A1 (en) | 2021-07-09 | 2023-01-12 | 江苏先声药业有限公司 | Cd19 antibody and application thereof |
TW202306985A (en) | 2021-07-12 | 2023-02-16 | 美商建南德克公司 | Structures for reducing antibody-lipase binding |
CN113514645A (en) * | 2021-07-13 | 2021-10-19 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | Application of CD138 antibody and Mum1 antibody in plasma cell detection |
CR20240074A (en) | 2021-07-14 | 2024-03-08 | Genentech Inc | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
EP4373859A1 (en) | 2021-07-22 | 2024-05-29 | F. Hoffmann-La Roche AG | Heterodimeric fc domain antibodies |
EP4378954A1 (en) | 2021-07-30 | 2024-06-05 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
IL311141A (en) | 2021-09-06 | 2024-04-01 | Genmab As | Antibodies capable of binding to cd27, variants thereof and uses thereof |
CN117940457A (en) | 2021-09-13 | 2024-04-26 | 山东先声生物制药有限公司 | Anti-human CD3 antibodies and uses thereof |
TW202328067A (en) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | Cyclic lipids and methods of use thereof |
EP4402121A1 (en) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
CN116064598B (en) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
AR127312A1 (en) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS |
KR20240090186A (en) | 2021-10-08 | 2024-06-21 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | Lipid Compounds and Lipid Nanoparticle Compositions |
AR127269A1 (en) | 2021-10-08 | 2024-01-03 | Chugai Pharmaceutical Co Ltd | ANTI-HLA-DQ2.5 ANTIBODY FORMULATION |
CN118234856A (en) | 2021-11-15 | 2024-06-21 | 德累斯顿工业大学 | Site-specific recombinase for efficient and specific genome editing |
WO2023098846A1 (en) | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | Anti-bcma nanobody and use thereof |
AR127887A1 (en) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND PLAP |
CA3237618A1 (en) | 2021-12-15 | 2023-06-22 | Genentech, Inc. | Stabilized il-18 polypeptides and uses thereof |
AU2022423749A1 (en) | 2021-12-20 | 2024-06-13 | F. Hoffmann-La Roche Ag | Agonistic ltbr antibodies and bispecific antibodies comprising them |
AU2022422983A1 (en) | 2021-12-23 | 2024-05-16 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compound and lipid nanoparticle composition |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023125888A1 (en) | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | Gprc5d antibody and application thereof |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
WO2023186756A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Interferon gamma variants and antigen binding molecules comprising these |
AR128876A1 (en) | 2022-03-28 | 2024-06-19 | Hoffmann La Roche | ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023198661A1 (en) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
US20240240156A1 (en) | 2022-11-15 | 2024-07-18 | Genentech, Inc. | Combined transposon-mediated integration and targeted integration of nucleic acids into host cells |
WO2024104933A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Antigen binding molecules |
WO2024126660A1 (en) | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
WO2024133940A2 (en) | 2022-12-23 | 2024-06-27 | Iomx Therapeutics Ag | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
US20240240175A1 (en) | 2023-01-12 | 2024-07-18 | Genentech, Inc. | Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO145164C (en) | 1978-11-06 | 1982-01-27 | Sintef | PROCEDURE FOR PREPARING POLYMER LATEKS. |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
ATE240401T1 (en) | 1989-03-21 | 2003-05-15 | Vical Inc | EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5316908A (en) | 1990-07-13 | 1994-05-31 | Life Technologies, Inc. | Size markers for electrophoretic analysis of DNA |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
EP0623025A1 (en) | 1991-12-24 | 1994-11-09 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5851829A (en) * | 1993-07-16 | 1998-12-22 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
FR2724320B1 (en) | 1994-09-13 | 1996-12-20 | Transgene Sa | NEW IMPLANT FOR THE TREATMENT OF ACQUIRED DISEASES |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US20040102389A1 (en) | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US6066258A (en) | 1997-12-05 | 2000-05-23 | Transgenomic, Inc. | Polynucleotide separations on polymeric separation media |
US6576133B2 (en) | 1996-11-13 | 2003-06-10 | Transgenomic, Inc | Method and system for RNA analysis by matched ion polynucleotide chromatography |
US5972222A (en) | 1996-11-13 | 1999-10-26 | Transgenomic, Inc. | Process for performing polynucleotide separations |
CA2304982A1 (en) | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | Sense mrna therapy |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6136195A (en) | 1998-04-10 | 2000-10-24 | Transgenomic, Inc. | MIPC column cleaning system and process |
BR9909918A (en) | 1998-05-06 | 2000-12-26 | Upjohn Co | Method for the release of a physiologically active growth hormone or protein cytokine, peptide or polypeptide to a non-human vertebrate |
FR2784997A1 (en) * | 1998-10-22 | 2000-04-28 | Transgene Sa | Biological material for preparation of pharmaceuticals useful e.g. as anticancer or antiviral agents, comprises a nucleic acid expressing an antibody that activates immune cells |
EP1619254B1 (en) | 1999-09-09 | 2010-12-22 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
EP1235852B1 (en) | 2000-01-26 | 2011-06-15 | TRANSGENOMIC, Inc. | Method for separating polynucleotides using monolithic capillary columns |
EP1224943A1 (en) * | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
EP1366167A2 (en) * | 2001-01-26 | 2003-12-03 | Transgene S.A. | Biological organism for preparing pharmaceutical compositions for treating mammals |
US6777187B2 (en) * | 2001-05-02 | 2004-08-17 | Rubicon Genomics, Inc. | Genome walking by selective amplification of nick-translate DNA library and amplification from complex mixtures of templates |
ES2344078T3 (en) | 2001-06-05 | 2010-08-17 | Curevac Gmbh | ARNM STABILIZED WITH AN INCREASED G / C CONTENT FOR GENETIC THERAPY. |
AU2002361642A1 (en) * | 2001-11-16 | 2003-06-10 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
EP1321176A1 (en) | 2001-12-18 | 2003-06-25 | Boehringer Ingelheim International GmbH | Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale |
DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
ATE417858T1 (en) | 2002-02-05 | 2009-01-15 | Genentech Inc | PROTEIN PURIFICATION |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
US7411045B2 (en) | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
US7125492B2 (en) | 2003-07-17 | 2006-10-24 | Agilent Technologies, Inc. | Additives for reversed-phase HPLC mobile phases |
DE10335833A1 (en) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
AT7634U1 (en) | 2004-06-29 | 2005-06-27 | Binder Co Ag | DETECTING DEVICE AND SORTING DEVICE |
DE102004035227A1 (en) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA mixture for vaccination against tumor diseases |
DE102004042546A1 (en) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Combination therapy for immune stimulation |
EP1669370A1 (en) | 2004-10-06 | 2006-06-14 | Institut Pasteur | Identification of regions of apical membrane antigen 1 of apicomplexan parasites suitable for targeting by vaccines and drugs by derivation and analysis of the three-dimensional structure |
AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
DE102005023170A1 (en) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimized formulation for mRNA |
ES2735531T3 (en) * | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | RNA containing modified nucleosides and methods of use thereof |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
DE102006035618A1 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria |
DE102006051516A1 (en) * | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Base) modified RNA to increase the expression of a protein |
DE102006061015A1 (en) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
DE102007001376B4 (en) | 2007-01-09 | 2009-04-16 | Greiner, Switbert, Dr. | Membrane element and method for covering surfaces |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
EA201591293A1 (en) | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | METHODS AND COMPOSITIONS FOR DELIVERY OF ANTIBODIES CODED BY mRNAs |
ES2806575T3 (en) | 2013-11-01 | 2021-02-18 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
WO2015105926A1 (en) | 2014-01-08 | 2015-07-16 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
MA40871A (en) | 2014-10-29 | 2017-09-05 | Novartis Ag | DIRECT EXPRESSION OF ANTIBODIES |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
-
2007
- 2007-01-09 DE DE102007001370A patent/DE102007001370A1/en not_active Ceased
-
2008
- 2008-01-08 EP EP08701020.3A patent/EP2101823B1/en not_active Revoked
- 2008-01-08 EP EP19192410.9A patent/EP3636669A1/en not_active Withdrawn
- 2008-01-08 ES ES16001146T patent/ES2904550T3/en active Active
- 2008-01-08 US US12/522,214 patent/US11421038B2/en active Active
- 2008-01-08 WO PCT/EP2008/000081 patent/WO2008083949A2/en active Application Filing
- 2008-01-08 EP EP17198401.6A patent/EP3329941A1/en not_active Withdrawn
- 2008-01-08 DK DK08701020.3T patent/DK2101823T3/en active
- 2008-01-08 ES ES08701020.3T patent/ES2614901T3/en active Active
- 2008-01-08 EP EP16001778.6A patent/EP3118224A1/en not_active Ceased
- 2008-01-08 EP EP16001146.6A patent/EP3115064B1/en active Active
-
2012
- 2012-12-10 US US13/709,897 patent/US20130195867A1/en not_active Abandoned
-
2016
- 2016-01-26 US US15/007,072 patent/US20160145346A1/en not_active Abandoned
- 2016-02-04 US US15/015,657 patent/US20160168254A1/en not_active Abandoned
- 2016-02-04 US US15/015,798 patent/US20160152706A1/en not_active Abandoned
- 2016-02-04 US US15/015,879 patent/US20160152691A1/en not_active Abandoned
- 2016-02-25 US US15/053,755 patent/US20160166691A1/en not_active Abandoned
- 2016-02-25 US US15/053,890 patent/US20160166690A1/en not_active Abandoned
- 2016-02-25 US US15/053,826 patent/US20160166692A1/en not_active Abandoned
- 2016-03-10 US US15/067,160 patent/US20160185840A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/392,004 patent/US20190284260A1/en not_active Abandoned
-
2022
- 2022-07-19 US US17/813,530 patent/US20220372158A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20160152691A1 (en) | 2016-06-02 |
WO2008083949A3 (en) | 2008-09-25 |
US11421038B2 (en) | 2022-08-23 |
US20160166691A1 (en) | 2016-06-16 |
EP3115064B1 (en) | 2021-11-24 |
US20160145346A1 (en) | 2016-05-26 |
US20130195867A1 (en) | 2013-08-01 |
US20160185840A1 (en) | 2016-06-30 |
EP2101823B1 (en) | 2016-11-23 |
ES2904550T3 (en) | 2022-04-05 |
US20160166690A1 (en) | 2016-06-16 |
US20160166692A1 (en) | 2016-06-16 |
EP2101823A2 (en) | 2009-09-23 |
US20160152706A1 (en) | 2016-06-02 |
DE102007001370A1 (en) | 2008-07-10 |
EP3636669A1 (en) | 2020-04-15 |
EP3329941A1 (en) | 2018-06-06 |
EP3118224A1 (en) | 2017-01-18 |
US20100189729A1 (en) | 2010-07-29 |
ES2614901T3 (en) | 2017-06-02 |
DK2101823T3 (en) | 2017-02-13 |
US20190284260A1 (en) | 2019-09-19 |
US20160168254A1 (en) | 2016-06-16 |
EP3115064A1 (en) | 2017-01-11 |
WO2008083949A2 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220372158A1 (en) | Rna-coded antibody | |
US20230293731A1 (en) | Rna encoding an antibody | |
US20230322920A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
EP2387999A1 (en) | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof | |
US20200157224A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
US11525004B2 (en) | Recombinant CD123-binding antibodies | |
JP2022101558A (en) | Pd-1 binding antibodies and uses thereof | |
CA3197951A1 (en) | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine | |
US20230398147A1 (en) | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer | |
JP2021523949A (en) | Antibodies that bind to PD-1 and their use | |
JP2021520850A (en) | PD-1 binding antibody and its use | |
US20230181640A1 (en) | Anti-bcma antibodies and chimeric antigen receptors | |
US20230117803A1 (en) | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 | |
CA3201008A1 (en) | Bcma-targeted chimeric antigen receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: CUREVAC SE, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:CUREVAC AG;REEL/FRAME:062522/0043 Effective date: 20220926 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |